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 i 
Abstract 
 
 
 Formyl peptide receptors (FPRs) belong to the family of G protein-coupled receptors 
(GPCRs) and play crucial roles in the regulation of innate immunity and host defence. FPRs 
include three family members; FPR1, FPR2/ALX and FPR3. They bind a wide variety of 
structurally and chemically diverse ligands that can exert various functions. Despite a plethora 
of research focusing on the role of FPRs in the regulation of immunity, there is a paucity of 
studies on their roles on the regulation of platelet haemostatic function. Here, we demonstrate 
the impact of both FPR1 and FPR2/ALX on the modulation of platelet reactivity, haemostasis 
and thrombosis.  By using selective pharmacological inhibitors for FPR1 and FPR2/ALX, and 
Fpr1- and Fpr2/3-deficient mice, we were able to establish instrumental roles for these 
receptors in the regulation of the normal platelet haemostatic function. Additionally, we report 
a crucial role for fMLF in the regulation of platelet function through FPR1 signalling. fMLF 
exerted a priming effect on platelet activation through inducing distinct functions and enhances 
thrombus formation under arterial flow conditions. These effects were diminished in the 
presence of FPR1-selective pharmacological inhibitors and in platelets obtained from Fpr1-
deficient mice. In addition, we investigated the role of LL37 in the regulation of platelet 
function and its modulation on platelet reactivity under pathological conditions, such as 
psoriasis, via acting through FPR2/ALX. We demonstrate that LL37 activates a range of 
platelet functions, enhances thrombus formation, and shortens the tail-bleeding time in mice. 
Moreover, we report the overexpression of mCRAMP (an LL37 murine orthologue) in affected 
skin and plasma of a murine [imiquimod (IMQ)-induced] model of human psoriasis and its 
ability to enhance platelet responses via Fpr2/3. We also report a role for Annexin A1 and its 
N-terminal peptide, Ac2-26, in the regulation of platelet function through FPR2/ALX. Ac2-26 
induced the activation of various platelet functions. Moreover, AnxA1-deficient mice 
demonstrate enhanced functional responses towards Ac2-26, which may be attributable to the 
overexpression of Fpr2/3 in these mice. Since both FPR1 and FPR2/ALX and their ligands 
play critical roles in various pathological conditions, their influence on the modulation of 
platelet activation and thrombus formation will provide novel insights into the mechanisms 
that control platelet-mediated complications under various disease settings. 
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1 – Introduction
 
 
1 
1.1 Platelets 
 
 Platelets are small circulating blood cells that play indispensable roles in the regulation 
of haemostasis to prevent excessive bleeding upon vascular injury. However, their unwarranted 
activation under pathological conditions leads to the formation of blood clots (thrombi) within 
the circulation1. This results in reduced blood supply to vital organs including the heart and 
brain, which can trigger heart attacks or strokes, respectively2. Moreover, certain pathological 
conditions such as inflammation and infection results in the activation of platelets, leading to 
aggregation, thrombus formation in the microvasculature and in later stages, sequestration of 
platelets in organs such as the lungs, instigating thrombocytopenia and bleeding 
complications3. Aside from their role in haemostasis, platelets also play pivotal roles in the 
regulation of innate immunity, inflammatory responses and clearance of microbial infection4-
6. In general, platelets act as sentinels7 due to their high number in the circulation, and they 
play critical roles in host defence against invading pathogenic microbes such as bacteria8. 
Platelets are also known to possess direct microbicidal activities against various bacterial 
species4, 7-9. They contain different types of intracellular granules and a wide range of receptors 
on their surface that aid in the modulation of haemostatic responses upon vascular injury. In 
addition, platelets express a wide range of inflammatory receptors and mediators that enable 
them to recognise to a broad spectrum of molecules. Here, we describe the role of different 
molecules released upon inflammation and/or infection in the regulation of platelet function. 
 
  
1.2 Platelet production  
 
Platelets are small anucleate circulating blood cells that range from 1 to 3 µm in 
diameter and are known to play a pivotal role in haemostasis and thrombosis10. They are 
produced from the fragmentation of the cytoplasm of the megakaryocytes (MKs) in the bone 
marrow. This process is regulated by the cytokine thrombopoietin (TPO), a hormone produced 
in the kidneys and liver11, 12, and its receptor c-Mpl13, 14. MKs are bone marrow cells that 
 
 
2 
originate from hematopietic stem cells and can also be found in the lungs and in the blood 
circulation15, 16. In order to produce platelets, MKs undergo endomitosis, which is DNA 
replication without cell division, that is stimulated by TPO and render MKs polypoid. This is 
followed by the maturation of MKs, wherein the nucleus is extruded, and the majority of the 
cytoplasm is packaged into several elongated processes known as proplatelets17-19. Each MK 
may extend 10 to 20 proplatelets, which elongates over time while thinning and branching20. 
At the tip of these proplatelets, the platelets develop and form while receiving organelles and 
granules transported from MKs21. The production of platelets can also occur in the lungs22, 
where it has been demonstrated recently that MKs in the bone marrow can migrate into the 
lungs, and back, and produce a significant number of platelets under thrombocytopenic 
conditions in mice23. Each megakaryocyte produces around 1000-3000 platelets24, and this 
process is usually completed in 5 days in human and 2-3 days in mice25-27. The platelet lifespan 
in human peripheral blood circulation is averaged between 7-10 days, while lasting 4-5 days 
in mouse circulation24, 28-30. The normal range for platelets produced by healthy individuals in 
the circulation is 150-400×109 per litre 31, 32.  
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 1.3 Platelet ultrastructure 
 
 The structure of platelets aids in the implementation of its haemostatic function, and it 
contains the following zones: peripheral, sol-gel, organelle and membranous zone33. The 
peripheral zone of the platelets contains receptors and glycoproteins that aid in the adhesion, 
activation and aggregation of platelets. The Sol-gel zone allows the platelets to maintain their 
discoid shape via the microtubules and microfilaments and also contains the actin cytoskeleton 
which allows shape changes upon platelet activation. Platelets contain three distinct types of 
granules, which comprise the organelle zone34-40. Alpha granules (a) which mainly contain 
proteins that mediate the secondary platelet activation including fibrinogen, P-selectin and von 
Willebrand factor, and are the largest (200-400 nm) and most numerous (50-60 per platelet) 
platelet granules35. Conversely, dense granules (δ) contain non-proteinous molecules including 
serotonin, calcium, phosphate, ADP and ATP, and are smaller (∼150 nm) and less numerous 
(3-8 per platelet) than a-granules. Moreover, platelets contain lysosomal granules (") which 
contain degrading enzymes that aid in the resolution of thrombi37. A diagram of the platelet 
structure is presented in Figure 1-1. Platelets also contain receptors that aid in their activation 
upon ligation with various agonists; a diagram of the different receptors expressed in platelets 
is presented in Figure 1-2. For example, collagen activates platelets via GPVI and the integrin 
α2β1, ADP activates platelets via acting through P2Y1 and P2Y12, while thromboxane A2 
(TXA2) activates the thromboxane prostanoid (TP) receptor on platelets. Another potent 
platelet agonist is thrombin, which acts on protease activated receptors (PAR1 and PAR4 in 
humans). Finally, the membranous zone which is related to the open canalicular system (OCS) 
and dense tubular system (DTS), is responsible for the synthesis and release of  TXA2, which 
aids the aggregation of platelets41.  
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Figure 1-1: Platelet structure. Diagram of the structure of platelets demonstrating the 
different platelet zones including: sol-gel, organelle and membranous zone. The Sol-gel zone 
contains microtubules and microfilaments that allow the platelets to maintain their discoid 
shape, and the actin cytoskeleton that allows shape change. Additionally, platelets contain an 
organelle zone comprising three distinct types of granules, including a-granules, dense δ-
granules "-granules. In addition to the membranous components of the platelets (plasma 
membrane, canalicular system, and dense tubular system), platelets contain mitochondria, 
microtubules, and glycogen. Adapted from (Li et al., 2017)42. 
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Figure 1-2: Diverse receptors expressed in platelets. Diagram of platelet receptors 
categorised by their major functions that are exerted in platelets. Platelets play crucial roles in 
the regulation of haemostasis (blue colour), immunity (red colour) or both (pink), whereas 
receptors of unknown functional roles are shown in grey. Adapted from (Li et al., 2017)43. 
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 1.4 Platelet function in health and disease 
 
 
1.4.1 Role of platelets in haemostasis 
 
 
Under normal physiological conditions, platelets circulate in a resting state. This state 
is regulated by molecules that inhibit the activation of platelets and are released from the intact 
endothelium. These molecules include nitric oxide (NO), prostacyclin (PGI2) and apyrase 
(which degrades ADP). The dysregulation of such molecules may lead to inappropriate 
platelets activation and contribute to pathological conditions44. Upon vascular injury however, 
platelets become activated and contribute to their physiological process, haemostasis, in which 
they are known to play a central role45. 
 
The haemostatic function of platelets can be categorised into the following stages: 
adhesion, activation, aggregation and contraction of platelets. Upon vascular injury, the 
subendothelial collagen is exposed, enabling the binding of von Willebrand factor (vWF), 
facilitating the binding to platelets and thus their adhesion to the injured vascular site. This 
binding is mainly facilitated by glycoprotein (GP) receptors on the surface of platelets, leading 
to the formation of a monolayer over the injured site to arrest the bleeding46-48. Notably, GPVI-
mediated binding of platelets to collagen leads to a reduced production of prostacyclins and 
increases the production of TXA2. Another potent platelet agonist is a synthetic peptide known 
as crosslinked collagen receptor peptide (CRP-XL), which is selective for GPVI only, and aids 
in the mechanistic investigation of signalling pathways in platelets. The binding and activation 
of platelets leads to initiation of various responses including, calcium mobilisation, granule 
secretion, tyrosine kinase signalling pathways and activation of platelet integrins. The release 
of platelet granules aids in the secondary platelet activation and release of chemotactic agents, 
attracting more platelets to the site of vascular injury. This allows the bridging of activated 
platelets via receptor-bound fibrinogen mediated through integrin αIIbβ3 and thus aggregation 
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of platelets and development of a stable platelet aggregate49, 50.  The aforementioned responses 
including platelet adhesion, activation and aggregation comprise the first wave of haemostasis, 
and are followed by the coagulation cascade (otherwise known as the second wave of 
haemostasis), that leads to the development of a stable thrombus.  
 
The activation of platelets can also lead to the exposure of phosphatidylserine on their 
surface, which induces a negatively charged phospholipid surface that harbours coagulation 
factors, rendering platelets procoagulant51-53. The coagulation cascade leads to the generation 
of thrombin, which is known as a strong platelet activator, that initiates signalling through 
protease activated receptor 1 (PAR1), 2 (PAR2) and GPIbα54, 55. In addition, thrombin 
facilitates the conversion of fibrinogen to fibrin, which aids in the development of a blood clot 
56, 57. In order to facilitate the repair the vascular wall damage, the platelet undergoes 
contraction, driving the retraction and stiffening of clots58. This aids in several responses, 
including the reinforcement of haemostasis, restoring the blood flow and promotes wound 
healing59-61. 
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1.4.2 Function of platelets in thrombosis and cardiovascular disease 
 
 
 Although platelets play a central role in the regulation of haemostasis, this 
process, if poorly regulated, leads to inadvertent thrombus formation and the occlusion 
of blood vessels, a process otherwise known as thrombosis. Thrombosis is one the 
leading causes of death worldwide62 and constitutes a major underlying pathology in 
multiple cardiovascular diseases, including strokes, ischemic heart disease and 
venous thromboembolism63. Additionally, thrombosis also occurs in atherosclerosis, 
wherein platelets may promote atherogenesis and augment vascular inflammation and 
remodelling of the arterial wall, resulting in formation of atherosclerotic plaques. The 
rupture of these plaques is implicated in coronary thrombosis. Various antiplatelet 
agents that target platelet activatory pathways have been proposed64. However, these 
agents could also target pathways that are involved in haemostasis. Therefore, their 
administration may lead to an increased risk of bleeding. 
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1.4.3 Role of platelets in innate immunity  
 
 In addition to their widely characterised role in haemostasis, platelets play an integral 
role in the regulation of immune and inflammatory responses and are essential in host defence, 
wound healing and pathogen surveillance65-67. A diagram of the various roles of platelets in 
haemostasis and immunity is presented in Figure 1-3. These roles were emphasised by the 
discovery of a plethora of immune receptors in platelets, including Toll-like receptors (TLRs), 
such as TLR2, TLR4 and TLR9, immunoglobulin receptors, Siglecs and complement 
receptors68-70. Additionally, platelets express formyl peptide receptors (FPRs), notably, FPR1 
was reported to add a chemotactic function to platelets71. Moreover, platelet granules contain 
immune and inflammatory modulators that are released upon the activation of platelets and 
translocated to the plasma membrane. Platelets contain cytokines, such as CD40L and 
chemokines (CCL5), which are mainly compartmentalised in alpha-granules and aid in the 
recruitment and activation of other immune cells or induction of endothelial cell-mediated 
inflammation72. Platelets can also play a protective role during microbial infections. Platelets 
are known to contain several antimicrobial peptides including platelet factor 4 (PF4), platelet 
basic protein (PBP) and its derivatives, connective tissue activating peptide 3 (CTAP-3), 
thymosin B-4 (TB-4), CAMP and fibrinopeptides A and B (FPA and FPB), and release them 
upon activation in order to control microbial infection73. In this study we were also able to 
report the expression of an antimicrobial peptide (AMP), LL37, in platelets which is the sole 
human cathelicidin. Platelets can also directly interact with and kill pathogens. For instance, 
platelets may bind and wrap bacteria74 or induce their aggregation75, leading to degranulation. 
In addition to AMPs, platelets contain other inflammatory mediators, including CD40 ligands 
(CD40L), Interleukin 1β (IL1β) and Regulated on Activation, Normal T Cell Expressed and 
Secreted (RANTES)76-80. Additionally, platelets interact with other inflammatory leukocytes 
to regulate inflammation and immunological responses by releasing chemokines and cytokines 
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that activate and recruit them to the site of infection81, 82. These interactions are also crucial for 
the clearance of bacterial, viral, and parasitic infections43. For instance, platelets interact with 
neutrophils to facilitate the release of reactive oxygen species (ROS), proteases and 
myeloperoxidase81. Moreover, prothrombotic and inflammatory gene expression can result 
from the interaction of platelets with monocytes83. Platelets also interact with lymphocytes to 
increase cytotoxic T-cell activity and mediate class-switching on B-cells84. 
 
 The activation of platelets is typically associated with eliciting pro-inflammatory 
responses. However, platelets have been shown to interact with anti-inflammatory and pro-
resolution responses as well, which is controversial, and the underlying mechanisms are not 
entirely clear85. Notably, it has been shown that Maresin-1 interacts with FPR2/ALX on 
platelets and enhances their aggregation and spreading, while suppressing the release of pro-
inflammatory mediators86. In line with this, another study has reported that the activation of 
platelets induces unforeseen anti-inflammatory properties87. 
 
 Although several of these effects are beneficial to the host to aid in resolving 
inflammation, their dysregulation can be detrimental and may lead tissue damage and vascular 
injury88. Moreover, it may contribute to disease and exacerbation of adverse effects in various 
inflammatory conditions including atherosclerosis, inflammatory lung, bowel, and skin 
diseases, ischemic and inflammatory hepatitis, cancer, arthritis, glomerulonephritis and 
sepsis89-93. While these mediators and receptors establish a role for platelets in immunity, there 
is a paucity of studies on the role of these receptors and mediators in the haemostatic platelet 
function. Exploring such roles can lead to novel mechanisms to eliminate adverse effects in 
diseases associated with platelets dysfunction. 
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Figure 1-3: Major roles of platelets in haemostasis and immunity.  Platelets are known to 
play pivotal roles in the regulation of haemostasis (A) and immunity (B). Upon vascular injury, 
platelets bind to collagen in the exposed endothelium layer (A1). Additionally, they detect 
molecules that are released from activated endothelium such as those released from the Weibel-
Palade (WP) bodies (A2), which also contribute to the activation of platelets, and the initiation 
of thrombosis (A3).  Meanwhile, platelets also regulate the permeability of blood vessels (A4) 
and prevent the loss of erythrocytes by sealing the vessels (A5). Moreover, platelets regulate 
the lymphovenous junction (A6). In addition to their role in haemostasis, platelets are able to 
detect pathogens directly (B1) or indirectly via interacting with leukocytes (B2). Platelets have 
the ability to directly bind to pathogens to initiate their killing (B3), or indirectly by recruiting 
leukocytes (B4). The interaction of platelets with leukocytes aids in the exchange of molecules, 
and thus initiates inflammatory responses. For example, platelets can synthesize thromboxane 
A2 (TXA2) from arachidonic acid (AA) supplemented from neutrophils (B5). Adapted from 
(Li et al., 2017)43.   
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 1.4.4 Platelet-associated inflammatory diseases 
 
 
While platelets play indispensable functions, both haemostatic and immune, that are 
essential for haemostasis, vascular integrity and systemic homeostasis, the dysregulation of 
such functions can have detrimental consequences, including thrombosis and bleeding. 
Uncontrolled platelet function leads to the formation of blood clots within the blood vessel 
(thrombosis), obstructing the blood flow through the circulatory system94. This is considered 
as a key factor in several cardiovascular diseases such as myocardial infarction, strokes, 
atherosclerosis, and venous and arterial thrombosis95. Moreover, platelets have been implicated 
in the development of cancer, inflammatory disease such as multiple sclerosis, inflammatory 
bowel disease (IBD), rheumatoid arthritis and psoriasis, and in infectious disease such as 
sepsis, malaria and dengue, whereby they contribute to unwarranted adverse effects 88, 96-100. 
The inhibition of platelet function and/or the decrease in the number of platelets 
(thrombocytopenia) leads to bleeding. Many treatment modalities for several chronic diseases 
have been associated with bleeding, including anticoagulant, antitumour, and anti-
inflammatory therapy101-103.  
 
Since platelets interact with endothelial cells and leukocytes to induce their function, 
the dysregulation of such interactions can drive pathological processes. Activated platelets can 
interact with and adhere to leukocytes, leading to the formation of platelet-leukocyte 
aggregates, which can exacerbate inflammatory conditions104. Moreover, platelets have been 
shown to be implicated in the formation of neutrophil extracellular traps (NETs), which can 
promote the activation of platelets and trigger a procoagulant state105, 106. NETs can also 
promote thrombosis by providing a scaffold that can stimulate platelet adhesion and 
aggregation107-109. Platelets can also interact with other cell types by the production of 
microparticles, which can aid in cancer metastasis110. A diagram of the various receptors that 
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are present on platelets to aid the interaction with other cells types, and thus the regulation of 
host defence is presented in Figure 1-4.   
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Figure 1-4: Interaction of platelets with other cell types via various receptors to initiate 
host defence. Platelets are able to interact with a variety of cell types in order to regulate host 
defence. The activation of platelets results in shape change and the formation of pseudopodia, 
facilitating the interaction with injured tissues and pathogens. Additionally, platelets can 
release host defense peptides (HDPs) that can kill pathogens. Platelets can induce the formation 
of neutrophil extracellular traps (NETs), which can trap pathogens. Additionally, platelets 
interact with antigen-presenting cells (APCs), such as monocytes and dendritic cells. Platelets 
also interact with T cells and B cells for the generation of cytokines and antibodies.  
Meanwhile, platelets also interact with the endothelium to initiate the formation of clots and 
regulate haemostasis. Adapted from (Yeaman, 2014)111.  
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1.4.5 Platelet-associated inflammatory disease; psoriasis  
 
  Psoriasis is a chronic inflammatory cutaneous disease affecting 2-4% of the worldwide 
population and is characterised by hyperproliferation and abnormal differentiation of 
keratinocytes112-114. Psoriatic vulgaris (otherwise known as plaque-like psoriasis) is the most 
common phenotype of psoriasis and is characterised by increased redness, thickness and 
scaling of the skin in affected areas throughout the body, all of which are used to assess the 
activity and severity of psoriasis in clinical practice115. The most commonly used tool to assess 
psoriasis is the Psoriasis Area and Severity Index (PASI) scoring system, which determines 
therapeutic efficacy116. The PASI scoring system is a five-point scale (0-4) that provides a 
grade of the average erythema (redness), induration (thickness) and desquamation (scaling) of 
psoriatic plaques in four body regions including head, upper extremities, trunk and lower 
extremities117.  
 
 Psoriasis fits under the umbrella of autoimmune diseases; it is triggered by an activated 
cellular immune system in the absence of infection or other stimuli118. It was previously 
believed that the pathomechanisms of psoriasis are limited to keratinocytes hyperplasia. 
However, the involvement of the immune system was later demonstrated by the accidental 
observation in 1979, which reported the therapeutic potential of cyclosporin A (CsA) in 
psoriasis, mainly by inhibiting the production of IL-2 by T-cells, which can stimulate 
keratinocytes119. CsA is an immunosuppressive agent derived from fungus that inhibits the 
activation and proliferation of T-cells. It acts by binding to cyclophilin, an immunosuppressant-
binding protein. This binding inhibits the enzyme calcineurin, which leads to the inhibition of 
signal transduction pathways that are dependent on the transcription factor, NF-AT (nuclear 
factor of activated T cells). This ultimately inhibits the production of cytokines such as IL-2 
and IFN-γ120. The hyperproliferation of keratinocytes in psoriasis is accompanied with the 
infiltration of inflammatory cells and mediators. Several effector cells were reported to 
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implicate psoriasis including T-helper cells, dendritic cells (DCs), neutrophils and 
macrophages. These cells contribute to the exacerbation of disease by releasing inflammatory 
mediators such as interferon (IFN)-γ, tumour necrosis factor (TNF)-α, interleukin (IL)-12, IL-
17A, IL-20, IL-22 and IL-23112. This can in turn trigger the production of proinflammatory 
cytokines (IL-1, IL-6, and TNF-α) and chemokines (IL-8 [CXCL8], CXCL10, and CCL20) 
from keratinocytes121.  
 In addition to the role of inflammatory cells and mediators, AMPs have been shown to 
play an integral role on the pathogenesis of psoriasis122. Keratinocytes are known to provide a 
rich source of AMPs while expressing more than 20 different types123, including: cathelicidins, 
defensins, S100 proteins, lysozyme, RNase 7, elafin, neutrophil gelatinase-associated lipocalin 
with several others124, 125. Among these, the cathelicidin LL-37, human β-defensin (HBD) 2 & 
3, and S100A7 protein (otherwise known as psoriasin) have been shown to be widely 
implicated in the development of psoriasis and highly up-regulated in psoriatic lesions126. 
Notably, LL37 has been highlighted as an immune modulatory peptide in psoriasis127 and has 
been shown to be overexpressed with concentrations reaching up to 300 μM in affected skin 
tissues128. HBD2 and HBD3 were demonstrated to be highly expressed in psoriatic lesions. 
Moreover, high HBD copy numbers were reported in psoriasis129-131. This increased expression 
is induced by inflammatory mediators that are highly expressed in psoriatic lesions, including 
TNF-α, IFN-γ, IL-17A and IL-22132, 133. Similarly, the S100A7 protein is expressed in response 
to TNF-α, IL-17A, IL-22 and IL-28, and have been thought to play a chemotactic role in 
psoriasis134. Although the overexpression of HBDs has been reported by many groups, their 
mechanisms of action in psoriasis are not fully understood128.  
 
 Psoriasis has been associated with complications and comorbidities that are related to 
systemic inflammation and cardiovascular diseases, mainly induced by the inflammatory 
milieu135. Psoriasis patients have increased risk for occlusive vascular disease, such as 
atherosclerosis, coronary artery disease and cerebrovascular diseases136-139. Psoriasis has been 
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suggested to be an independent risk factor for cardiovascular disease140. In 2006, the risk of MI 
and atherosclerosis has been reported in psoriasis141-143. This is mainly due to the activation 
and hypercoagulability of platelets, which has been shown to contribute to the pathogenesis of 
psoriasis144. Moreover, platelets have been shown to contribute to cutaneous inflammation and 
consequently atherosclerosis plaques137, 145, 146.   
 
 Platelet indices has been demonstrated as useful indicators for the activation of platelets 
during psoriasis. In addition to the platelet distribution width (PDW), the mean platelet volume 
(MPV) have been reported to be increased in psoriasis147, 148. This is indicative of the presence 
of larger platelets, which are associated with increased reactivity, granule release, and GPIb 
expression. Moreover, these platelets demonstrate augmented collagen-, ADP- or thrombin-
induced aggregation149. Additionally, the platelet mass index (PMI), formulated as MPV 
multiplied by platelet count, is elevated in psoriasis141. Unlike the MPV and PDW, the PMI not 
only has been shown to be a useful marker for the activation of platelets but is also indicative 
of the functionality of platelets; especially that associated with their capability of the formation 
of atherosclerotic plaques. Because the PMI was shown to be correlated with erythrocyte 
sedimentation rate (ESR), a marker for inflammation, it is considered as a better predictor of 
inflammation and atherosclerotic plaque formation in psoriasis compared to the MPV141, 150, 
151. In addition to the platelet indices, the in vitro platelet aggregation was shown to be a useful 
predictor of platelet activation and was increased in psoriatic patients, wherein thrombin- or 
ADP-induced platelet aggregation was potentiated compared to the controls152, 153.  
 
 In addition to the aforementioned markers, the elevated plasma levels of platelet 
inflammatory mediators have been reported in psoriasis. These mediators were shown to 
exacerbate the disease by mediating the activation and the recruitment of leukocytes to the site 
of cutaneous inflammation154, 155. Moreover, they mediate the leukocyte adhesion to platelets 
and the endothelium, all of which can contribute to the development of atherosclerosis72. These 
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mediators include soluble P-selectin (sP-selectin) and platelet-derived microparticles 
(PDMPs), which are also increased in psoriatic patients96, 138, 156-159. PDMPs were also shown 
to facilitate thrombus formation, endothelial dysfunction and atherosclerosis154, 155. 
Furthermore, the plasma levels of chemokines released from platelets, such as platelet factor 4 
(PF4) and β-thromboglobulin (β-TG) were increased in psoriasis160. The elevated levels of 
these mediators positively correlated with the PASI scoring and thus disease severity, and their 
levels were reduced after treatment96, 137, 161.  
 
 In addition to platelet indices and activation, markers of systemic inflammation were 
also increased, and these include: serum high sensitivity C-reactive protein (hs-CRP)162 and 
IL-6163, which has been shown to induce thrombocytosis and platelet activation163, 164. 
Moreover, IL-6 can perpetuate inflammation by inhibiting the functions of regulatory T 
cells164. These findings indicate that platelet activation and inflammation may perpetuate each 
other and facilitate the development of cardiovascular risks.  
 
 
 The use of antiplatelet agents for the treatment of psoriasis has not been explored 
previously. However, several biological drugs including infliximab, adalimumab and 
etanercept (TNF-α inhibitors), and ustekinumab (IL-12/23 inhibitor)  have been associated with 
a reduction in PASI scoring and P-selectin expression 165. This suggests a link between 
inflammation and platelet activation in psoriasis. Conversely, in a case report of cardiovascular 
and psoriasis comorbidity, the use of clopidogrel (an irreversible P2Y12 inhibitor) was 
plausibly regarded ineffective as its re-challenge in patients exacerbated and perpetuated 
psoriasis166. Moreover, re-challenge of ticlopidine or aspirin are also known to exacerbate 
psoriasis. However, dipyridamole, a platelet aggregation inhibitor that causes dilated blood 
vessels was suggested as an alternative. 
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1.4.6 Platelet-associated infectious disease; sepsis 
 
 Sepsis or septic shocks are characterised by life-threatening organ dysfunction 
stemming from dysregulated host responses to infection167, 168. It is the leading cause of death 
in intensive care units (ICUs) 169. Cardiac arrest and organ failure are among the leading causes 
of death in septic shocks170, 171. Reported incidences of sepsis are increasing with age and as a 
complication of other diseases including diabetes mellitus, cancer, immunosuppression and 
chronic organ failure169, 171, 172.  
 
 Platelets play a significant role in the pathophysiology of sepsis, and several modes of 
action have been proposed173, 174. Firstly, the activation of platelets175, which may result in 
thrombus formation in the vasculature and hypercoagulability of blood176, which can result in 
acute disseminated intravascular coagulation (DIC) and localised venous 
thromboembolism177. This consequently leads to the consumption of platelets and coagulation 
proteins, manifesting a bleeding diathesis in most cases of sepsis178. Additionally, it has been 
shown that systemic microvascular dysfunction due to thrombosis comprises the hallmark of 
organ damage in sepsis173. In addition to thrombosis, infection-related endothelial activation 
and dysfunction may also contribute to the microvascular dysfunction and leakage of blood179, 
180. Another mode of action in which platelets may affect the clinical outcomes of sepsis is 
through the destabilisation of the endothelial barrier. Platelets are a major source of 
angiopoietin 1 (Ang-1), which stabilises the endothelium and prevents microvascular leakage. 
In severe cases of sepsis, the plasma and serum levels of Ang-1 are significantly declined3, 181. 
Thus, thrombocytopenia can contribute to the adverse outcomes by decreasing the delivery of 
Ang-1 to the endothelium.  
 
 Secondly, platelets can contribute to the pathophysiology of sepsis by interacting with 
other immune cells and regulating immune and inflammatory responses. As detailed 
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previously, platelets can elicit innate immune responses and contribute to clearance of 
pathogens and tissue repair66, 68, 76, 182-184. Additionally, platelets contribute to acute and chronic 
inflammatory responses, which can result in tissue and vascular injury66, 185, 186. All of which, 
can be mediated by activated platelets and exacerbated in sepsis. 
 
 Thirdly, thrombocytopenia is implicated in the pathophysiology of sepsis and can 
contribute to unwarranted complications and can serve as a prognostic factor for disease 
severity187. Sharma et al. reported a strong association between mortality and 
thrombocytopenia in 69 patients suffering from septic shock188. In addition, Claushuis et al. 
reported this association in a large cohort consisting of 931 septic patients3. The low platelet 
count in these patients upon their admission to ICUs is associated with elevated plasma levels 
of cytokines such as interleukin (IL)-6189, IL-8190 and IL-10191, intercellular adhesion molecule 
1 (ICAM-1)192 and the chemokine fractalkine193. Additionally, coagulation activity is increased 
as evidenced by decreased antithrombin194, and the vascular integrity is reduced as evident by 
the increased ration of angiopoietin Ang-2 to Ang-1181. It has been also shown that 
thrombocytopenia, independent of disease severity, is associated with increased mortality in 
sepsis. Thus, identifying the causes of thrombocytopenia is crucial for the management of 
septic patients195. Several causes of thrombocytopenia in sepsis, acting individually or in 
combination, have been previously reported174, and include the reduced production of platelets 
in the bone marrow. This can be due to pre-existing conditions or the inhibition of 
haematopoiesis in response to drugs, inflammatory mediators or pathogenic toxins.  In addition 
to bone marrow, the platelet count can be compromised in the periphery circulation. The 
increased consumption of platelets can occur by the activation of platelets and the reduction of 
their half-life can be triggered by pathogens or pathogenic products.  Moreover, pathogen-
induced apoptosis, lysis and increased phagocytic clearance of platelets can contribute to their 
consumption. Platelet consumption and activation can also occur by their sequestration by 
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leukocytes and inflammatory cells in the vascular bed. Additionally, thrombosis and 
coagulopathy of blood, such as in DIC, can contribute to thrombocytopenia174, 196-200. In 
addition to the aforementioned causes, the administration of drugs can induce 
thrombocytopenia, bleeding, hemophagocytosis and hemodilution195, and can cause defective 
platelet function201, 202. 
 
 Since platelets play an integral role in the pathophysiology of sepsis, platelet-targeted 
therapeutic intervention has been proposed174. The transfusion of platelets has been proposed 
to restore the platelet blood count and has been mostly used to prevent or treat bleeding in 
sepsis203, whereas it was demonstrated to be ineffective in non-bleeding ICU patients204, 205. 
However, transfused platelets can present detrimental effects to the host by contributing to the 
inflammation, intravascular platelet activation and coagulopathy effects in sepsis195, 204, 206. 
Moreover, data collected recently from a large transfusion registry identifies platelet 
transfusion in sepsis as ineffectual since its association with platelet count elevation is 
inadequate207. Hence, the transfusion of platelets can be either deleterious or ineffectual, 
consequently, presenting a challenge in platelet-targeted therapeutic interventions in sepsis.  
An otherwise effective alternative strategy for restoring the blood count in sepsis that has been 
demonstrated recently is the clinical administration of human thrombopoietin, the main 
regulator of platelet production208-211. Conversely, TPO blockade by a chimeric (mTPOR-
MBP) has been demonstrated to reduce organ damage severity in two murine experimental 
models; acute endotoxemia and a polymicrobial sepsis model induced by cecal ligation and 
puncture (CLP)210. Targeting platelet-associated inflammatory modulatory responses, 
including the inhibition of cytokines such as TNF-α and IL-1212, platelet activating factors213, 
214, cyclooxygenase (COX)215 and bradykinins216 has been shown to be an ineffective 
therapeutic strategy in sepsis. However, activated protein C (APC) has been shown to be 
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effective and is approved by the Food and Drug Administration (FDA) for the treatment of 
human sepsis217. 
 
 In addition to the aforementioned therapeutic strategies, the administration of 
antiplatelet agents has been proposed for targeting several platelet defects and deleterious 
pathways in sepsis174, 218. In mouse experimental models of acute kidney injury (AKI) and acute 
lung injury (ALI), the depletion of platelets or the inhibition of platelet function by 
administration of antiplatelet drugs has demonstrated protective roles219. Notably, antiplatelet 
therapy exhibited a reduced risk of ICU mortality, and such impact has been demonstrated over 
several cohorts. Notably, the blockade of P2Y12 reduced the pro-inflammatory and pro-
thrombotic mechanisms in humans220. Additionally, the administration of acetylsalicylic acid 
(ASA) and GPIIb/IIIa antagonists demonstrated reduced complications and mortality in 
patients221. However, the administration of antiplatelet drugs has its drawbacks and can 
contribute to resistance in patients and undesirable side effects such as bleeding222-224. 
Moreover, it has been shown that antiplatelet agents demonstrate differential effects in 
platelets; aspirin-treated platelets can still be activated by potent platelet agonists such as 
thrombin174.  
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1.5 Formyl peptide receptors (FPRs) 
 
 
1.5.1 FPR family members 
 
 Formyl peptide receptors (FPRs) are a group of chemoattractant receptors that belong 
to a family of G protein-coupled receptors (GPCRs) that are mainly expressed in phagocytic 
leukocytes and are known to play a pivotal role in the regulation of host defence and 
inflammation225. The expression of these receptors in platelets has been demonstrated 
previously; the expression of FPR1 at protein level in platelets, and at transcript level in 
megakaryocytes71, and the expression of FPR2/ALX in megakaryocytes, and human and 
mouse platelets at transcript level has been reported previously71,226.  FPRs are so called 
because they were originally discovered by their ability to recognise peptides bearing N-formyl 
methionine (fMet), such as those derived from mitochondrial or bacterial proteins. Hence, these 
receptors are known as pattern recognition receptors with the ability to bind pathogen-
associated molecular patterns (PAMPs) derived from bacteria, or damage-associated molecular 
patterns (DAMPs) derived from the mitochondria of damaged cells227-229. Nonetheless, it was 
later discovered that FPR ligands are not only limited to N-formyl peptides, but they bind 
numerous chemically- and structurally-diverse ligands, including non-formyl peptides, 
synthetic peptides, non-peptides including glycoproteins, lipids and eicosanoids such as lipoxin 
A4 (LXA4).  
 
1.5.1.1 Human FPRs 
 The FPRs family is encoded by three genes in humans and comprises three members; 
FPR1, FPR2/ALX and FPR3230. FPR2/ALX is called so to convey its ability to interact with 
Lipoxin A4 and aspirin-triggered lipoxins231. FPR1 and FPR2/ALX share overlapping 
functions and significant sequence homology (69 % amino acid identity)232, whereas FPR3 
shares 58 % and 72 % identity with FPR1 and FPR2, respectively233. Unlike FPR1 and 
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FPR2/ALX which are expressed in both neutrophils and monocytes, FPR3 is only expressed 
in monocytes. Besides myeloid cells, FPR1 is expressed in astrocytes, microglial cells, 
hepatocytes and immature dendritic cells. In contrast to FPR1, FPR2/ALX displays a broader 
expression pattern and is found in non-myeloid cells including epithelial cells, hepatocytes, 
microvascular endothelial cells, astrocytoma cells, neuroblastoma cells, in addition to 
phagocytic leukocytes. The expression of these receptors in a variety of cells other 
than phagocytic cells implies their ability to activate functions beyond that of host defence. 
While FPR1 binds to bacterial-derived N-formyl peptides with high affinity, 
FPR2/ALX displays low affinity to these peptides and largely binds to mitochondrial-derived 
formyl peptides234, 235. Whereas FPR3 does not bind N-formyl peptides233. Moreover, studies 
have shown that long amphipathic α-helical N-formyl peptides favour FPR2/ALX over FPR1 
binding236, 237. The ligation of N-formyl peptides to FPRs in immune cells triggers a range of 
signalling cascades resulting in numerous biological responses including chemotaxis, 
degranulation, production of superoxide anions225, 238, calcium mobilisation239, lysosomal 
enzyme240 and cytokine release, and expression of various surface markers241, 242. Due to their 
ubiquitous expression and their interaction with a wide variety of ligands, FPRs have been 
implicated in various pathological conditions. Notably, FPR1 is largely implicated in infectious 
inflammation and metastasis, while FPR2/ALX has been implicated in chronic inflammatory 
conditions including atherosclerosis, systemic lupus erythematous and cancer metastasis243-246.   
 
1.5.1.2 Mouse FPRs 
 Several orthologs of the human FPR1 gene (FPR1) have been identified in other 
mammalian species including mice, rabbits, horses and guinea pigs234. Although they share an 
overall sequence homology, the genes between humans and other mammalian species vary 
significantly in their number and sequences. Notably, the murine FPR gene family comprises 
at least eight members including Fpr1, Fpr2 (also known as formyl peptide receptor, related 
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sequence 2 [Fpr-rs2]), Fpr3 (also known as Fpr-rs1), Fpr-rs3, Fpr-rs4, Fpr-rs5, Fpr-rs6, Fpr-
rs7 and Fpr-rs8. The Fpr1, Fpr2 and Fpr3 genes code for receptors expressed in phagocytic 
leukocytes and display similarity to their human counterparts247. The gene product of Fpr1 is 
the mouse ortholog of human FPR1. The human FPR2/ALX corresponds to two genes; Fpr2 
and Fpr3 in mice, thus Fpr2/3 is the mouse ortholog to human FPR2/ALX234, 247-249. 
 
While Fpr1 displays low-affinity binding to the tri-peptide N-formyl-methionyl-leucyl-
phenylalanine (fMLF)248, 250, it shows higher affinity to several other N-formyl peptides, 
including bacterial fMIFL, fMIVIL and fMIVTLF, and mitochondrial fMMYALF247, 250. In 
contrast, Fpr2 has been found to be less responsive to fMLF and fMIFL247,  but serves as a 
receptor for endogenous peptide agonists for FPR2/ALX, including amyloidogenic proteins 
SAA (serum amyloid A)251  and Aβ42252, as well as F2l, which is a highly potent agonist for 
human FPR3253. Both Fpr2 and Fpr3 respond to Lipoxin A4 (LXA4) and aspirin-triggered 
lipoxin A4 (ALX)254, 255.  
 
The targeted deletion of Fpr1 or Fpr2 renders mice more susceptible to bacterial 
infection. Notably, neutrophils obtained from Fpr1-deficient mice displayed increased 
susceptibility to Listeria infection, suggesting a pivotal role for FPRs in host defence against 
bacterial infection256, 257. Moreover, Fpr1- and Fpr2-deficient mice displayed increased 
inflammatory responses and severe liver injury after stimulation with LPS258, 259. These mice 
were shown to behave normally under unstimulated settings. However, in several models of 
human diseases, both Fpr1−/− and Fpr2−/− mice respond differently compared with wildtype 
mice, demonstrating a regulatory role for these receptors in host defence and inflammation. 
The deletion of Fpr2/3 has been associated with dysregulated responses. Fpr2/3-deficient mice 
displayed exacerbated inflammatory responses following cerebral ischaemia/reperfusion (I/R) 
injury, where it has been shown to mediate neutrophil-platelet aggregation260, 261. Furthermore, 
 
 
26 
in an experimental polymicrobial sepsis model, Fpr2/3-deficient mice displayed aggravated 
host responses, exacerbated disease severity, and myocardial dysfunction249. 
 
1.5.2 FPR signalling 
 
The activation of FPRs induces a variety of responses, including chemotaxis, 
degranulation, and production of superoxide anion225, 238 and lysosomal enzyme release240.  
FPRs belong to the Gi subfamily of heterotrimeric GPCRs. This was evidenced by their ability 
to mediate cellular responses in a pertussin toxin (PTX)-sensitive manner, where the major 
fMLF-stimulated functions in neutrophils were largely inhibited following the treatment of 
cells with PTX262-264.  Upon agonist binding, Gi protein coupled to FPRs undergo conversion 
of guanosine diphosphate (GDP) to guanosine triphosphate (GTP)65. This induces their 
dissociation into α and βγ subunits, which leads to a series of signal transduction cascades263. 
This leads to the activation of the phospholipase Cβ2 (PLCβ2)265 and the phosphoinositide 3-
kinase γ (PI3Kγ)266 signalling cascades. PLCβ2 hydrolyses plasma membrane-bound 
phosphoinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate 
(IP3). This mediates the release of calcium from the intracellular calcium stores, mainly from 
the endoplasmic reticulum. The interplay of calcium and DAG subsequently leads to the 
activation of protein kinase C (PKC) and is crucial for the regulation of reactive oxygen species 
(ROS) production and NADPH oxidase.54 Meanwhile, PI3Kγ triggers protein kinase B (PKB, 
also known as Akt) signalling and facilitates the conversion of PIP2  to phosphoinositol-3,4,5-
trisphosphate (PIP3), which mediates superoxide generation267, cytoskeletal reorganization, 
oxidative burst and chemotaxis in neutrophils10, 47268, 269. The subsequent activation of several 
kinases occurs, including extracellular signal-regulated kinases (ERK) and p38 mitogen-
activated protein kinase (MAPK) signalling pathways. 
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 Many cellular functions, including chemotactic responses in neutrophils, require a 
transient rise in intracellular calcium270. Recent studies indicate that chemotaxis and calcium 
responses in FPRs are mediated by CD38, a transmembrane glycoprotein, which catalyses the 
production of cyclic ADP-ribose (cADPR) from its substrate NAD+ 271. cADPR has been 
described as a regulator of calcium signalling and acts at ryanodine receptors to release calcium 
ions (Ca2+) from intracellular stores and results in a sustained influx of extracellular 
Ca2+ required for fMLF-induced neutrophil migration272-274. This was evidenced by the failure 
of  neutrophils obtained from CD38-deficient mice to migrate in response to fMLF in vitro and 
fail to accumulate at sites of Streptococcus pneumoniae infection in vivo 274. Moreover, the 
ability of fMLF to induce calcium mobilisation through FPR1 in platelets has been previously 
reported71. The mobilisation of calcium in platelets is implicated with activatory responses, 
including the activation of integrin αIIbβ3 and granule release275.  
 
The activation of Gi protein-coupled receptors are known to inhibit adenylate cyclase 
276 and thus, reduce the levels of  cyclic adenosine monophosphate (cAMP). In addition to the 
aforementioned signalling pathways, the production of cAMP is involved in the regulation of 
chemotaxis277.  Several studies have shown that elevation of cAMP levels inhibits chemotaxis 
in neutrophils278-281. The main target for cAMP is protein kinase A (PKA), which can regulate 
various signalling components, including Rho and vasodilator-stimulated 
phosphoprotein (VASP)282. cAMP signalling in platelets play a crucial role in the regulation of 
their function and is associated with the inhibition of platelet aggregation283.  
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1.5.3 FPR ligands 
 
 FPRs are known to recognise a wide variety of ligands with diverse chemical and 
structural properties and can exert both pro- and anti-inflammatory responses. These ligands 
include formyl and non-formyl peptides, and nonpeptides such as proteins and lipids. The 
peptides can be categorised into three subtypes; pathogen-derived, host-derived and synthetic. 
The nonpeptides can either be synthetic or host derived234.  
 
  1.5.3.1 Agonists 
Bacterial-derived N-formyl peptides are considered as a class of pathogen-associated 
molecular patterns (PAMPs) as the bacterial protein synthesis is initiated with N-formyl 
methionine (fMet)284. These PAMPs are recognised by specialised receptors on the innate 
immune cells, including TLRs and FPRs229. The E. coli-derived tripeptide fMLF was one of 
the first characterised chemotactic formyl peptide and is the most frequently used to study 
neutrophil functions. It is the smallest N-formyl peptide that displays potent agonistic activities 
towards FPRs. In addition to its chemotactic responses in leukocytes, fMLF can induce 
intestinal epithelial cell migration and can regulate epithelial restitution and wound healing. 
These responses are mediated through FRP1. N-formyl peptides that derived from other 
bacterial strains have been identified, and these include pentapeptide fMIVIL from Listeria 
monocytogenes and a tetrapeptide fMIFL derived from Staphylococcus aureus and 
Mycobacterium avium-derived peptide fMFEDAVAWF285. Several other pathogen-derived 
nonformyl peptides have been identified to act upon FPRs. For instance, Hp (2–20), a peptide 
derived from Helicobacter pylori, has been shown to induce proliferation and the expression 
of vascular endothelial growth factor (VEGF) in gastric epithelial cells, suggesting that this H. 
pylori peptide may promote gastric mucosal healing234. Furthermore, it has been shown that 
HIV-1 envelope proteins can interact with FPRs286. Other peptides from viral strains have been 
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identified to interact with FPRs, including gG-2p20, which is derived from Herpes simplex 
virus type 2 (HSV-2)234.  
 
In addition to pathogen-derived peptides, FPRs can bind a variety of host-derived 
peptides. These include mitochondria-derived N-formyl peptides that can attract leukocytes to 
sites of inflammation and tissue damage. Among these, the N-formylated hexapeptides 
corresponding to the N terminus of mitochondrial NADH dehydrogenase subunits 4 
(fMLKLIV) and 6 (fMMYALF), and cytochrome c oxidase subunit I (fMFADRW).  All of 
which can act on both FPR1 and FPR2/ALX while fMMYALF can also act on FPR3235. 
Moreover, fMYFINILTL and its nonformylated fragment (MYFINILTL) that derived from 
mouse NADH dehydrogenase subunit 1 act on FPR2/ALX287.  
 
Another class of host-derived peptides that act on FPRs includes endogenous peptides 
associated with inflammatory and bacterial responses. These include the human cathelicidin 
antimicrobial peptide LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES), 
which is expressed in human neutrophils and derived from the enzymatic cleavage of its pro-
form the human cationic antibacterial protein of 18 kDa (hCAP-18). In addition to its 
bactericidal activities, LL37 activates FPR2/ALX to promote chemotaxis in leukocytes and 
angiogenesis on endothelial cells234. This was evidenced by studies using CRAMP-deficient 
mice, wherein neovascularization was compromised during wound repair. Another 
antibacterial protein involved with FPR1 signalling is cathepsin G, which is a serine protease 
found in neutrophil granules and mediates wound healing234. These antimicrobial peptides are 
released upon cellular stimulation and aid in the recruitment of phagocytic leukocytes to the 
sites of infection and mediate the killing and clearance of the invading bacteria. In addition to 
these antimicrobial peptides, FPRs can bind peptides that play a role in the resolution of 
inflammation. Namely, annexin A1 (Anx A1, also called lipocortin I) and its terminal peptides 
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are also known to act through FPRs. Anx A1 is a glucocorticoid-regulated protein known to 
exert both pro- and anti-inflammatory activities through FPRs. It is abundantly expressed in 
neutrophils and plays a prominent role in the resolution of inflammation as it has been shown 
to induce neutrophil detachment and apoptosis288. 
 
Several other host-derived peptides have been shown to act through FPR2/ALX, some 
of which are associated with amyloidogenic diseases and chronic inflammation, including 
serum amyloid A (SAA), β amyloid peptide Aβ42, and PrP106–126. SAA is an acute-phase 
protein and its increase has been associated with inflammatory disease such as rheumatoid 
arthritis. Aβ42 is a 42-amino acid cleavage product of the amyloid precursor protein in the 
brain and is implicated in Alzheimer’s disease. PrP106–126 is a protein fragment produced in 
the brain during prion disease, which can activate leukocytes through FPR2/ALX and thus 
contribute to inflammatory response during disease. Another endogenous host-derived peptide 
that can act upon FPRs is humanin (MAPRGFSCLLLLTSEIDLPVKRRA) which  exerts 
neuroprotective activity289 and binds to FPR2/ALX and FPR3290. It has been shown that the N-
formylated humanin is more potent than the nonformylated form, demonstrating the 
significance of N-formylation in enhancing agonistic activity291.  
 
 Several synthetic peptides that are potent chemotactic agents for leukocytes have been 
identified to act through FPRs. Although physiologically-irrelevant, these peptides comprise 
beneficial pharmacological agents for the characterization of FPRs, the investigation of their 
signalling pathways, and for the development of potential therapeutic agents.  Among these, a 
hexapeptide Trp-Lys-Tyr-Met-Val-d-Met-NH2  (WKYMVm)292, which has been shown to 
stimulate lymphocytes, monocytes and neutrophils and can act on FPR1 and FPR2/ALX to a 
higher affinity, rendering it its most potent agonist293. In addition, MMK-1 
(LESIFRSLLFRVM) peptide exerts potent agonistic activity towards FPR2/ALX 
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selectively294, 295. The peptide MMWLL (Met-Met-Trp-Leu-Leu) is also identified as a potent 
FPR1 agonist, which is 1000-fold more potent upon N-formylation296. This demonstrates the 
preferential recognition of N-formylmethionine-containing peptides by FPR1. Several 
synthetic nonpeptide compounds that act through FPRs have been identified. Among these, is 
a quinazolinone derivative known as Quin-C1 (4-butoxy-N-[2-(4-methoxy-phenyl)-4-oxo-1,4-
dihydro-2H-quinazolin-3-yl]-benzamide) is a highly selective agonist for FPR2/ALX and 
induces chemotaxis and calcium mobilization in neutrophils297. Additionally, a series of 
compounds were shown to exert anti-inflammatory properties through FPR2/ALX, including 
the two pyrazolones (Compound 24 and 43)298. Other synthetic nonpeptide compounds that act 
through FPR2/ALX include Compounds 1 and 2, and arylcarboxylic acid hydrazide 
derivatives, which were shown to induce the production of TNFα by macrophages299. 
Nonpeptides that act through FPR1 have been also identified including AG-14, which has been 
shown to activate neutrophils at nanomolar concentration300.  
 
  One of the first described lipid ligands for FPR2/ALX is the endogenous lipoxin A4 
(LXA4) (5S,6R,15S-trihydroxy-7,9,13-trans-11-eicosatetraenoic acid) which is biosynthesised 
from arachidonic acid and is shown to exert anti-inflammatory and pro-resolving activities in 
various inflammatory cells301. LXA4 acts through FPR2/ALX to induce apoptosis and 
phagocytosis302, attenuate neutrophil activity303, inhibit production of pro-inflammatory 
cytokines304, promote detachment of adherent leukocytes305 and inhibits neutrophil infiltration 
255, 306, 307. Furthermore, LXA4 has been shown to reduce inflammation-induced pain in various 
pathological conditions, including ischaemia/reperfusion injury, dermal cystic fibrosis, 
inflammation, infections and colitis308.  
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  1.5.3.2 Antagonists for FPRs 
The pivotal roles of FPRs in the regulation of microbial infections, host immune 
defence and inflammatory responses suggest that targeting such receptors may attenuate 
complications associated with diseases where FPRs play critical roles. Several antagonists for 
FPRs have been identified and include pathogen-derived, host-derived and synthetic 
compounds. Among these is the fungus-derived inverse agonists cyclosporin H (CsH) and A 
(CsA), which were shown to suppress fMLF-induced neutrophil stimulation activities through 
FPR1225, 309, 310. Additionally, FPR2/ALX-inhibitory protein (FLIPr) derived from 
Staphylococcus aureus directly binds both FPR1 and FPR2/ALX and inhibits fMLF-induced 
cell activation274. Additional pathogen-derived peptides that exert antagonistic activity for 
FPR1 include bacteria-derived chemotaxis inhibitory protein of S. aureus (CHIPS), and 
retrovirus-derived immunosuppressive hexapeptide LDLLDL311. The release of peptides by 
pathogens that exhibits antagonistic activities reveals mechanisms by which these pathogens 
may invade host defence. Host-derived endogenous antagonists for FPR1 have been identified 
and these include the bile acids deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) 
and the opioid spinorphin (LVVYPWT)312-315.  
 
 In addition to pathogen- and host-derived antagonists for FPRs, several synthetic 
compounds have been identified. Previous studies have indicated that the replacement of the 
N-formyl group of fMLF with tertiary butyloxycarbonyl group (t-Boc) converts the peptide 
into an antagonist316. Both t-Boc-Met-Leu-Phe (Boc-1) and t-Boc-Phe-d-Leu-Phe-d-Leu-Phe 
(Boc-2) were originally demonstrated as  selective antagonists for FPR1 when used at low 
concentrations316. However, several studies have demonstrated an inhibitory response of Boc-
2 to FPR2/ALX when used at high concentrations (100 μM)305, 317-320.  It was later demonstrated 
that Boc-2 is a pan-antagonist that partially inhibits FPR2/ALX at high micromolar 
concentrations in addition to FPR1321. A more selective antagonist for FPR2/ALX was later 
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identified, this includes the peptide WRWWWW (WRW4)321, 322. In addition to WRW4, the 
cell-permeable antagonist PBP10, which is derived from a PIP2-binding domain of the 
cytoskeleton protein gelsolin, demonstrates FPR2/ALX antagonistic activity by acting on the 
intracellular domains in the receptor. Quin-C7, which is developed through chemical 
modification of the FPR2/ALX agonist Quin-C1, is also identified as a highly selective 
FPR2/ALX antagonist323.  
 
1.5.4 Role of FPRs in health and disease 
 
 Given the ubiquitous expression of FPRs and their interaction with a wide variety of 
ligands, they have been associated in various pathological conditions, including acute and 
chronic inflammation, ischaemia–reperfusion injury324, atherosclerosis325, inflammatory bowel 
disease326, neurodegenerative disease327, diabetes and cancer244, 328, 329.  
 
 FPRs play indispensable roles in the regulation of inflammation and resolution. This is 
evidenced by findings on Fpr1-deficient mice, wherein exacerbated infection and increased 
mortality were observed in these mice upon bacterial infection256, 257. Moreover, Fpr2/3 
deficiency caused an increase in inflammatory responses in multiple mouse inflammation 
models259. During acute inflammation, several inflammatory responses including adhesion and 
cellular transmigration are regulated by FPRs330, 331. FPR1 exerts antimicrobial responses upon 
binding with pathogen-derived peptides, such as the bacterial chemotactic peptide fMLF240, 332. 
Moreover, the endogenous antimicrobial peptide, LL37, is released from host cells and can 
interact with FPR2/ALX333. The dysregulated expression of these peptides has been associated 
with many pathological conditions, including the overexpression of LL37 in chronic skin 
inflammatory disease, such as psoriasis and the overexpression of fMLF in inflammatory 
bowel disease and metabolic diseases. Additionally, annexin A1 (ANXA1), which can exhibit 
both pro- and anti-inflammatory roles can interact with both FPR1 and FPR2/ALX to exert its 
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functions and has been associated with chronic inflammation334, 335. Another class of ligands 
that can interact with FPR2/ALX are lipoxins and resolvins, which play indispensable roles in 
the resolution of inflammation and anti-inflammatory responses336. Taken together, these 
demonstrate the critical role of FPRs in the regulation of inflammation and resolution, which 
can progress into pathophysiological responses if not regulated properly. 
 
FPRs are also associated with neurodegenerative diseases and amyloidosis. FPR2/ALX 
interacts with amyloid-related peptides such as SAA, Aβ42, and PrP106–126. These peptides 
are elevated in inflammatory settings and can exacerbate inflammation and lead to organ 
damage. This may also contribute to the progression of Alzheimer's disease. Additionally, 
humanin has been shown to interact with FPR2/ALX to exert neuroprotective roles by 
competing with Aβ42 for binding to FPRs and inhibiting their effects290, 291. Moreover, 
FPR2/ALX has been associated with the progression of inflammation in prion disease337. 
 
FPRs were also shown to be implicated in acquired immune deficiency 
syndrome (AIDS), wherein the recombinant HIV-1 gp120 and gp41 have been shown to 
suppress the expression and function of FPRs338, 339. It has been shown that FPR ligands such 
as SAA and fMLF can significantly reduce the fusion and infection of HIV-1340. Thus, it has 
been suggested that FPR ligands may be useful for the development of anti-HIV-1 agents. In 
addition, FPRs have been implicated in metabolic disorders, including diabetes and obesity. It 
has been shown that the elevated levels of fMLF can contribute to glucose intolerance and 
insulin resistance via FPR1341. On the other hand, it has been shown that RvD1 via FPR2/ALX 
can enhances glucose tolerance, restore systemic insulin sensitivity and prevent macrophage 
accumulation in adipose tissue in obesity-induced diabetes animal model342. 
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Inflammation is closely associated with cancer. Many inflammatory cells are involved 
in the regulation of tumour cell proliferation, metastasis and survival343. FPRs have been shown 
to play a role in the tumour growth and the progression of angiogenesis225, 344. In particular, 
ANXA1 was found to promote the growth of glioblastoma via the activation of FPR1345. 
Additionally, acute-phase reactant SAA and antimicrobial LL37346  have been implicated in 
tumourigenesis347-349. On the contrary, LXA4 and its analogue, BML-111, have been shown to 
exert anti-tumour effects350-352. Studies have found that these compounds can inhibit VEGF 
accumulation, tumour growth and angiogenesis and promoted apoptosis of tumours in vivo353, 
354. Collectively, these findings uncover novel therapeutic strategies for the treatment of a broad 
spectrum of diseases associated with FPRs. 
 
1.6 Bacterial peptide fMLF 
1.6.1 Definition and function  
 
 
N-formyl peptides are produced from the degradation of bacterial or mitochondrial 
proteins355. While FPR1 binds with high affinity to bacterial-derived N-formyl peptides, 
FPR2/ALX binds those derived from mitochondria234, 235. The ligation of N-formyl peptides to 
FPRs in immune cells triggers a cascade of signalling pathways, resulting in a number of 
biological activities. Escherichia coli-derived fMLF is one of the most potent chemotactic 
peptides that facilitates innate immune responses against bacteria via FPR1 signalling241, 242, 
356. During infection, invading bacteria produce N-formyl peptides that facilitate the 
recruitment of immune cells to the site of bacterial infection and tissue damage, expediting 
rapid clearance of microbial infection and tissue damage repair357. fMLF is known to act 
mainly through FPR1 in immune cells234. The stimulation of neutrophils with fMLF induces a 
wide variety of cellular responses leading to cell migration and chemotaxis, superoxide anion 
generation and granule secretion358, 359. This triggers the release of inflammatory mediators 
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including the platelet-activating factor (PAF) Acetyl-glyceryl-ether-phosphoryl-
choline (AGEPC)360, proteases such as cathepsin G361 and ROS 362, which mediate pathogen 
killing but can ultimately cause severe tissue injury at the site of infection363. Apart from its 
stimulatory role in neutrophils, fMLF has been shown to induce platelet chemotaxis through 
FPR1 to mediate innate immune responses71.  
1.6.2 Role of fMLF in disease 
 
Despite the ability of fMLF to mediate innate immune responses, it has been associated 
with the pathogenesis of microbial infection and inflammatory conditions. It has been 
implicated in bacterial cystitis364, pneumococcal pneumonia365, inflammatory bowel diseases 
(IBDs)366, pouchitis, colitis367 and juvenile peridontitis368. Furthermore, it has been shown that 
the inhalation or injection of fMLF may cause bronchial inflammation369, and induce rapid 
neutropenia, increasing susceptibility to infections370. Since the intestinal microbiota is a major 
source of enteric E.coli, and the disruption of its homeostasis has been widely implicated in the 
pathogenesis of IBDs, where the effect of fMLF in exacerbating the progression of this disease 
has been reported356. Moreover, fMLF (at concentrations of 1 nM to 1 µM) induced 
spasmogenic effects, which can contribute to abdominal cramps. The concentrations of fMLF 
in intestinal milieu has been reported to be at least in the micromolar range371. The implication 
of fMLF in glucose intolerance was also observed, wherein high-fat diet-fed mice displayed 
elevated plasma levels of circulating fMLF, sourced from enteric bacteria, which impaired 
glucose tolerance and insulin secretion341. Many of these infectious and inflammatory 
conditions are associated with a risk for platelet reactivity and thrombotic events that can 
contribute to cardiovascular complications372-374.  
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1.6.3 Emerging role for fMLF in platelet function 
 
A role for fMLF, albeit indirect, on the regulation of the haemostatic platelet function 
has been previously explored. fMLF has been shown to induce the upregulation of adhesion 
molecules375 and severe cell aggregation in neutrophils376.  This in turn may activate platelets 
and facilitates their adhesion to leukocytes and the endothelium within the blood vessel wall. 
The interaction between platelets and leukocytes can lead to the formation of heterotypic 
aggregates with leukocytes, known as platelet-leukocyte aggregates (PLAs), and may modulate 
their functions81. PLAs are mainly driven by the ligation of P-selectin on the surface of 
activated platelets with P-selectin glycoprotein ligand-1 (PSGL-1) on the leukocyte surface377. 
Other modes of interaction between platelets and leukocytes have been suggested and include 
platelet integrin αIIbβ3 binding to the neutrophil Mac-1 via fibrinogen as well as direct binding 
of Mac-1 on neutrophils to platelet GPIbα. These interactions consequently trigger signals that 
amplify prothrombotic and proinflammatory responses378. In line with this, fMLF has been 
shown to induce PLA formation379, and several reports indicate that this is driven by linking 
via fibrinogen (as evidenced by the blockade of αIIbβ3380) and P-selectin381. Moreover, 
previous studies have reported the aggregation of platelets in response to fMLF-induced 
neutrophil stimulation382-384. These findings were attributed to the release of mediators such as 
platelet-activating factors (PAFs)385 and cathepsin G361, 386, consequential to fMLF-induced 
neutrophil stimulation, that can directly activate platelets and subsequently induce their 
aggregation380, 384.  
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1.7 Antimicrobial peptide LL37 
 
1.7.1 Definition and function  
 
 Cathelicidins are a group of endogenous cationic peptides ranging from 12-97 amino 
acids. They are also referred to as host defence peptides (HDPs) or AMPs, and play a crucial 
role in innate immune defence. They exhibit various functions including direct antimicrobial 
activity against bacteria, viruses, fungi, and parasites. In addition to anti-inflammatory 
activities, they exert immunomodulatory responses. Cathelicidins are widely distributed in 
both invertebrates and vertebrates, and are characterised by their pre-pro peptide sequences. 
All cathelicidins have a highly homologous prosequence at their N-terminus (a cathelin-like 
domain) followed by a highly variable C-terminal mature peptide. They are paradoxically 
termed so because their N-terminal signal peptide (a highly conserved prosequence) is 
homologous to that of cathelin, a 96-amino acid isolated from porcine neutrophils that acts as 
a cathepsin L protease inhibitor387-389. It was later shown that cathelidicins do not exert protease 
inhibitory roles but display anti-infective roles390.  
 
In order to be biologically active, cathelicidins need to undergo proteolytic processing 
that leads to the liberation of the mature peptide. They are initially synthetized as pre-
propeptides containing the signal sequence, cathelin domain and the mature peptide. The signal 
sequence transports the propeptide to the granules or cell membranes. In neutrophils, the pre-
propeptides are inactive and are stored at high concentrations in the azurophilic granules. Upon 
the activation of neutrophils, it undergoes proteolytic processing by appropriate proteases to 
liberate a biologically active, mature peptide391. This proteolytic cleavage is processed by 
serine proteases such as elastases, proteinase 3 and kallikreins392. Once the mature peptide is 
released, it becomes resistant to proteolytic degradation391. Cathelicidins are widely distributed 
in a variety of tissues and cells including skin, intestine, lungs, mucosa and oral cavity. They 
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are also largely found in the unprocessed form (pre-pro) in the granules of neutrophils as well 
as epithelial cells, mast cells, keratinocyte and lymphocytes. In their processed forms, they are 
found in various body fluids, including plasma, saliva, sweat, gastric juice, breast milk, semen 
and airway surface liquid393, 394. 
 
1.7.2 Human Cathelicidins  
The only cathelicidin expressed by humans is the human cationic antimicrobial peptide 
of 18 kDa (hCAP18), which is encoded by the CAMP gene (chromosome 3p21.3)388, 395. The 
expression of hCAP18 is transcriptionally controlled by inflammation, Vitamin D metabolites, 
and endoplasmic reticulum stress via NF-κB activation396. Once the pre-propeptide is 
translated, it undergoes cleavage of the signaling sequence, resulting in the mature hCAP18 
form. This form is then further processed by proteolytic enzymes (by proteinase 3 in 
neutrophils and kallikreins in keratinocytes) to liberate the mature, biologically active peptide 
LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES), which is named to its 37 
amino acid length and two leading leucine residues397-399. The α-helical structure of the peptide 
assembles into dimers or trimers, thus avoiding peptide degradation400. It facilitates the 
penetration and destabilisation of bacterial membranes, and generation of transmembrane 
pores401-404. Moreover, LL37 neutralises endotoxin by direct binding, and exhibits chemotactic 
activity for human neutrophils, monocytes, and resting T cells mediated by FPR2/ALX333.   
 
LL37 is expressed in various immune cells, including neutrophils, macrophages, 
dendritic cells, NK cells and epithelial cells. It is secreted in response to infection, pro-
inflammatory stimuli and/or injury in keratinocytes126. The dysregulated expression of LL37 
has been implicated in various pathological conditions. For instance, LL37 is upregulated in 
chronic inflammatory diseases, including Crohn’s disease405, 406, rheumatoid arthritis407, 
psoriasis408 and eczema409. Its downregulation has been implicated in enteric infection410, acute 
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myeloid leukaemia411, 412, atopic dermatitis128, 413 and chronic epithelial ulcers414. Additionally, 
patients suffering from Kostmann disease, an autosomal recessive disorder characterized by 
severe neutropenia and early onset of bacterial infections, report deficiency in LL37415. 
 
1.7.3 Mouse Cathelicidins 
Similar to humans, mice solely express one cathelicidin, which is encoded by the Camp 
gene (chromosome 9) and shares 80% sequence homology with its human orthologue hCAP18. 
The mouse cathelin-related antimicrobial peptide (mCRAMP), a 34 amino acid 
(GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ)415, is processed to release an active 5 
kDa amphipathic peptide compromised of two α-helices that are joined by a flexible region. 
Unlike hCAP18, mCRAMP is not transcriptionally regulated by vitamin D metabolites. 
Despite differences in peptide sequence, mCRAMP exhibits significant similarities to human 
LL37, which renders it a useful model to investigate the function and regulation of human 
cathelicidins416. 
Several studies supported by CRAMP-deficient mice demonstrate the pivotal role of 
cathelicidins in bacterial defence417-420. These mice were more susceptible to bacterial and viral 
infection, including P.aeruginosa, E.coli, Citobacter rodentium, Klebsiella pneumonia, 
vaccinia virus (VV) and influenza (IAV), and are prone to increased disease severity419, 421-425. 
Similarly, these mice have increased colonisation and invasion of pathogenic bacteria in the 
colon421  and are more susceptible to urinary tract infections419. Moreover, these mice display 
decreased vascularisation during wound repair, this indicates that cathelicidin-mediated 
angiogenesis is important for cutaneous wound neovascularisation in vivo 426. 
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1.7.4 Role of LL37 in disease   
 
 LL37 has been implicated in various pathological conditions, including inflammatory 
bowel disease, infectious and sterile inflammation, inflammatory skin disease, autoimmune 
disease, atherosclerosis427. Given the recent advances in understanding their role in multiple 
pathological conditions, cathelicidins can act as potential targets for the development of 
therapeutic strategies. The therapeutic potential of cathelicidins against infections have been 
explored428. LL37 demonstrates a promising target for the development of therapeutic agents 
as a substitute to systemic antibiotics429. Additionally, cathelicidin derivates were shown to not 
only provide improved therapeutic potential, but also eliminate the undesirable cytotoxic 
effects associated with natural cathelicidins. For instance, Omiganan, a bovine cathelicidin 
derivative, has been found greatly effective against pathological inflammatory conditions and 
infections in clinical trials394. In addition to infections, the utilisation of cathelicidins in wound 
healing has been explored. The application of cathelicidins have been shown to promote 
angiogenesis and re-epithelialisation and angiogenesis in gastrointestinal disorders430.  In 
addition, a novel use of cathelicidin as vaccine adjuvants has been proposed394. LL37 fragments 
has also been proposed for the development of anticancer drugs since it can suppress tumour 
growth in gastric cancers431. The evolving role of LL37 in multiple autoimmune diseases, 
renders it a potential target for the modulation of immune responses. Given the roles of LL37 
on TLR signalling, it may provide a therapeutic strategy in pathological conditions associated 
with such signalling pathways. In particular, the neutralisation of TLR signalling was an 
effective strategy in diseases such as sepsis, colitis, psoriasis and chronic pain432. In addition 
to the development of therapeutic agents, cathelicidins can act as biomarkers for disease. LL37 
may serve as a biomarker for inflammatory conditions such as inflammatory skin disease and 
chronic pulmonary disease409, 433.  
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1.7.5 Role of LL37 in psoriasis 
 
 As described previously, psoriasis is associated with the hyperproliferation of 
keratinocytes, inflammation of skin, increased cytokine production including type I interferons 
and the overexpression of AMPs including LL37112, 434. The upregulation of LL37 expression 
was first reported in 1997, wherein it was suggested that this induction is associated with a 
protective role in disease and that it plays a role in antimicrobial defence435. Contrasting to 
normal skin or skin from other inflammatory skin diseases, psoriatic lesions express 
cathelicidin in the form of LL37 exclusively436. Moreover, the level of LL37 in normal skin 
was minimal compared of that to inflamed skin from rosacea patients437. The normal skin 
mostly expresses cathelicidins (not in the form of LL37) at low levels.  In inflammatory skin 
disease such as rosacea, the level of cathelicidin increases and is usually associated with 
different forms of cathelicidin437. Whereas in psoriasis, cathelicidins are upregulated and are 
expressed exclusively in the form of LL37.  Another study has suggested that the increased 
upregulation of LL37 in psoriatic lesions is associated with low rate infection, where patients 
were found to be more susceptible to bacterial and viral infections due to the dysregulated 
expression of AMPs128. It was later proposed that LL37 plays an immune-modulatory role in 
psoriasis, where it was shown to modulate inflammation by directly activating plasmacytoid 
dendritic cells (pDCs) and myeloid dendritic cells (mDCs) and forming self-DNA and -RNA 
complexes, which leads to the activation of TLR8 in mDCs, and TLR7 and TLR9 in pDMs127, 
438 . The activation of TLR9 in turn leads to the overproduction of type I interferons (IFN-α 
and IFN-β)112. Moreover, it has been shown that LL37 reduces apoptosis in keratinocytes, 
which may also contribute to their hyperproliferation in psoriasis and exacerbation of 
inflammatory responses439. Serum levels of LL37 are also shown to be higher than normal in 
psoriatic patients and were reduced upon treatment with CsA440. 
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1.7.6 Role of LL37 in atherosclerosis 
 
In addition to psoriasis, the role of LL37 has been implicated in atherosclerosis, which 
is associated with innate immune responses including upregulation of type I interferons, which 
contribute to the development of atherosclerotic plaques and disease pathogenesis441-444. 
Similar to psoriasis, the upregulation of LL37 contributes to the development of atherosclerotic 
lesions in atherosclerosis445. It has been shown that LL37 plays a key role in the modulation of 
cytokines and the recruitment of inflammatory cells to atherosclerotic plaques. Notably, LL37 
promotes the production of type I interferon445. Furthermore, atherosclerotic aortas in humans 
demonstrate increased transcription of LL37446. This was also associated with increased 
apoptosis of vascular smooth muscle cells in humans447. The association of cathelicidins with 
atherosclerosis has also been demonstrated in mice. In studies using pro-atherosclerotic 
apolipoprotein E (apoE)-deficient mice, the levels of neutrophil-associated mCRAMP were 
elevated in the carotid arteries of mice fed with high-fat chow. Moreover, these mice 
demonstrate significant protection in plaque size and recruitment of macrophages upon 
crossing to mice strains deficient in mCRAMP448. LL37 also contributes to the recruitment of 
inflammatory cells by activating endothelial cells and the upregulation of ICAM-1 in 
atherosclerosis, this in turn leads to the recruitment of inflammatory cells to the site if 
inflammation and may cause prothrombotic responses426. 
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1.7.7 Emerging role for LL37 in platelet function 
  
Only three studies have explored the direct role of LL37 in the regulation of platelet 
function. In 2006, Bucki and Janmey demonstrated the role of lipopolysaccharides (LPS) and 
lipoteichoic acid (LTA) on several endogenous antimicrobial peptides, including PBP 10, 
mellitin, magainin II and LL37402. In an effort to demonstrate the mechanisms by which PBP 
10 triggers bacterial killing, it was compared to the aforementioned AMPs. In this study, the 
cytotoxic activity of such peptides on circulating blood cells including red blood cells (RBCs) 
and platelets was investigated. Only mellitin (5 uM) demonstrated cytotoxicity towards 
platelets; LL37 (5 uM) failed to exert any cytotoxicity towards platelets. Additionally, LL37 
(5 uM) failed to aggregate platelets on its own and demonstrates no effects on thrombin-
induced aggregation of gel-filtered platelets. LL37 (1 or 5 uM) also failed to exert any effect 
on calcium mobilisation using Fura-2-labelled platelets.  
 
In 2016, Su et al. suggested an inhibitory role for LL37 in the regulation of platelet 
function449. The study shows that LL37 inhibits the aggregation of gel-filtered human platelets 
upon stimulation with ADP (10 μM), collagen (2 μg/mL), thrombin (0.26 U/mL) or U46619 
(3 μM). Moreover, the study demonstrates that LL37 inhibits alpha-granule secretion induced 
by the aforementioned platelet agonists. Additionally, LL37 demonstrated antithrombotic 
effects in an arterio-venous shunt thrombosis model in mice. In addition, platelet spreading on 
immobilized fibrinogen was inhibited by pretreatment with LL37 (0.3, 0.6 and 1.2 mM). The 
study suggested the involvement of Src/PI3K/Akt signalling as evidenced by changes in 
phosphorylation upon pretreatment with LL37 (0.6 mM).  The findings in this study are likely 
to be improbable; as the concentration of LL37 are exceptionally high and are not 
physiologically-relevant and even more so have been reported to exert cytotoxicity towards 
various eukaryotic cells401.   
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On the contrary, a recently published study by Pircher et al. in 2018 demonstrated the role 
of LL37 in thrombo-inflammation450.  This study demonstrates a priming role for LL37 in 
platelets, which was evidenced by reduced platelet activation and arterial thrombosis in 
CRAMP-deficient mouse models. Moreover, LL37 induced alpha-granule secretion evident by 
P-selectin expression. However, LL37 failed to exert a direct effect on platelet aggregation, 
and did not affect collagen- ADP-, or thrombin receptor activating peptide (TRAP)-induced 
platelet aggregation in platelet-rich plasma (PRP). In addition, LL37 failed to induce fibrinogen 
binding or platelet spreading on immobilized fibrinogen. In an attempt to explore the signalling 
mechanisms underlying such effects, the FPR2/ALX signalling was explored amongst other 
pathways. Notably, the inhibition of such signalling by an FPR2/ALX-selective inhibitor, 
WRW4, did not affect LL37 effects. It is worth noting that none of the studies mentioned above 
explored the effects of LL37 on FPR2/ALX signalling on platelets except for Pircher et al., 
wherein a very low concentration (1 uM) of WRW4 was used. 
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1.8 Resolving protein Annexin A1  
 
1.8.1 Definition and function 
 
Annexin A1 (AnxA1) is a 37 kDa pro-resolving protein that belongs to the annexin 
superfamily451. Annexins are calcium-dependent phospholipid binding proteins that share two 
distinctive regions; the core and the amino (N)-terminus. The core region is highly conserved 
between the annexin subfamilies, while the N-terminal sequence is unique to each protein452.  
It is a glucocorticoid-regulated protein that is known to play a role in the regulation of 
inflammation, and cell proliferation, differentiation and apoptosis453.  It is expressed in the 
cytosol of various resting cells including neutrophils, monocytes, macrophages and epithelial 
cells288. Furthermore, a limited number of studies have reported its expression in platelets454, 
455. The activation of such cells leads to the externalisation of AnxA1 on the cell membrane 
and/or its secretion456. The extracellular AnxA1 then undergoes conformational changes, 
exposing its active form, the N-terminal region that mediates the binding to FPR2/ALX335, 457. 
The externalisation and secretion of AnxA1 is typically accompanied by a proteolytic cleavage 
of its N-terminal region458-460, such cleavage is implicated with the down-regulation of AnxA1, 
rather than the release of bioactive peptides. This was validated in a study whereby a cleavage-
resistant AnxA1, termed Super Annexin A1 (SAnxA1), retained a prolonged function in the 
microvasculature461. While the full-length N-terminus has been shown to be inactive, a 
synthetic peptide containing the first 26 amino acids of its sequence displayed functionality462. 
The N-Acetyl 2–26 (Ac2-26) has been shown to act as a pharmacophore463  and plausibly 
maintain the properties of the full-length protein305, 461, 464-467. Nonetheless, a limited number 
of studies reported an opposing effect334, 468, 469. Both full-length and cleaved forms of the 
protein have been found in inflammatory exudates and other extracellular biological fluids470-
473. 
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1.8.2 Role of Annexin A1 in disease 
 
AnxA1 has been shown to play a protective role in various inflammatory diseases that 
are associated with platelet reactivity474, including atherosclerosis475-479, myocardial 
infarctions480, 481 and strokes260, 261, 465, 478, 482. Furthermore, the dysregulation of AnxA1 
expression has been implicated in various pathological conditions; its up-regulation is 
reported in cancer483, melanoma484, breast cancer485-487, periods of remission in ulcerative 
colitis488, and its downregulation in Crohn’s disease489, thyroid cancer490,  signifying its 
prognostic significance and therapeutic efficacy. Conversely, a pathogenic role of Ac2-26 has 
been previously described in cancer, wherein it facilitated metastasis/pro-invasiveness491, and 
in rheumatoid arthritis, where it facilitated the secretion of matrix metalloproteinases 
(MMPs)468.  
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1.9  Hypothesis  
 
Formyl peptide receptors regulate haemostasis in platelets through the modulation of 
thrombus formation and haemostasis. The chemotactic bacterial peptide fMLF primes platelet 
activation and modulates thrombus formation through FPR1. The antimicrobial peptide LL37 
exhibits prothrombotic effects and thus may implicate the pathogenesis of cutaneous 
inflammatory diseases such as psoriasis through interaction with platelets via FPR2/ALX. The 
Annexin A1 N-terminal peptide, Ac2-26, affects platelet haemostasis through FPR2/ALX. 
 
1.10  Research objectives  
 
The aim of this study is to determine the role of formyl peptide receptors in the 
regulation of platelet function. Thus, the main objectives of this study: 
• Investigate the role of a range of FPR ligands in the activation of platelets, and 
analyse the signalling mechanisms that regulate these effects 
• Determine the role of bacterial formyl peptide fMLF in the regulation of platelet 
function via FPR1 
• Determine the role of antimicrobial peptide LL37 in the regulation of platelet 
function via FPR2/ALX, and its role in modulating platelet function during inflammatory 
disease such as psoriasis 
• Determine the role of resolving protein Annexin A1 in the regulation of platelet 
function via FPR2/ALX 
  1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
2 – The formyl peptide fMLF primes platelets and 26 
augments thrombus formation selectively via formyl 27 
peptide receptor 1 28 
49 
 
 1 
The formyl peptide fMLF primes platelets and augments thrombus 2 
formation selectively via formyl peptide receptor 1 3 
 4 
Maryam F. Salamah1, Divyashree Ravishankar1, Rajendran Vaiyapuri2, Ketan Patel3, Mauro Perretti4, 5 
Jonathan M. Gibbins3 and Sakthivel Vaiyapuri1 6 
1School of Pharmacy, University of Reading, Reading, United Kingdom 7 
2School of Pharmacy, University of Reading Malaysia, Johar, Malaysia 8 
3School of Biological Sciences, University of Reading, Reading, United Kingdom 9 
4William Harvey Research Institute, London, United Kingdom 10 
 11 
Corresponding author: Dr Sakthivel Vaiyapuri, School of Pharmacy, University of Reading, 12 
Reading, United Kingdom. Phone: +44 118 378 8015; Email: s.vaiyapuri@reading.ac.uk     13 
 14 
2.1 Abstract 15 
 Formyl peptide receptors (FPRs) are a group of G protein-coupled receptors that play pivotal 16 
roles in the regulation of innate immunity and host defence. FPRs include three family members; 17 
FPR1, FPR2/ALX and FPR3. The activation of FPR1 by its high affinity ligand, N-formyl-methionyl- 18 
leucyl-phenylalanine (fMLF) (a bacterial chemoattractant peptide), triggers intracellular signalling in 19 
immune cells such as neutrophils and exacerbates inflammatory responses to accelerate the clearance 20 
of microbial infection. Notably, fMLF has been demonstrated to induce intracellular calcium 21 
mobilisation and chemotaxis in platelets that are known to play significant roles in the regulation of 22 
innate immunity and inflammatory responses. Despite a plethora of research focused on the roles of 23 
FPR1 and its ligands such as fMLF on the modulation of immune responses, their impact on the 24 
regulation of haemostasis and thrombosis remains unexplored. Here, we demonstrate the effect of 25 
fMLF on the modulation of platelet reactivity, haemostasis and thrombus formation. fMLF primes 26 
platelet activation through inducing distinctive function and enhances thrombus formation under 27 
arterial flow conditions. By using selective inhibitors for FPR1 and Fpr1-deficient mice, we have 28 
established a fundamental role for FPR1 in the regulation of fMLF-mediated effects in platelets. 29 
Moreover, FPR1 regulates normal platelet function as its deficiency in mouse or blockade in human 30 
platelets using a pharmacological inhibitor resulted in diminished agonist-induced platelet activation. 31 
Since FPR1 plays critical roles in numerous disease conditions, its influence on the modulation of 32 
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platelet activation and thrombus formation will provide insights into the mechanisms that control 1 
platelet-mediated complications under diverse pathological settings.  2 
2.2 Introduction 3 
Platelets are small circulating blood cells that play indispensable roles in the regulation of 4 
haemostasis to prevent excessive bleeding upon vascular injury. However, their unwarranted 5 
activation under pathological conditions leads to the formation of blood clots (thrombi) within the 6 
circulation1. This results in reduced/retarded blood supply to vital organs including the heart and 7 
brain, which leads to heart attacks or strokes, respectively2. Moreover, platelet activation during 8 
microbial infection results in their aggregation, thrombus formation in the microvasculature and in 9 
later stages, sequestration of platelets in organs such as the lungs, instigating thrombocytopenia and 10 
bleeding complications3. In addition to their prominent roles in haemostasis and thrombosis, platelets 11 
play a crucial role in the regulation of innate immunity, inflammatory responses and clearance of 12 
microbial infection4-6. Platelets contain a broad spectrum of receptors that induce inflammatory 13 
responses during microbial infection and other pathological conditions. In addition, platelets secrete 14 
various inflammatory and immunomodulatory molecules from their granules upon activation. They 15 
also possess antimicrobial proteins including thrombocidins, cathelicidins and human β-defensins 16 
that trigger direct microbicidal activities4. Furthermore, platelets can directly bind and internalise 17 
invading microbes7. The presence of major inflammatory molecules such as formyl peptide (FPRs) 18 
and toll-like receptors (TLRs) facilitates platelets to recognise a diverse array of endogenous damage- 19 
associated molecular patterns (DAMPs) and exogenous pathogen-associated molecular patterns 20 
(PAMPs). Collectively, these properties render platelets effector and sentinel cells in primary host 21 
defence against invading pathogenic microbes7, 8. 22 
FPRs belong to a family of G protein-coupled receptors (GPCRs) and are predominantly 23 
expressed in immune cells, where they play a prominent role in the regulation of inflammatory 24 
responses and host defence. In humans, three FPR family members were identified; FPR1, 25 
FPR2/ALX and FPR39. Although they were originally identified by their capability to recognise N- 26 
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formyl peptides produced from bacteria or mitochondria of damaged cells, FPRs can bind a wide 1 
variety of structurally and functionally diverse ligands. These include bacterial and mitochondrial 2 
formyl peptides, non-formylated peptides/proteins, and small lipid molecules10. While FPR1 binds to 3 
bacterial-derived N-formyl peptides with high affinity, FPR2/ALX largely binds to mitochondrial 4 
formyl peptides9, 11. The ligation of N-formyl peptides to FPRs in immune cells triggers a range of 5 
signalling cascades resulting in numerous biological activities. For example, the stimulation of FPR1 6 
by N-formyl-methionyl-leucyl-phenylalanine (fMLF) in neutrophils induces degranulation, 7 
chemotaxis, production of superoxide anions, calcium mobilisation, cytokine release and expression 8 
of various surface markers12, 13. During microbial infection, invading bacteria release N-formyl 9 
peptides that facilitate the recruitment of immune cells to the site of infection and accelerate the 10 
clearance of microbial infection and repair of tissue damage14.  11 
Czapiga et al.15 reported the presence of FPR1 in platelets and its ability to induce chemotactic 12 
and migratory responses upon ligation with N-formyl peptides, which emphasise a crucial role for 13 
FPR1 in platelet-mediated immune responses. Notably, bacterial or synthetic fMLF has been shown 14 
to act as a potent chemotactic agent through FPR1 in platelets. Despite numerous reports on the 15 
immune functions of FPR1, its impact upon ligation with fMLF on the modulation of haemostasis 16 
and thrombosis remains uncharacterised. Here, we report the ability of fMLF to prime platelets and 17 
augment thrombus formation, and the significance of FPR1 in the regulation of platelet function in 18 
the presence and absence of fMLF.  19 
 20 
  21 
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2.3 Results 1 
 2.3.1 Platelets express FPR1 2 
The expression of FPR1 in human platelets at protein level, and in megakaryocytes at 3 
transcript level has been previously reported15. Furthermore, the presence of FPR1 transcripts in 4 
human and mouse platelets was demonstrated16. In line with these findings, here we confirmed the 5 
presence of FPR1 on the surface of human platelets by flow cytometry (Figure 2-1Ai) and in platelet 6 
lysates using immunoblot analysis (Figure 2-1Aii). Notably, the activation of platelets using 1 µg/mL 7 
cross-linked collagen-related peptide (CRP-XL) increased the level of FPR1 on the surface as 8 
determined by flow cytometry, while the level of proteins identified by immunoblots remained 9 
unchanged. These data confirm the presence of FPR1 in platelets, possibly in granules or the open 10 
canalicular system (OCS) or both, and their increase on the surface upon activation.  11 
 12 
 2.3.2 fMLF selectively binds to FPR1 on the platelet surface 13 
A fluorescently-labelled fMLF (FITC-fMLF) was used to investigate its binding to FPR1 on 14 
the surface of platelets by flow cytometry. To ascertain the selective binding of fMLF to FPR1, 15 
platelets obtained from Fpr1-/- and Fpr2/3-/- (an orthologue of human FPR2/ALX) mice along with 16 
their controls were used in this assay. The absence of Fpr1 in platelets obtained from Fpr1-/- mice 17 
was confirmed by immunoblot analysis (Figure 2-1Bi). The level of Fpr1 identified in Fpr2/3-/- mouse 18 
platelets was found to be same as the controls. The binding of FITC-fMLF (5 µM) was significantly 19 
reduced in Fpr1-/- mouse platelets compared to the control and Fpr2/3-/- mice platelets (Figure 2- 20 
1Bii). These data confirm the selective binding of fMLF to Fpr1 in mouse platelets.  21 
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 1 
Figure 2-1: Expression of FPR1 in platelets. A, the expression of FPR1 on the surface of resting or 2 
CRP-XL(1 μg/mL)- activated human platelets was analysed using FPR1-selective and fluorescent- 3 
labelled secondary antibodies by flow cytometry (i). Data represent mean ± SEM (n=8). Similarly, 4 
the presence of FPR1 in human platelet lysates was confirmed by immunoblot analysis using selective 5 
antibodies (ii). B, the absence of Fpr1 was confirmed in platelet lysates obtained from Fpr1-/- in 6 
comparison to the control and Fpr2/3-/- mice by immunoblot analysis using selective antibodies (i). 7 
Platelets obtained from control, Fpr1-/- and Fpr2/3-/- mice were pre-incubated with 10 μM FITC- 8 
conjugated fMLF and their level of binding to platelet surface was measured by flow cytometry (ii). 9 
Data represent mean ± SEM (n=5). The blots shown are representative of three separate experiments. 10 
The statistical significance was calculated by two-tailed unpaired Student’s t test in data shown in 11 
panel A and by one-way ANOVA followed by Bonferroni’s correction in data shown in panel B 12 
(*p<0.01 and **p<0.001). 13 
 14 
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 2.3.3 fMLF stimulates platelet activation  1 
To determine whether fMLF is able to stimulate platelet activation upon binding to FPR1, a 2 
range of platelet functional assays were performed. Platelet activation triggers inside-out signalling 3 
to integrin aIIbb3 on the platelet surface and converts it to a high affinity state to allow fibrinogen 4 
binding and subsequent platelet aggregation17. To examine whether fMLF influences the inside-out 5 
signalling to integrin aIIbb3 platelets, the level of fibrinogen binding on the platelet surface was 6 
measured as a marker for inside-out signalling to integrin aIIbb3. Indeed, fMLF has increased the 7 
level of fibrinogen binding in human platelets [platelet-rich plasma (PRP)] in a concentration- 8 
dependent manner (Figure 2-2i). A minimum concentration of 1 µM fMLF has shown significant 9 
increase in fibrinogen binding compared to the resting platelets. Similarly, the level of P-selectin 10 
exposure on the platelet surface was measured as a marker for a-granule secretion by flow cytometry. 11 
The results indicate that fMLF has induced a-granule secretion in human platelets (PRP) in a 12 
concentration-dependent manner (Figure 2-2ii). Together, these data confirm the impact of fMLF on 13 
the modulation of platelet activation. 14 
  15 
55 
 
 1 
 2 
Figure 2-2: The impact of fMLF on platelet activation. Different concentrations of fMLF were 3 
used to determine their impact on platelet activation in human PRP by quantifying the level of 4 
fibrinogen binding (i) and P-selectin exposure (ii) using flow cytometry. Data represent mean ± SEM 5 
(n=10). The statistical significance was calculated by one-way ANOVA followed by Bonferroni’s 6 
correction (*p<0.01. **p<0.001 and ***p<0.0001). 7 
 8 
  9 
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 2.3.4 fMLF augments thrombus formation  1 
Microbial infection and various inflammatory diseases including sepsis are associated with 2 
the risk of disseminated intravascular coagulation or thrombosis in the microvasculature18. To 3 
investigate whether fMLF has a direct impact on thrombosis, its effect on thrombus formation under 4 
arterial flow conditions was analysed. Human DiOC6-labelled whole blood was pre-incubated with a 5 
control (non-formylated peptide, MLF) or fMLF (5 µM) for 10 minutes prior to perfusion over 6 
collagen-coated Vena8™ biochips. Thrombus formation was monitored for 10 minutes by acquiring 7 
fluorescent images at every 30 seconds. The images were analysed by calculating the mean 8 
fluorescence intensity. Indeed, fMLF has increased the mean fluorescence intensity of thrombi by 9 
approximately 122% compared to the controls (Figure 2-3). These data demonstrate the direct impact 10 
of fMLF on thrombus formation under arterial flow conditions in human whole blood. The effect of 11 
fMLF on other blood cells mainly leukocytes and their subsequent influence on thrombus formation 12 
cannot be ruled out under these circumstances.  13 
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 1 
Figure 2-3: The impact of fMLF on thrombus formation. The effect of fMLF on the modulation 2 
of thrombus formation was analysed by using human DiOC6-labelled whole blood that pre-incubated 3 
with a vehicle control or fMLF (5 μM) for 10 minutes prior to perfusion over collagen-coated (400 4 
μg/mL) Vena8TM Biochips. Data represent mean ± SEM (n=3). Images shown are representative of 5 
three separate experiments (10x magnification; scale bar - 10 μm). The statistical significance was 6 
calculated by two-tailed unpaired Student’s t test (**p<0.001). 7 
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 2.3.5 Agonist-induced platelet aggregation is amplified by fMLF 1 
 Following the determination of the effects of fMLF on thrombus formation and platelet 2 
activation, aggregation assays were performed to establish its effects on isolated platelets. Human 3 
isolated platelets were incubated with various concentrations of fMLF (1, 5, 10 and 20 µM) prior to 4 
stimulation with different platelet agonists such as CRP-XL (0.25 µg/mL), collagen (0.5 µg/mL) and 5 
thrombin (0.05 U/mL), and the level of aggregation was monitored for 5 minutes by optical 6 
aggregometry. Notably, fMLF has failed to induce platelet aggregation on its own (Figure 2-4A) 7 
although the pre-incubation of platelets with fMLF markedly enhanced agonists-induced platelet 8 
aggregation. Maximum aggregation (100%) was obtained in human isolated platelets that treated with 9 
20 µM fMLF and 0.25 µg/mL CRP-XL for 5 minutes (Figure 2-4A). Similar results were obtained 10 
with collagen- (Figure 2-4B) and thrombin- (Figure 2-4C) induced platelet aggregation. These data 11 
confirm the ability of fMLF to prime platelets and amplify their aggregation upon stimulation with 12 
different agonists although it was unable to aggregate platelets on its own. 13 
  14 
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 2 
Figure 2-4: The impact of fMLF on platelet aggregation. The effects of fMLF on CRP-XL (A), 3 
collagen (B) or thrombin (C)- induced platelet activation were measured using isolated human 4 
platelets by optical aggregometry. Data represent mean ± SEM (n=5). The statistical significance was 5 
calculated by one-way ANOVA followed by Bonferroni’s correction ( **p<0.001 and ***p<0.0001).  6 
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 2.3.6 fMLF selectively acts through FPR1 in platelets 1 
A large number of studies indicate that fMLF binds primarily to FPR1 and exert its effects in 2 
immune cells19-21. The functional dependence of fMLF on FPR1 in platelets was determined using a 3 
pharmacological inhibitor for FPR1, Boc-MLF in human platelets and platelets obtained from Fpr1- 4 
/- mice through measuring the levels of fibrinogen binding and P-selectin exposure by flow cytometry. 5 
Similar to human platelets, fMLF increased the level of fibrinogen binding [Figure 2-5Ai (isolated 6 
platelets) and 2-5Aii (whole blood)] and P-selectin exposure [Figure 2-5Bi (isolated platelets) and 2- 7 
5Bii (whole blood)] on platelets obtained from control mice. However, the level of platelet activation 8 
by fMLF was significantly reduced in Fpr1-/- mouse platelets, which demonstrates its functional 9 
dependence on FPR1. Notably, the characterisation of platelets obtained from Fpr1-/- mice failed to 10 
display any defects in the size and number of platelets or the levels of major platelet receptors such 11 
as GPVI (Figure S1i), GPIbα (Figure S1ii), αIIbβ3 (Figure S1iii) and ɑ2β1 (Figure S1iv) in 12 
comparison to the control mouse platelets. To establish the functional dependence of fMLF on FPR1 13 
in human platelets, similar assays were performed in the presence or absence of Boc-MLF. The pre- 14 
incubation of human isolated platelets with different concentrations of Boc-MLF diminished fMLF- 15 
induced (5 µM) platelet activation as measured by the levels of fibrinogen binding (Figure 2-5Ci) and 16 
P-selectin exposure (Figure 2-5Cii). These data emphasise the involvement of FPR1 in the regulation 17 
of fMLF-mediated effects in platelets.  18 
  19 
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Figure 2-5: The effects of fMLF on platelet activation are mediated through FPR1. The platelet 3 
activation upon stimulation with various concentrations of fMLF was quantified by measuring the 4 
level of fibrinogen binding (A) using FITC-conjugated fibrinogen antibodies and P-selectin exposure 5 
(B) using PECy5-conjugated P-selectin antibodies in isolated platelets (i) or whole blood (ii) obtained 6 
from control and Fpr1-/- mice by flow cytometry. Data represent mean ± SEM (n=6 for isolated 7 
platelets & n=5 for whole blood). C, human isolated platelets were stimulated with fMLF (5 μM) in 8 
the presence or absence of different concentrations of Boc-MLF (1, 5, 10 and 20 μM), and the levels 9 
of fibrinogen binding (Ci) and P-selectin exposure (Cii) were analysed by flow cytometry. Data 10 
represent mean ± SEM (n=5). * Represents the significant difference between the various 11 
concentrations of fMLF within the Fpr1+/+ group. # Represents the significant difference between 12 
Fpr1+/+ and Fpr1−/− groups. The statistical significance was calculated by two-way ANOVA followed 13 
by Bonferroni’s correction in most of the experiments except the data shown in panel C, which were 14 
analysed by one-way ANOVA followed by Bonferroni’s correction (*p<0.01. **p<0.001 and 15 
***p<0.0001).  16 
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 2 
Supplementary Figure 2-1: Characterisation of platelets obtained from Fpr1-/- mice. The 3 
expression levels of major platelet receptors such as GPVI (i), GPIbα (ii), αIIbβ3 (iii) and ɑ2β1 (iv) 4 
in platelets obtained from control and Fpr1-/- mice were analysed by flow cytometry using selective 5 
fluorescent-labelled antibodies.  Data represent mean ± SEM (n=8). The statistical significance was 6 
analysed by a two-tailed unpaired Student’s t test. 7 
  8 
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 2.3.7 Inhibition of FPR1 reduces the agonists-induced platelet activation 1 
In order to study the importance of FPR1 in the regulation of normal platelet activation, further 2 
experiments were performed using human isolated platelets in the presence or absence of Boc-MLF. 3 
CRP-XL (0.25 µg/mL)-induced platelet aggregation was significantly reduced in the presence of 4 
different concentrations of Boc-MLF (1, 5, 10 and 20 μM). For example, the addition of Boc-MLF 5 
(20 µM) reduced the platelet aggregation by around 98% (Figure 2-6A). Similar results were obtained 6 
with ADP-induced platelet aggregation, wherein Boc-MLF (20 µM) reduced aggregation by 7 
approximately 70% (Figure 2-6B). Moreover, CRP-XL (0.25 µg/mL)- induced dense granule 8 
secretion as evidenced by the ATP release was significantly reduced by Boc-MLF (Figure 2-6C). 9 
Similarly, to determine if FPR1 has any influence on the outside-in signalling triggered by integrin 10 
aIIbb3, platelet spreading assay was performed on fibrinogen-coated glass surfaces and analysed 11 
using confocal microscopy. The pre-incubation of platelets with Boc-MLF (1, 5, 10 and 20 μM) 12 
significantly decreased the number of adhered (Figure 2-7i) and spread (Figure 2-7ii) platelets, and 13 
the relative surface area of spreading on fibrinogen-coated surfaces (Figure 2-7iii) indicating a role 14 
for FPR1 in the modulation of integrin aIIbb3-mediated outside-in signalling in platelets. In order to 15 
corroborate the involvement of FPR1 in the regulation of platelet function, cyclosporin H (CsH), an 16 
inverse agonist for FPR1 was employed. CsH inhibited CRP-XL (0.5 µg/ml)-induced platelet 17 
activation as measured by the levels of fibrinogen binding (Figure 2-8i) and P-selectin exposure 18 
(Figure 2-8ii). Furthermore, CsH decreased the mean fluorescence intensity of thrombi under arterial 19 
flow conditions by approximately 60% compared to the controls (Figure 2-9). These results highlight 20 
the prominent roles of FPR1 in the regulation of normal platelet function. 21 
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 1 
Figure 2-6: Blockade of FPR1 using a pharmacological inhibitor reduces agonists-induced 2 
platelet activation. The effect of different concentrations of Boc-MLF on CRP-XL (0.25 μg/mL) 3 
(A) or ADP (2 μM) (B)- induced aggregation using human isolated platelets was analysed by optical 4 
aggregometry. The level of aggregation obtained with the vehicle control was taken as 100% to 5 
calculate the extent of inhibition with Boc-MLF treated-samples. Data represent mean ± SEM (n=3). 6 
Similarly, the level of ATP secretion in human platelets upon activation with CRP-XL (0.25 μg/mL) 7 
in the presence and absence of different concentrations of Boc-MLF was measured by lumi- 8 
aggregometry (C). Data represent mean ± SEM (n=3). P values shown are as calculated by one-way 9 
ANOVA followed by Bonferroni's correction (*p<0.01, **p<0.001 and ***p<0.0001). 10 
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 1 
Figure 2-7: Effect of FPR1-selective inhibitor, Boc-MLF, on platelet adhesion and spreading. 2 
The platelet adhesion and spreading on fibrinogen-coated glass surface was analysed in the absence 3 
or presence of Boc-MLF (1, 5, 10 and 20 μM) by confocal microscopy (60x magnification; scale bar 4 
- 10 μm). The number of adhered (i) and spread platelets (ii), and the relative surface area of spread 5 
platelets (iii) were determined by analysing the images using ImageJ. Ten random fields of view were 6 
recorded for each sample. Data represent mean ± SEM (n=3). Data represent mean ± SEM (n=3). P 7 
values shown are as calculated by one-way ANOVA followed by Bonferroni's correction (**p<0.001 8 
and ***p<0.0001). 9 
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 1 
Figure 2-8: Effect of FPR1-selective inhibitor, CsH, on platelet activation. The levels of 2 
fibrinogen binding (i) and P-selectin exposure (ii) were analysed in human PRP by flow cytometry 3 
upon stimulation with CRP-XL (0.5 μg/mL), in the presence and absence of different concentrations 4 
of CsH (1, 5, 10, 20 and 30 μM). Data represent mean ± SEM (n=3). P values shown are as calculated 5 
by one-way ANOVA followed by Bonferroni's correction (*p<0.01, **p<0.001 and ***p<0.0001). 6 
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 1 
Figure 2-9: Effect of FPR1-selective inhibitor, CsH, on thrombus formation. The impact of CsH 2 
on the modulation of thrombus formation was analysed using human DiOC6-labelled whole blood 3 
that pre-incubated with a vehicle control or 10 μM CsH for 10 minutes prior to perfusion over 4 
collagen-coated (400 μg/mL) Vena8TM Biochips. Images shown are representative of three separate 5 
experiments (10x magnification; scale bar - 10 μm). Data represent mean ± SEM (n=3). P values 6 
shown are as calculated by two-tailed unpaired Student’s t test, respectively. (***p<0.0001). 7 
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 2.3.8 Deletion of Fpr1 affects mouse platelet activation 1 
To further examine the impact of FPR1 in platelets, the whole blood obtained from control 2 
and Fpr1−/− mice was used to assess the platelet activation upon stimulation with a range of 3 
conventional platelet agonists by measuring the levels of fibrinogen binding and P-selectin exposure 4 
using flow cytometry. Similar to the results obtained with human platelets (Figure 2-10), the level of 5 
fibrinogen binding (i) and P-selectin exposure (ii) in platelets obtained from Fpr1−/− mice upon 6 
stimulation with CRP-XL (Figure 2-10A), ADP (Figure 2-10B), AY-NH2 (a PAR4 agonist) (Figure 7 
2-10C) and U46619, an analogue of TXA2 (Figure 2-10D) was largely reduced compared to their 8 
controls. To determine the influence of FPR1 on the modulation of haemostasis, tail bleeding assay 9 
was performed in control and Fpr1-deficient mice. A mean bleeding time of 429 seconds was 10 
observed in the control group, however Fpr1-/- mice significantly increased the bleeding time to a 11 
mean of 1128 seconds (Figure 2-11). These data indicate the importance of FPR1 in the modulation 12 
of platelet function and the maintenance of haemostasis under physiological conditions. 13 
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 1 
Figure 2-10: Deletion of Fpr1 in mice reduces the agonists-induced platelet activation. The levels 2 
of fibrinogen binding (i) and P-selectin exposure (ii) were analysed in isolated platelets obtained from 3 
control or Fpr1-/- mice upon stimulation with various concentrations agonists such as CRP-XL (A), 4 
ADP (B), AY-NH2 (C) or U46691 (D) by flow cytometry. Data represent mean ± SEM (n=4). * 5 
Represents the significant difference between the various concentrations of agonists within the 6 
Fpr1+/+ group. # Represents the significant difference between Fpr1+/+ and Fpr1−/− groups. Data 7 
represent mean ± SEM (n=4). The statistical significance was calculated by two-way ANOVA 8 
followed by Bonferroni’s correction (*p<0.01. **p<0.001 and ***p<0.0001). 9 
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 1 
Figure 2-11: Deletion of Fpr1 in mice affects haemostasis. The impact of FPR1 on the modulation 2 
of haemostasis was analysed by tail bleeding assay in control or Fpr1-/- mice. Data represent mean ± 3 
SEM (n=8). The statistical significance was calculated by non-parametric Mann-Whitney test. 4 
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 2.3.9 FPR1 exerts its effects through cyclic AMP (cAMP)  1 
 cAMP is a potent inhibitor of platelet function and its level is generally reduced upon platelet 2 
activation. Stimulants of cAMP generation are known to inhibit platelet activation22. FPRs are Gi 3 
protein-coupled receptors23, which are known to inhibit adenylate cyclase and thus, lead to a reduction 4 
in cAMP levels. Therefore, the deletion of genes for Gi-coupled receptors in mice generally increases 5 
the basal levels of cAMP in target cells24, 25. To investigate whether the effects of FPR1 in platelets 6 
are driven through cAMP-dependent signalling, the level of cAMP was quantified in platelets using 7 
a cAMP assay kit. The inhibition of FPR1 in human platelets with Boc-MLF (20μM) significantly 8 
elevated the level of cAMP compared to the controls (Figure 2-12i). Similarly, Fpr1−/− mouse 9 
platelets exhibited elevated basal levels of cAMP compared to the control mouse platelets at resting 10 
conditions (Figure 2-12ii). These data illustrate that the level of cAMP plays a key role in the 11 
regulation of FPR1-mediated function in platelets. 12 
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 1 
Figure 2-12: Deletion of Fpr1 in mice affects cAMP levels. The level of cAMP in human isolated 2 
platelets in the presence or absence of Boc-MLF (i), and in control and Fpr1-/- mouse platelets (ii) 3 
was analysed using a cAMP assay kit. The statistical significance was calculated by two-tailed 4 
unpaired Student’s t test (***p<0.0001). 5 
 6 
  7 
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2.4 Discussion 1 
N-formyl peptides are released from bacteria or mitochondria of damaged cells26, 27. They 2 
have been demonstrated to play substantial roles in the initiation of chemotaxis and subsequent 3 
inflammatory responses in immune cells including monocytes, mast cells, eosinophils and neutrophils 4 
via FPRs9.  Despite their ability to mediate innate immune responses, they have been associated with 5 
the pathogenesis of microbial infection and inflammatory diseases. Notably, E. coli-derived fMLF28 6 
has been implicated in bacterial cystitis29, pneumococcal pneumonia30, inflammatory bowel disease31, 7 
pouchitis, colitis32 and juvenile peridontitis33. It has been shown that inhalation or injection of fMLF 8 
can cause bronchial inflammation34, and induce rapid neutropenia, thereby increasing susceptibility 9 
to infection35. The plasma levels of fMLF were increased in these conditions, and also in high fat diet 10 
treated mice due to altered microbiome where it impaired the glucose tolerance and insulin 11 
secretion36. Many of these infectious and inflammatory conditions are associated with a risk for 12 
thrombosis and other platelet-mediated complications37-39. The concentrations of fMLF in the 13 
intestinal milieu have been reported to be at least in micromolar ranges40. In this study, we 14 
demonstrate that fMLF is able to prime platelets and augment thrombus formation in micromolar 15 
concentrations. Therefore, the increased levels of fMLF under the aforementioned pathological 16 
conditions may lead to platelet activation and contribute towards thrombotic complications.  17 
The activation of platelets facilitates their adhesion to leukocytes and leads to the formation 18 
of platelet-leukocyte aggregates (PLAs)41. P-selectin on the surface of activated platelets drives the 19 
formation of PLAs via binding to P-selectin glycoprotein ligand-1 (PSGL-1) on the surface of 20 
leukocytes42. In addition, the fibrinogen binding to integrin αIIbβ3 in platelets and Mac-1 in 21 
neutrophils was suggested to play an important role in the formation of PLAs43. PLAs are known to 22 
amplify thrombotic and proinflammatory responses in diverse inflammatory settings44. Indeed, fMLF 23 
has been reported to induce PLA formation45 through fibrinogen binding in platelets and 24 
neutrophils43. Moreover, previous studies have reported the aggregation of platelets in response to 25 
fMLF-induced neutrophil stimulation46-48 through release of platelet-activating factor (PAF)49 and 26 
cathepsin G50, 51,. In line with these, we demonstrate that fMLF has failed to induce aggregation of 27 
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isolated platelets although the pre-treatment of platelets with fMLF augmented agonist-induced 1 
aggregation. Furthermore, fMLF (but not MLF) augmented thrombus formation under arterial flow 2 
conditions in whole blood. Given that fMLF is able to upregulate the expression of adhesion 3 
molecules52, 53 and aggregate neutrophils43, 48, its effects on thrombus formation may be partly 4 
attributed to its interactions with leukocytes. Therefore, fMLF-induced fibrinogen binding and P- 5 
selectin exposure in platelets may directly trigger PLA formation as detailed above54. Although in 6 
this study, the direct impact of fMLF on platelet-mediated inflammatory responses was not analysed, 7 
the role of fMLF cannot be excluded in such responses. Together, these data demonstrate a prominent 8 
priming role for fMLF in platelets, which may augment thrombotic and proinflammatory responses 9 
through interactions with leukocytes in pathological settings. 10 
 FPR1 is a chemoattractant receptor that is widely expressed in various cell types including 11 
neutrophils, macrophages, and platelets15. Despite its well-characterised role in the modulation of 12 
inflammatory responses, the role of FPR1 in the regulation of platelet function is poorly studied. 13 
Here, we report a crucial role for FPR1 on the regulation of the platelet activation, haemostasis and 14 
thrombosis. In line with a previous study15, we confirm the presence of this receptor in human 15 
platelets by immunoblot analysis, and its upregulation upon activation of platelets with an agonist. 16 
By using selective pharmacological inhibitor, Boc-MLF and an inverse agonist, cyclosporin H (CsH), 17 
the significance of FPR1 in the regulation of fMLF- and agonist -induced (such as CRP-XL and ADP) 18 
platelet activation was established. The blockade of FPR1 resulted in reduced ATP release upon 19 
activation with CRP-XL, which not only affects secondary platelet activation but may also influence 20 
the modulation of inflammatory responses55. Similarly, the inhibition of FPR1 impaired the ability of 21 
platelet spreading on fibrinogen, which is essential for thrombosis and subsequent wound repair56. 22 
The prominent role of FPR1 on the regulation of platelet activation was also corroborated using 23 
platelets obtained from Fpr1-deficient mice, wherein the effects of fMLF and platelet agonists were 24 
largely diminished. The selective binding of fMLF to Fpr1 was confirmed using platelets obtained 25 
from Fpr1-deficient mice. In addition, the haemostasis in Fpr1-deficient mice was affected further 26 
emphasising its significance in the regulation of platelet function.  Fpr1-deficient mice displayed 27 
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severe inflammation, higher mortality during pneumococcal meningitis57, increased susceptibility 1 
to Listeria monocytogenes infection and impaired antibacterial host defence58, 59. In addition, Fpr1- 2 
deficient mice demonstrate major roles in sterile inflammation triggered by mitochondrial N-formyl 3 
peptides as demonstrated by the attenuation of inflammation in response to sterile acute lung injury 4 
in these mice60. In line with these studies, here we demonstrate the dysfunction of platelets and 5 
affected haemostasis in Fpr1-deficient mice, which may also substantiate the reduced inflammatory 6 
responses due to significant contribution of platelets in inflammation and innate immunity.  7 
As a Gi protein-coupled receptor, FPR1 triggers downstream signalling via various molecules 8 
such as phospholipase C (PLC), PI3K/AKT and MAPK, and modulates calcium mobilisation in 9 
neutrophils13. The ability of fMLF to induce calcium mobilisation in platelets has been previously 10 
reported15. Here, we report the impact of FPR1 on cAMP-mediated signalling in platelets using Boc- 11 
MLF and platelets obtained from Fpr1-deficient mice. Indeed, the inhibition of FPR1 in human or its 12 
deletion in mouse platelets resulted in elevated levels of cAMP, which is a potent inhibitor for platelet 13 
activation. This confirmed the involvement of cAMP-dependent signalling in the regulation of FPR1- 14 
mediated effects in platelets. 15 
Given the significance of FPRs and their ligands under various clinical settings, the 16 
therapeutic potential of these are being largely investigated. Notably, honokiol, a plant-derived 17 
bioactive agent has been recently demonstrated to reduce the proinflammatory responses induced by 18 
fMLF in neutrophils through inhibiting FPR161. In conclusion, this study demonstrates a prominent 19 
role for fMLF for priming platelet activation and augmenting thrombus formation under arterial flow 20 
conditions. Using an FPR1 selective inhibitor and Fpr1-deficient mice, the functional dependence of 21 
fMLF on this receptor was established. Therefore, the priming effects of fMLF on platelets may 22 
significantly contribute towards the development of thrombotic and proinflammatory diatheses 23 
during pathological settings. Hence, FPR1 may act as a potential therapeutic target and its ligands 24 
may provide a powerful platform to develop novel therapeutic agents in order to treat and prevent 25 
thrombotic and inflammatory complications during diverse pathophysiological settings.  26 
 27 
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2.5 Methods 1 
Preparation of human platelet-rich plasma and isolated platelets 2 
The University of Reading Research Ethics Committee approved all the experimental 3 
procedures using human blood from healthy volunteers. The blood samples were collected from 4 
healthy, aspirin-free volunteers after obtaining written informed consent. The blood was collected 5 
into VACUETTE® blood collection tubes containing 3.2% (w/v) sodium citrate. The blood samples 6 
were then centrifuged at 102g for 20 minutes at room temperature to obtain platelet-rich plasma 7 
(PRP). The PRP was rested at 30°C for 30 minutes prior to use. For the preparation of isolated 8 
platelets, the blood was mixed with ACD [2.5% (w/v) sodium citrate, 2% (w/v) D-glucose and 1.5% 9 
(w/v) citric acid] at 1 (ACD): 9 (blood) ratio and centrifuged at 102g for 20 minutes. The PRP was 10 
collected, mixed with appropriate volume of ACD, and centrifuged at 1413g for 10 minutes at room 11 
temperature. The resultant platelet pellet was resuspended in modified Tyrodes-HEPES buffer 12 
(134mM NaCl, 2.9mM KCl, 0.34mM Na2HPO4, 12mM NaHCO3, 20mM HEPES and 1mM MgCl2, 13 
pH 7.3) with appropriate volume of ACD, and centrifuged once again at 1413g for 10 minutes at 14 
room temperature. The resultant platelet pellet was resuspended to a final density of 4×108 cells/mL 15 
in modified Tyrode’s-HEPES buffer and allowed to rest for 30 minutes at 30ºC prior to use. 16 
 17 
Mouse blood collection and platelet preparation 18 
The mouse strains of Fpr1−/−1 and Fpr2/3−/−2 on a C57BL/6 background obtained from 19 
William Harvey Research Institute, London, UK and wild type C57BL/6 mice from Envigo, UK were 20 
used in this study. The mice were sacrificed with CO2 and the blood was directly collected by cardiac 21 
puncture into a syringe containing 3.2% (w/v) sodium citrate at 1 (citrate):9 (blood) ratio. The blood 22 
was then centrifuged at 203g for 8 minutes at room temperature and the PRP was collected. The 23 
remaining blood was resuspended in 500 µL of modified Tyrode’s-HEPES buffer and centrifuged 24 
once again at 203g for 5 minutes. The resultant PRP then centrifuged at 1028g for 5 minutes. The 25 
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resultant platelet pellet was resuspended in modified Tyrode’s-HEPES buffer at a density of 2x108 1 
cells/mL. 2 
In vitro thrombus formation assay 3 
In vitro thrombus formation was performed as described previously3, 4. In brief, human 4 
DiOC6-labelled (Sigma Aldrich, UK) human whole blood was pre-incubated with a vehicle, fMLF 5 
(5 µM) or CsH (10 µM) for 10 minutes before perfusion over collagen (400µg/mL)-coated Vena8™ 6 
Biochips (Cellix Ltd, Ireland) at a shear rate of 20 dynes/cm2. Z-stack fluorescence images of thrombi 7 
were obtained every 30 seconds for up to 10 minutes using a Nikon eclipse (TE2000-U) microscope 8 
(Nikon Instruments, UK). The fluorescence intensity was calculated by analysing the data using 9 
ImageJ software (National Institutes of Health, USA). 10 
 11 
Tail bleeding assay 12 
Tail bleeding assay was performed as described previously5. The British Home Office 13 
approved the experimental procedures. In brief, C57BL/6 (10-12 weeks old; Envigo, UK) or Fpr1−/− 14 
mice were anaesthetised using ketamine (80 mg/kg) and xylazine (5 mg/kg) administered via the 15 
intraperitoneal route and placed on a heated mat (37°C). The tail tip (1mm) was dissected, and 16 
immersed in sterile saline. The time to cessation of bleeding was measured and the assay was 17 
terminated at 20 minutes. 18 
 19 
Platelet aggregation assay 20 
In vitro platelet aggregation assays were performed by optical aggregometry using a two- 21 
channel platelet aggregometer (Chrono-Log Corporation, USA). Platelets obtained from human PRP 22 
(270 µL) were added into a siliconised cuvette and pre-warmed at 37°C for 90 seconds. Upon the 23 
addition of an agonist, the platelets were allowed to aggregate under continuous stirring at 1200rpm 24 
for 5 minutes at 37ºC and the level of aggregation was monitored. The platelets were pre-treated with 25 
different concentrations of fMLF (1, 5, 10 and 20 µM) for 5 minutes before the addition of CRP-XL 26 
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(0.25 μg/mL), collagen (0.5 μg/mL) or thrombin (0.05 U/mL) and the level of aggregation was 1 
monitored. Data were analysed by calculating the percentage of maximum platelet aggregation 2 
obtained at 5 minutes. 3 
 4 
ATP secretion assay   5 
To assess the level of dense granule secretion in platelets, ATP secretion was measured using 6 
a luciferin–luciferase luminescence substrate by lumi-aggregometry (Chrono-log, USA). The level 7 
of ATP released from platelets upon stimulation with a platelet agonist, CRP-XL (0.25 µg/mL), in 8 
the presence and absence of different concentrations of Boc-MLF was measured by observing the 9 
level of luminescence released. 10 
 11 
Flow cytometry-based assays 12 
 In order to measure the level of fibrinogen binding and P-selectin exposure on the platelet 13 
surface, flow cytometry-based assays were performed. Five microliters of PRP or isolated platelets 14 
or whole blood were incubated with 1 μl of FITC-conjugated fibrinogen antibody (1:50) and 1 μl of 15 
PECy5-conjugated anti-CD62P (P-selectin) (1:50) antibody in the presence and absence of various 16 
concentrations of fMLF or platelet agonists. The final volume was made up to 50 μl using HEPES- 17 
buffered saline (HBS) (150mM NaCl, 5mM KCl, 1mM MgSO4 and 10mM HEPES, pH 7.4) and the 18 
samples were incubated for 20 minutes at room temperature. Following fixation in 0.2% formyl 19 
saline, the samples were analysed using an Accuri C6 flow cytometer (BD Biosciences, UK) by 20 
counting 5000 events within the gated population for platelets. The median fluorescence intensity 21 
was calculated using Accuri C6 software to quantify the levels of fibrinogen binding and P-selectin 22 
exposure on the surface of platelets. Similarly, for the analysis of FPR1 expression on platelets, five 23 
microliters of PRP were incubated with 1 μl of anti-FPR1 (5 μg/mL) and 2 μl of Cy5-conjugated anti- 24 
mouse IgG (80 μg/mL) with or without 1 μg/mL CRP-XL. Following 20 minutes incubation at room 25 
temperature, the platelets were fixed in 0.2% formyl saline and analysed by flow cytometry. For the 26 
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fMLF binding assay, following the incubation of isolated platelets with FITC-conjugated fMLF (5 1 
μM) or vehicle control for 20 minutes, the platelets were fixed in 0.2% formyl saline and analysed by 2 
flow cytometry.  3 
 4 
SDS-PAGE and immunoblotting analysis 5 
Immunoblot analysis was performed using platelet lysates that prepared under reducing 6 
conditions. The samples were heated to 90°C for 10 minutes and subjected to SDS-PAGE using 10% 7 
resolving gels. The gels were then transferred to polyvinylidene difluoride (PVDF) membranes and 8 
blocked by incubation in 5% bovine serum albumin (BSA) in TBS-T (20mM Tris, 140mM NaCl and 9 
Tween-20, pH 7.6). Following an overnight incubation with primary anti-FPR1 antibody (1:500) 10 
(Abcam, UK), the blots were washed with TBS-T and incubated with secondary Cy5-conjugated goat 11 
anti-rabbit IgG antibodies (1:1000) (Invitrogen, UK) in TBS-T containing 5% BSA for one hour at 12 
room temperature. Following washing in TBS-T for one hour at room temperature, the blots were 13 
analysed using a Typhoon 9400 Variable Mode Imager system (GE Healthcare, UK). Equal loading 14 
of proteins in each lane was determined using anti-human 14-3-3# antibodies (1:1000) (Santa Cruz 15 
Biotechnology, USA). 16 
 17 
Cyclic nucleotide assay  18 
A cAMP ELISA kit (Cambridge Bioscience, UK) was used for the detection of the total 19 
cellular levels of cAMP in human and mouse platelets. Human isolated platelets were pre-incubated 20 
for 10 minutes with a selective inhibitor for FPR1, Boc-MLF. Similarly, platelets obtained from 21 
control or Fpr1−/− mice were also used. The platelets were incubated with 0.1M HCl and the levels 22 
of cAMP were calculated according to the manufacturer’s protocol. 23 
Platelet adhesion and spreading on fibrinogen  24 
 Isolated human platelets were treated with different concentrations of an FPR1-selective 25 
inhibitor, Boc-MLF, prior to loading onto fibrinogen (100 µg/mL)-coated coverslips and incubation 26 
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for 30 minutes. The coverslips were then washed with PBS to remove non-adhered platelets. Adhered 1 
platelets were fixed with 0.2% formyl saline for 10 minutes prior to permeabilisation with 0.2% 2 
Triton X-100 for five minutes at room temperature. Adhered platelets were stained with Alexa Fluor 3 
488-conjugated phalloidin for 30 minutes at room temperature. The coverslips were then mounted 4 
onto slides and scanned using a Nikon A1-R confocal microscope (60x objective).  Ten random fields 5 
of view were recorded for each sample. The data were analysed to quantify the number of adhered 6 
and spread platelets, and the relative area of spread platelets using ImageJ. The relative surface area 7 
of spread platelets was obtained by subtracting the surface area of resting platelets.  8 
 9 
Statistical analysis 10 
Data obtained in this study are represented as mean ± SEM. The statistical significance was 11 
analysed using two-tailed unpaired Student’s t test for two-sample comparisons for the data obtained 12 
from the flow cytometric assay for FPR1 expression and platelet receptor characterisation and cAMP 13 
assay. For multiple comparisons, statistical significance was established using one-way or two-way 14 
ANOVA followed by Bonferroni's correction for data obtained from in vitro thrombus formation, 15 
fMLF binding, ATP release, platelet aggregation and activation. Data obtained from the tail bleeding 16 
assay were analysed using a non-parametric Mann-Whitney test. All statistical analyses were 17 
performed using Graphpad Prism 7 software (GraphPad Software Inc., USA). 18 
 19 
 20 
 21 
 22 
 23 
 24 
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3.1 Abstract 18 
Platelet-associated complications including thrombosis, thrombocytopenia and haemorrhage 19 
are commonly observed during various inflammatory diseases such as psoriasis, sepsis and 20 
inflammatory bowel disease. Despite the reported evidence on numerous mechanisms/molecules that 21 
may contribute to the dysfunction of platelets, the primary mechanisms that underpin the platelet- 22 
associated complications during inflammatory diseases are yet to be determined. Here, we report the 23 
discovery of a formyl peptide receptor, FPR2/ALX in platelets, and its primary role in the 24 
development of platelet-associated complications via ligation with its ligand, LL37. LL37 acts as a 25 
powerful endogenous antimicrobial peptide but it also regulates innate immune responses. We 26 
demonstrate the impact of LL37 on the modulation of platelet reactivity, haemostasis, and thrombosis 27 
under pathophysiological conditions. LL37 activates a range of platelet functions, enhances thrombus 28 
formation, and shortens the tail-bleeding time in mice. By utilising a pharmacological inhibitor and 29 
Fpr2/3 (an orthologue of human FPR2/ALX)-deficient mice, the functional dependence of LL37 on 30 
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FPR2/ALX was determined. Our data demonstrate the overexpression of mCRAMP (an LL37 murine 1 
orthologue) in affected skin and plasma of a murine [imiquimod(IMQ)-induced] model of human 2 
psoriasis and its ability to enhance platelet responses via Fpr2/3. Since the level of LL37 is increased 3 
in numerous inflammatory diseases, these results point towards a critical role for LL37 and 4 
FPR2/ALX in the development of platelet-related complications in such diseases. Hence, a better 5 
understanding of the clinical relevance of LL37 and FPR2/ALX in diverse pathophysiological 6 
settings will pave the way for the development of improved therapeutic strategies for a range of 7 
inflammatory diseases. 8 
 9 
 10 
 11 
 12 
 13 
  14 
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3.2 Introduction 1 
Platelets (small circulating blood cells) play pivotal roles in the regulation of haemostasis. 2 
However, their inappropriate activation under pathological conditions leads to the formation of blood 3 
clots (thrombosis) within the circulation, which is a major cause of premature death1, 2. Platelets also 4 
play significant roles in the regulation of innate immunity, inflammatory responses and microbial 5 
infection3, 4. Activation of platelets during inflammatory diseases such as psoriasis induces the 6 
formation of blood clots or disseminated intravascular coagulation in capillaries, resulting in the 7 
blockage of blood supply to tissues5, 6. Moreover, platelet activation results in the aggregation and 8 
sequestration of platelets, thus instigating thrombocytopenia7, 8. Several mechanisms have been 9 
reported to be contributing to the dysfunction of platelets under inflammatory diseases, however, the 10 
primary mechanisms that underpin the platelet activation are not yet established. In this study, we 11 
discovered the presence of FPR2/ALX in platelets and its ability to activate platelets via its ligand, 12 
the human antimicrobial cathelicidin, LL37.  13 
Cathelicidins are a group of antimicrobial peptides produced by numerous mammalian cells 14 
in response to microbial infections9-11. Among these, the human cationic antimicrobial peptide 18 15 
(hCAP18) is the only cathelicidin known to be expressed in human cells12. The expression of hCAP18 16 
has been reported in cell types that remain in contact with the external environment, including 17 
epithelial cells in airways, intestine and skin, and innate immune system cells such as neutrophils, 18 
natural killer cells and monocytes11, 13. Normally, hCAP18 is synthesised as an inactive precursor and 19 
stored in the granules of immune cells14, 15; higher levels of hCAP18 have been found in neutrophils16. 20 
During microbial infection, the activation of immune cells releases hCAP18 to the external milieu, 21 
where it is processed by proteolytic enzymes (e.g. proteinase 3) to liberate the short, active 37 amino 22 
acid peptide LL37 (so called as it has two N-terminal leucine residues)15, 17. LL37 acts as a powerful 23 
antimicrobial peptide against bacteria18, fungi19 and viral particles20. Additionally, it modulates innate 24 
and adaptive immune responses by stimulating specific receptor-mediated signalling within the 25 
immune cells21. LL37 modulates these responses predominantly through formyl peptide receptor 2 26 
(FPR2/ALX)22. Other receptors such as CXCR223, P2Y1124 and P2X725 have also been reported to 27 
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bind LL37. The binding of LL37 activates immune cells and thus exacerbates inflammatory responses 1 
to accelerate the clearance of infection11, 13. Despite detailed research on the roles of LL37 in the 2 
modulation of inflammatory responses in various pathological settings, specifically psoriasis26, 27, the 3 
effects of LL37 in the regulation of thrombosis and other platelet-related complications remained 4 
unknown for a long time. During the preparation of this manuscript, we have identified a very recent 5 
article describing a role for cathelicidins in the regulation of thrombo-inflammation, confirming some 6 
of our findings28.  7 
Since the level of LL37 released during inflammation is significantly higher than normal15, 16, 8 
understanding its critical functions in the modulation of platelet reactivity will pave the way for the 9 
determination of the fundamental mechanisms underlying platelet-related complications in various 10 
inflammatory diseases and offer the potential for the development of improved therapeutic strategies 11 
for such diseases. In this study, we investigated the effects of LL37 at concentrations (≤ 50 μM) that 12 
are relevant to several pathological conditions (including psoriasis29) on a range of platelet functional 13 
assays, and established its roles in the modulation of platelet reactivity, thrombosis and haemostasis 14 
under physiological and pathological conditions such as psoriasis using an appropriate disease model. 15 
 16 
  17 
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3.3 Results 1 
 3.3.1 Platelets store LL37 and release it upon activation 2 
The expression of LL37 has been reported in several cell types including neutrophils where it 3 
is mainly stored in granules30, 31. Notably, the expression of cathelicidin antimicrobial peptide 4 
(CAMP) has been reported in human and mouse platelets at the transcript level32. Hence, to determine 5 
whether LL37 is present in platelets, a range of experiments were performed. The presence of LL37 6 
in platelets was confirmed by immunofluorescence microscopy. Human isolated platelets were 7 
stained with antibodies against LL37 and phalloidin (a marker for actin), wherein LL37 appeared to 8 
be dispersed in the cytoplasm (Figure 3-1A). In order to further determine whether platelets possess 9 
LL37 and release it upon activation, an enzyme-linked immunosorbent assay (ELISA) was performed 10 
using selective antibodies for LL37. Resting and activated [by 1µg/mL cross-linked collagen-related 11 
peptide (CRP-XL)] human platelets were centrifuged, and the supernatant and platelet pellet were 12 
separated to analyse the level of LL37 by ELISA. In the resting state, the presence of LL37 was 13 
significantly higher in the lysed platelet pellet (1559±433 pM) compared to the supernatant (41±12 14 
pM) (Figure 3-1B). However, upon activation of platelets with CRP-XL, the presence of LL37 was 15 
significantly increased in the supernatant (1490±581.7 pM) in comparison to the lysed platelet pellet 16 
(59±7.6 pM). In order to corroborate these results, the release of LL37 in human plasma (in the 17 
presence or absence of platelets) was investigated over a two-hour period by mass spectrometry. The 18 
level of LL37 was stable and significantly increased in platelet-rich plasma (PRP) over two hours 19 
compared to platelet-poor plasma (PPP), indicating its release from platelets; by contrast the level of 20 
LL37 was significantly reduced in PPP over two hours (Figure 3-1C). Together, these data confirm 21 
the presence of LL37 in platelets (between pM and nM concentrations), and its release upon agonist- 22 
induced platelet activation. Although the main source of LL37 may be neutrophils and other cells, 23 
platelets may also contribute to the elevation of LL37 upon activation within the local environment.  24 
  25 
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 1 
Figure 3-1: Presence of LL37 in platelets. A, Human platelets were stained with antibodies against 2 
LL37 (purple) and phalloidin (green) and analysed by confocal microscopy (100x magnification; 3 
scale bar - 10 µm). Images shown are representative of three independent experiments. B, the level 4 
of LL37 in resting and activated (1 µg/mL CRP-XL) platelet pellets and supernatants (SN) was 5 
measured by an ELISA using LL37-selective antibodies. Data represent mean ± SEM (n=5). C, the 6 
stability/release of LL37 in plasma was analysed by mass spectrometry (LC-MS). Graph indicates 7 
LL37 intensities (100μg/mL) spiked in platelet-rich plasma (PRP) and platelet-poor plasma (PPP) at 8 
different time points over 120 minutes. Control represents the intensity of LL37 at 100 μg/mL 9 
(unspiked). Data represents mean ± SEM (n=3). The statistical significance was established by one-way 10 
ANOVA followed by Bonferroni’s correction except for the data shown in panel B, which was analysed 11 
by two-tailed unpaired Student’s t test (*p<0.05 and **p<0.01). 12 
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 3.3.2 LL37 augments thrombus formation under arterial flow conditions 1 
Disseminated intravascular coagulation or thrombosis in microvasculature is a common 2 
phenomenon during inflammatory diseases such as psoriasis33. Therefore, to determine whether LL37 3 
has a direct influence on thrombotic complications during inflammatory diseases, its effects on 4 
thrombus formation under arterial flow conditions were investigated using a microfluidics system by 5 
fluorescence microscopy. Human DiOC6-labelled whole blood was pre-incubated with a scrambled 6 
peptide or different concentrations of LL37 (10, 20 and 50 µM) for 10 minutes prior to perfusion over 7 
collagen-coated Vena8™ biochips. Thrombus formation was monitored for 10 minutes by acquiring 8 
fluorescent images every 30 seconds (Figure 3-2i). LL37 significantly increased the mean 9 
fluorescence intensity of thrombi in a concentration dependent manner (Figure 3-2ii); the highest 10 
concentration of LL37 used (50 µM) increased the thrombus intensity by approximately 70% 11 
compared to the vehicle-treated samples (Figure 3-2iii). These data demonstrate a direct role for LL37 12 
in the augmentation of thrombus formation under arterial flow conditions in human whole blood. 13 
  14 
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 1 
Figure 3-2: The impact of LL37 on thrombus formation. The effects of LL37 in the modulation of 2 
thrombus formation. Human DiOC6-labelled whole blood was pre-incubated with a scrambled 3 
peptide or LL37 (10, 20 and 50 µM) for 10 minutes prior to perfusion over collagen-coated (400 4 
µg/mL) Vena8™ Biochips. Images (i) (at 10 minutes) shown are representative of three separate 5 
experiments (10x magnification; scale bar - 10 µm). Data represent mean ± SEM (n=3). The statistical 6 
significance was established by one-way ANOVA followed by Bonferroni’s (*p<0.05 and **p<0.01).  7 
  8 
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 3.3.3 Role of LL37 in the modulation of haemostasis in mice 1 
 Since LL37 directly influenced the thrombus formation under arterial flow conditions, its 2 
effects in the modulation of haemostasis in mice under physiological conditions were determined by 3 
tail bleeding assay. Following the administration of anaesthetics to C57BL/6 mice, 20 µM of 4 
scrambled peptide or LL37 was infused via the femoral artery five minutes prior to the dissection of 5 
1mm tail tip and the measurement of bleeding time. A mean bleeding time of 371±47 seconds was 6 
observed in the vehicle-treated group, however the infusion of LL37 significantly shortened the 7 
bleeding time in mice to a mean of 225±19 seconds (Figure 3-3). These data demonstrate the effects 8 
of LL37 in the modulation of haemostasis in mice under physiological settings, and reflect its 9 
probable function in the modification of haemostatic responses during inflammatory diseases. 10 
  11 
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 1 
 2 
Figure 3-3: The impact of LL37 on haemostasis. The impact of LL37 (20 µM) on the modulation 3 
of haemostasis. C57BL/6 mice (10-12 weeks old) were anaesthetised 20 minutes before the infusion 4 
of a scrambled peptide or LL37 (20 µM) via femoral artery 5 minutes before the dissection of 1 mm 5 
of tail tip, and monitoring of time to cessation of bleeding. Data represent mean ± SEM (n=6 per 6 
group). The statistical significance was established by non-parametric Mann-Whitney test.  7 
  8 
96  
 
 3.3.4 LL37 induces platelet activation 1 
Following the confirmation of the effects of LL37 in the modulation of thrombus formation 2 
and haemostasis, a range of platelet functional assays were performed to determine the role of LL37 3 
in the regulation of distinctive platelet functions. To examine the effects of LL37 on platelet 4 
activation, aggregation assays were performed using human isolated platelets. The platelets were 5 
treated with a vehicle control or different concentrations of LL37 (5, 10 and 20 µM) and the platelet 6 
aggregation was monitored for 5 minutes by optical aggregometry. The addition of LL37 directly 7 
induced platelet aggregation in a concentration-dependent manner. Maximum aggregation (100%) 8 
was obtained with 20 µM LL37 at 5 minutes in isolated human platelets (Figure 3-4). These data 9 
confirm the activatory effects of LL37 in platelets.  10 
  11 
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 1 
 2 
Figure 3-4: The impact of LL37 on platelet aggregation. The effects of LL37 on platelet activation 3 
was measured by optical aggregometry using human isolated platelets. Data represent mean ± SEM (n=6). 4 
The statistical significance was established by one-way ANOVA followed by Bonferroni’s correction 5 
(*p<0.05. **p<0.01 and ***p<0.001).  6 
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 3.3.5 Effect of LL37 on inside-out signalling to integrin aIIbb3 and a-granule 1 
secretion in platelets 2 
Platelet activation triggers inside-out signalling to integrin aIIbb3 on the platelet surface and 3 
converts it to a high affinity state to allow fibrinogen binding and subsequent platelet aggregation34. 4 
To determine whether LL37 influences the inside-out signalling in platelets, the level of fibrinogen 5 
binding was measured on the platelet surface (as a marker for inside-out signalling to integrin aIIbb3) 6 
using FITC-conjugated fibrinogen antibodies by flow cytometry. Indeed, LL37 increased the level of 7 
fibrinogen binding in a concentration-dependent manner in human isolated platelets (Figure 3-5Ai). 8 
A minimum concentration of 5 μM LL37 significantly increased fibrinogen binding compared to the 9 
resting platelets, and the highest response was obtained at 50 μM LL37. Furthermore, to determine 10 
whether the presence of plasma proteins intercedes with the response of LL37 on platelets, the effect 11 
of LL37 on platelet activation was analysed using PRP by measuring the level of fibrinogen binding. 12 
Similar to the findings observed in isolated platelets, LL37 increased the level of fibrinogen binding 13 
in a concentration-dependent manner in PRP (Figure 3-5Aii). Together, these data suggest that LL37 14 
stimulates inside-out signalling to integrin aIIbb3, and thus increases fibrinogen binding upon platelet 15 
activation, and its function is unaffected by the presence of plasma proteins.  16 
Platelets contain three distinct types of granules and upon activation of platelets, the contents 17 
of such granules are released in order to enhance the secondary activation of additional platelets and 18 
recruit them to the developing thrombus. To determine the impact of LL37 on granule secretion, the 19 
level of P-selectin exposure (as a marker for α-granule secretion) was measured by flow cytometry. 20 
The results indicate that LL37 induced a-granule secretion in human isolated platelets (Figure 3-5Bi) 21 
and PRP (Figure 3-5Bii) in a concentration-dependent manner. These data confirm the impact of 22 
LL37 in the modulation of a-granule secretion.   23 
24 
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 2 
Figure 3-5: The impact of LL37 on platelet activation. A, the level of fibrinogen binding was 3 
analysed using FITC-conjugated fibrinogen antibodies by flow cytometry in human isolated platelets 4 
(Ai) or PRP (Aii). B, the level of P-selectin exposure was measured in human isolated platelets (Bi) 5 
or PRP (Bii) using PECy5-labelled P-selectin antibodies by flow cytometry. Data represent mean ± 6 
SEM (n=3). The statistical significance was established by one-way ANOVA followed by Bonferroni’s 7 
correction (*p<0.05 and **p<0.01).  8 
 9 
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 3.3.6 Impact of LL37 on integrin aIIbb3-mediated outside-in signalling to 1 
platelets 2 
Following fibrinogen binding, the integrin aIIbb3 transduces signalling responses into 3 
platelets to allow their spreading and clot retraction. The potential of LL37 to mediate such signalling 4 
responses was measured by their ability to induce adhesion and spreading of platelets on immobilised 5 
fibrinogen under static conditions (Figure 3-6). Upon stimulation of platelets with different 6 
concentrations of LL37 (5, 10 and 20 µM), a significant increase in the number of adhered platelets 7 
to fibrinogen was observed compared to the controls (Figure 3-6i). Furthermore, LL37 displayed a 8 
marked increase in the number (Figure 3-6ii) and the relative surface area (Figure 3-6iii) of spread 9 
platelets compared to the controls. These data demonstrate the role of LL37 in the modulation of 10 
integrin aIIbb3-mediated outside-in signalling to platelets.  11 
  12 
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 1 
Figure 3-6: The impact of LL37 on platelet spreading. Platelet adhesion and spreading on 2 
immobilised fibrinogen was analysed by using platelets treated with LL37 (5, 10 and 20 µM) by 3 
confocal microscopy (60x magnification; scale bar - 10 µm). The number of adhered (i) and spread 4 
platelets (ii), and the relative surface area of spread platelets (iii) was determined via analysing the 5 
images using ImageJ. Ten random fields of view were recorded and analysed for each sample. Data 6 
represent mean ± SEM (n=3). The statistical significance was established by one-way ANOVA followed 7 
by Bonferroni’s correction (*p<0.05, **p<0.01 and ***p<0.001.  8 
 9 
 10 
 11 
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 3.3.7 Intracellular calcium levels were elevated by LL37 in human platelets 1 
The activation of platelets results in the mobilisation of Ca2+ stored in the dense tubular system 2 
in platelets and the influx of extracellular Ca2+ across the plasma membrane35. Such elevation of 3 
intracellular Ca2+ levels plays a pivotal role in the regulation of platelet function including shape 4 
change, degranulation, aggregation and ultimately thrombus formation36. To assess the effects of 5 
LL37 in the modulation of calcium mobilisation, intracellular calcium levels were measured in Fluo- 6 
4 AM dye-loaded human isolated platelets. LL37 induced calcium mobilisation in a concentration- 7 
dependent manner with a maximum effect achieved with 50 µM. The level of calcium release 8 
obtained with 50 µM LL37 is similar to the level obtained with a GPVI-selective agonist, CRP-XL 9 
(1 µg/mL), although the initial kinetics of calcium release appeared to be faster for LL37 (Figure 3- 10 
7). These data suggest that LL37 is involved in the elevation of intracellular calcium levels upon 11 
platelet activation. 12 
13 
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 2 
Figure 3-7: The impact of LL37 on calcium mobilisation. Ca2+ mobilisation was measured using 3 
Fluo-4 AM dye-loaded human isolated platelets upon stimulation with LL37 by spectrofluorimetry. 4 
Data represent mean ± SEM (n=4). The statistical significance was established by one-way ANOVA 5 
followed by Bonferroni’s correction (*p<0.05 and **p<0.01).  6 
 7 
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 3.3.8 LL37 does not exhibit cytotoxic effects in platelets at lower 1 
concentrations 2 
A previous study37 reported the inhibitory effects of LL37 in platelets at exceptionally high 3 
concentrations including 0.1, 0.3, 0.6 and 1.2 mM. From the literature38, it is apparent that such 4 
concentrations are not relevant to pathological conditions except in psoriasis, where the levels of 5 
LL37 can reach up to 300 µM in affected skin tissues39. In addition, it has been shown previously 6 
that LL37 exhibits cytotoxic effects in eukaryotic cells, such as neutrophils and monocytes at 7 
concentrations of higher than 50 µM40. Such toxic effects may well be the reason behind the inhibitory 8 
effects of LL37 demonstrated in the previous study37. In order to determine whether the 9 
concentrations of LL37 used in the present study (≤50 µM) exhibit any cytotoxic effects in platelets, 10 
lactate dehydrogenase (LDH) cytotoxicity assay was performed. Human isolated platelets were 11 
pretreated with different concentrations of LL37. The level of LDH released was measured using a 12 
LDH cytotoxicity assay kit. The various concentrations of LL37 used in this study (1, 5, 10, 20 and 13 
50 µM) failed to exert any significant cytotoxic effects in human isolated platelets, although 100 µM 14 
LL37 displayed significant toxicity in platelets (Figure 3-8). These results confirm that LL37 at 15 
concentrations up to 50 µM do not display any toxic effects in platelets, although higher 16 
concentrations can exhibit cytotoxic effects and thus reduction in platelet function. Such a reduction 17 
in platelet function through cytotoxicity may lead to bleeding at conditions where the level of LL37 18 
is increased (100 µM or more).  19 
  20 
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Figure 3-8: The effect of LL37 on platelet cytotoxicity. The cytotoxic effects of LL37 were measured 3 
in human isolated platelets using a LDH cytotoxicity assay kit. Data represent mean±SEM (n=4). The 4 
statistical significance was established by one-way ANOVA followed by Bonferroni’s correction 5 
(*p<0.05).  6 
 7 
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 3.3.9 Expression of FPR2/ALX in platelets 1 
A large number of studies indicate that LL37 acts primarily through FPR2/ALX to exert its 2 
effects in immune cells22, 41, 42. The expression of FPR2/ALX in megakaryocytes and human and 3 
mouse platelets at transcript level has been reported previously43,32. Here, we confirmed the presence 4 
of FPR2/ALX in human platelet lysates using immunoblotting analysis (Figure 3-9i) and on their 5 
surface by flow cytometry (Figure 3-9ii). Notably, the activation of platelets with 1 µg/mL CRP-XL 6 
increased the level of FPR2/ALX on the platelet surface as determined by flow cytometry although 7 
the level of protein identified by immunoblots remained unchanged. Additionally, we were able to 8 
confirm the presence of FPR2/ALX in mouse platelet lysates, and its absence in Fpr2/3-/- (Fpr2/3 is 9 
an orthologue to human FPR2/ALX) mice that were utilised in this study (Figure 3-9iii). These data 10 
confirm the presence of FPR2/ALX in platelets at protein level, and their increase on the platelet 11 
surface upon activation, which may be due to their presence in granules and/or the open canalicular 12 
system (OCS).  13 
14 
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 1 
Figure 3-9: Expression of FPR2/ALX in platelets. The presence of FPR2/ALX was confirmed in 2 
human (i) and mouse (iii) platelet lysates by immunoblot analysis using selective antibodies. The 3 
blots are representative of three separate experiments. The expression of FPR2/ALX on the surface 4 
of resting or activated (1 µg/mL CRP-XL) human platelets was analysed using FPR2/ALX-selective 5 
and fluorescent-labelled secondary antibodies by flow cytometry (ii). Data represent mean ± SEM 6 
(n=4). The statistical significance was calculated using a two-tailed unpaired Student’s t test was used 7 
(*p<0.05).  8 
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 3.3.10 LL37 activates platelets through FPR2/ALX  1 
In order to determine the functional dependence of LL37 on FPR2/ALX, the binding of LL37 2 
to the platelet surface was confirmed using a fluorescent-labelled LL37 (5-FAM-LC-conjugated 3 
LL37) by flow cytometry. 20 μM 5-FAM-LL37 displayed marked binding to the surface of human 4 
platelets compared to a fluorescence-labelled scrambled LL37 (5-FAM-conjugated sc-LL37) (Figure 5 
3-10i). Similarly, LL37 (20 μM) binding was analysed using platelets obtained from control, Fpr1- 6 
or Fpr2/3-deficient mouse platelets. The platelets obtained from control and Fpr1−/− mice exhibited 7 
marked binding to 5-FAM-LL37 compared to Fpr2/3−/− mouse platelets (Figure 3-10ii). 8 
Furthermore, the interactions between LL37 and FPR2/ALX was examined by molecular docking 9 
analysis using a homology model of human FPR2/ALX, which was generated based on the structural 10 
template of human delta opioid 7 transmembrane receptor (PDB code- 4N6H; 1.8 Å) using 11 
MODELLER-ModWeb server44. The docking analysis using PatchDock server predicted that the 12 
LL37 peptide forms prominent hydrogen bonds with key residues such as Gln-89, Ser-182, Asn-285 13 
and Gly-275 of FPR2/ALX, that are identified to be crucial for receptor activation (Figure 3-10iii and 14 
Table 1). Together, these data confirm the binding of LL37 primarily to FPR2/ALX in human and 15 
mouse platelets. 16 
Following the corroboration of LL37 binding to FPR2/ALX, the functional dependence of 17 
LL37 on this receptor was analysed by using a range of platelet functional assays. The activatory 18 
effects of LL37 (5, 10, 20 and 50 µM) were substantially reduced in Fpr2/3−/− mouse platelets both 19 
in isolation (Figure 3-11Ai) or whole blood (Figure 3-11Aii) compared to the controls as analysed by 20 
fibrinogen binding using flow cytometry. Similar results were obtained by analysing P-selectin 21 
exposure levels in mouse platelets in isolation (Figure 3-11Bi) or whole blood (Figure 3-11Bii). 22 
Notably, the characterisation of platelets obtained from Fpr2/3−/− mice failed to display any defects 23 
in the size and number of platelets or the levels of major platelet receptors such as GPVI (Figure 3- 24 
12i), GPIbα (Figure 3-12ii), αIIbβ3 (Figure 3-12iii) and ɑ2β1 (Figure 3-12iv) in comparison to the 25 
control mouse platelets.  26 
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To further analyse the functional dependence of LL37 on FPR2/ALX, specific platelet 1 
functional assays were performed in the presence of a selective antagonist to FPR2/ALX 2 
(WRWWWW [WRW4]) in human and mouse platelets. The addition of WRW4 (5 µM) in human 3 
isolated platelets prior to activation with 20 µM LL37 inhibited platelet aggregation by approximately 4 
40% (Figure 3-13). Similarly, the effects of LL37 (20 µM) on fibrinogen binding (Figure 3-14i) and 5 
P-selectin exposure (Figure 3-14ii) were significantly reduced in WRW4-treated (5 µM) control 6 
platelets. These data demonstrate the involvement of FPR2/ALX in the regulation of LL37-mediated 7 
effects in platelets. 8 
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Figure 3-10: Binding of LL37 to FPR2/ALX in platelets. The binding of LL37 to platelets was 3 
analysed by flow cytometry. Human isolated platelets were incubated with 20μM 5-FAM-LC- 4 
conjugated LL37 or scrambled LL37, and the level of binding was analysed by flow cytometry (i). 5 
Data represent mean ± SEM (n=4). Similarly, platelets obtained from control, Fpr2/3-/- and Fpr1-/- 6 
mice were analysed with 20 μM 5-FAM-LC-conjugated LL37 or scrambled LL37 (ii). Data represent 7 
mean ± SEM (n=7). The interactions between LL37 and FPR2/ALX was analysed through structural 8 
modelling and molecular docking analysis (iii). The statistical significance was calculated using one- 9 
way ANOVA followed by a two-tailed unpaired Student’s t test was used (*p<0.05).  10 
11 
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Table 1. Summary of polar contacts between LL37 and FPR2/ALX  1 
 
Hydrogen bond interactions 
Interacting 
LL37 residues  
Interacting 
FPR2/ALX residues 
Average 
distance (Å) 
 
Gly-3 (N) Arg-26 (NH2) 2.76 
Ser-9 (OG) Glu-89 (OE1) 3.12 
Ser-9 (O) Glu-89 (OE2) 2.61 
Lys-10 (N) Glu-89 (OE2) 2.81 
Ser-9 (OG) Asn-171 (ND2) 3.00 
Gln-22 (NE2) Ser-182 (N) 3.20 
Gln-22 (OE1) Ser-182 (OG) 2.91 
Gln-22 (NE2) Ser-182 (OG) 3.14 
Gln-22 (NE2) Ser-182 (OG) 3.18 
Glu-11 (OE2) Gly-275 (N) 3.23 
Lys-8 (NZ) Lys-276 (O) 2.53 
Arg-7 (NH1) Asn-285 (OD1) 3.08 
Arg-7 (NE) Asn-285 (OD1) 3.29 
 2 
N, amide nitrogen; O, carbonyl oxygen; OG, gamma oxygen; NE2, epsilon nitrogen 2; OE1, epsilon 3 
oxygen 1; OE2, epsilon oxygen 2; NZ, zeta nitrogen; NH1, eta nitrogen 1; NE, epsilon nitrogen; NH2, 4 
eta nitrogen 2; ND2, delta nitrogen 2; OG, gamma oxygen; OD1, delta oxygen 1. 5 
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 5 
Figure 3-11: FPR2/ALX-mediated platelet activation by LL37. A, the level of fibrinogen binding 6 
upon stimulation with LL37 in isolated platelets (Ai) or whole blood (Aii) obtained from Fpr2/3-/- or 7 
control mice was analysed by flow cytometry.  Data represent mean ± SEM (n=10 for Ai; n= 8 for 8 
Aii). B, Similarly, the level of P-selectin exposure was analysed using isolated platelets (Bi) or whole 9 
blood (Bii) from these mice. Data represent mean ± SEM (n=10 for Bi; n= 13 for Bii). The statistical 10 
significance was calculated using one-way ANOVA followed by Bonferroni’s correction (*p<0.05, 11 
**p<0.001 and ***p<0.0001).  12 
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 1 
Figure 3-12: Expression of major platelet receptors in Fpr2/3-deficient mouse platelets. The 2 
expression levels of major platelet receptors such as GPVI (i), GPIbα (ii), αIIbβ3 (iii) and ɑ2β1 (iv) in 3 
platelets obtained from Fpr2/3−/− and control mice were analysed by flow cytometry using selective 4 
fluorescent-labelled antibodies. Data represents mean ± SEM (n=8 per group). The statistical 5 
significance was calculated a two-tailed unpaired Student’s t test was used.  6 
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 1 
Figure 3-13: Inhibition of LL37-mediated platelet aggregation by WRW4. The effect of a 2 
selective inhibitor for FPR2/ALX, WRW4 (5 µM) upon LL37-induced platelet activation was 3 
measured by optical aggregometry. Data represent mean ± SEM (n=3). The statistical significance 4 
was calculated using a two-tailed unpaired Student’s t test was used (*p<0.05).  5 
 6 
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 1 
Figure 3-14: Inhibition of LL37-mediated platelet activation by WRW4. Mouse isolated platelets 2 
were stimulated with LL37 (20 μM) in the presence or absence WRW4 (5 μM), and the level of 3 
fibrinogen binding (i) and P-selectin exposure (ii) were analysed by flow cytometry. Data represent 4 
mean ± SEM (n=4). The statistical significance was calculated using a two-tailed unpaired Student’s 5 
t test was used (*p<0.05).  6 
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 3.3.11 FPR2/ALX regulates platelet activation in general  1 
In order to validate the importance of FPR2/ALX in the regulation of platelet activation in 2 
general, further experiments were performed using human isolated platelets in the presence or 3 
absence of WRW4. CRP-XL (0.25 µg/mL)-induced platelet aggregation was significantly reduced in 4 
the presence of different concentrations of WRW4 (2.5, 5 and 20 μM). For example, the inhibition of 5 
FPR2/ALX with WRW4 (20 µM) reduced the platelet aggregation by around 89% (Figure 3-15A). 6 
Similar results were obtained with ADP-induced platelet aggregation, wherein WRW4 (20 µM) 7 
reduced aggregation by approximately 82% (Figure 3-15B). Moreover, dense granule secretion 8 
(evidenced by ATP release) was significantly reduced in the presence of WRW4 (Figure 3-15C). 9 
Furthermore, the platelet activation was also assessed using whole blood obtained from control and 10 
Fpr2/3−/− mice upon stimulation with conventional platelet agonists such as CRP-XL, ADP, AY- 11 
NH2 (activates protease activated receptor, PAR4) and U46619, an analogue of thromboxane A2 12 
(TXA2) [activates thromboxane prostanoid (TP) receptor] by measuring the level of fibrinogen 13 
binding and P-selectin exposure. Similar to human platelets, the activation of platelets obtained from 14 
Fpr2/3−/− mice upon stimulation with CRP-XL (Figure 3-16A), ADP (Figure 3-16B), AY-NH2 15 
(Figure 3-16C) and U46619 (Figure 3-16D) was significantly reduced compared to the controls. 16 
Additionally, pre-incubation of human platelets with WRW4 (1.25, 2.5, 5 and 20 μM) significantly 17 
decreased the number of adhered (Figure 3-17i) and spread (Figure 3-17ii) platelets, and the relative 18 
surface area of spreading on fibrinogen-coated surfaces (Figure 3-17iii), indicating the involvement 19 
of FPR2/ALX in the regulation of integrin aIIbb3–mediated outside-in signalling to platelets. The 20 
impact of Fpr2/3 on the modulation of haemostasis in mice was determined by tail bleeding assay. A 21 
mean bleeding time of 428.5±64.8 seconds was observed in the control group, however Fpr2/3- 22 
deficient mice significantly increased the bleeding time to a mean of 1128±71.9 seconds (Figure 3- 23 
18). These results indicate the prominence of this receptor in the maintenance of haemostasis under 24 
physiological conditions. Together, these data emphasise the impact of FPR2/ALX on the regulation 25 
of normal platelet function through a positive feedback mechanism, and thus the inhibition or deletion 26 
of this receptor results in diminished platelet function in general. This positive feedback may occur 27 
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mainly through LL37 that is released from platelets upon activation within the local environment 1 
where their concentration might be sufficient to inhibit platelet function. The presence of other 2 
FPR2/ALX ligands for platelet activation is also inevitable under these circumstances.  3 
4 
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 1 
Figure 3-15: The effect of FPR2/ALX blockade by WRW4 on platelet aggregation and ATP 2 
release. The effects of different concentrations of WRW4 on CRP-XL (0.25 µg/mL) (A) or ADP (2 µM) 3 
(B) -induced human isolated platelet aggregation was analysed by optical aggregometry. C, the level of 4 
ATP secretion in platelets treated with WRW4 prior to activation with CRP-XL (0.25 µg/mL) was 5 
measured by lumi-aggregometry. Data represent mean ± SEM (n=3). P values shown are calculated by 6 
one-way ANOVA followed by Bonferroni's correction (*p<0.05 and **p<0.01).   7 
8 
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 1 
Figure 3-16: Deletion of Fpr2/3 in mice reduces agonist-induced platelet activation. The levels of 2 
fibrinogen binding (i) and P-selectin exposure (ii) were analysed in platelets obtained from control or 3 
Fpr2/3−/− mice upon stimulation with various concentrations of CRP-XL (A), ADP (B), AY-NH2 (C) 4 
or U46691 (D) by flow cytometry. Data represent mean ± SEM (n=3). P values shown are calculated 5 
by two-way ANOVA followed by Bonferroni's correction (*p<0.05).   6 
 7 
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Figure 3-17: Effect of FPR2-selective inhibitor, WRW4, on platelet adhesion and spreading. 3 
Platelet adhesion and spreading on fibrinogen-coated glass surface was analysed in the absence and 4 
presence of WRW4 (1.25, 2.5, 5 and 20 µM) by confocal microscopy (60x magnification; scale bar – 5 
10 µm). The number of adhered (i) and spread platelets (ii), and the relative surface area of spread 6 
platelets (iii) was determined by analysing the images using ImageJ. Ten random fields of view were 7 
recorded for each sample. Data represent mean ± SEM (n=3). P values shown are calculated by one- 8 
way ANOVA followed by Bonferroni's correction (*p<0.05 and **p<0.01). 9 
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 1 
Figure 3-18: Deletion of Fpr2/3 in mice affects haemostasis. The impact of FPR2/ALX in the 2 
modulation of haemostasis was analysed using tail bleeding assay in control or Fpr2/3−/− mice. Data 3 
represent mean ± SEM (n=8 per group). P values shown are calculated non-parametric Mann- 4 
Whitney test. 5 
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 3.3.12 FPR2/ALX exerts its effects through cyclic AMP-dependent signalling  1 
 Cyclic AMP (cAMP) is a potent inhibitor of platelet function, and its generation is reduced 2 
upon platelet activation. Moreover, stimulants of cAMP generation are known to reverse platelet 3 
activation45. FPRs are Gi-coupled receptors46, which are known to inhibit adenylate cyclase, leading 4 
to the reduction of cAMP levels. Therefore, the deletion of Gi-coupled receptor genes in mice 5 
increases the basal cAMP levels in target cells47, 48. In order to investigate whether the inhibition of 6 
FPR2/ALX in human or deletion of Fpr2/3 in mouse platelets is influenced by the cAMP-dependent 7 
signalling pathways, the level of cAMP was quantified in platelets using a cAMP assay kit. The 8 
inhibition of FPR2/ALX with WRW4 (20 μM) significantly elevated the cAMP levels compared to 9 
the vehicle control in human platelets (Figure 3-19i). Similarly, resting Fpr2/3−/− platelets exhibited 10 
elevated levels of cAMP compared to control mouse platelets (Figure 3-19ii). These data suggest that 11 
the level of cAMP plays a key role in the regulation of FPR2/ALX-mediated functions in platelets 12 
and explain the inhibition of platelet function in general upon blocking or deletion of this receptor in 13 
platelets. 14 
15 
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Figure 3-19: Deletion of Fpr2/3 in mice affects cAMP levels. The level of cAMP in human isolated 3 
platelets in the presence or absence of WRW4 (i), and control and Fpr2/3-/- mouse platelets (ii) was 4 
analysed using a cAMP assay kit. Data represent mean ± SEM (n=4). P values shown are calculated 5 
by two-tailed unpaired Student’s t test (*p<0.05 and ***p<0.001).   6 
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 3.3.13  Impact of LL37 in the modulation of platelet activation and haemostasis 1 
during psoriasis  2 
  3.3.13.1 Characterisation of a psoriasis mouse model  3 
 The level of LL37 is known to be overexpressed during psoriasis with concentrations up to 300 4 
μM in affected skin tissues39. In order to determine the impact of LL37 in the modulation of platelet 5 
function and haemostasis during psoriasis, we used an animal model with psoriasis-like symptoms. 6 
Psoriasis vulgaris (plaque-type), the most common phenotype of psoriasis, is a skin inflammatory disease 7 
characterised by skin thickening along with red plaques and dry scales. In order to study the effects of 8 
LL37 under this inflammatory condition, a psoriasis mouse model was utilised.49 To mimic human 9 
plaque-type psoriasis, mice were treated topically with a Vaseline cream containing 5% imiquimod 10 
(IMQ), an immunomodulatory agent that ligates toll-like receptor 7 (TLR7)50. IMQ-treated mice 11 
displayed psoriatic symptoms compared to control vaseline-treated mice. For example, IMQ-treated mice 12 
displayed significant differences in the body (Figure 3-20i) and spleen (Figure 3-20ii) weight, and skin 13 
thickness (Figure 3-20iii) compared to the control mice over five days. Moreover, based on the Psoriasis 14 
Area and Severity Index (PASI) scoring system, the clinical manifestations of psoriasis including 15 
erythema (Figure 3-20iv) and desquamation (Figure 3-20v) were significantly altered in IMQ-treated 16 
mice compared to vaseline-treated mice. Figure 3-20vi depicts the lesions on the back skin of IMQ-treated 17 
mice compared to the controls. Together, these data confirm the development of psoriasis-like symptoms 18 
in the IMQ-treated mice, rendering them an appropriate model to study human plaque-like psoriasis. 19 
  20 
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 1 
Figure 3-20: Characterisation of a psoriasis mouse model. Characterisation of a psoriasis mouse 2 
model was performed by measuring the body weight (i), spleen weight (ii) and skin thickness (iii) in 3 
IMQ-treated mice compared to the controls (Vaseline-treated mice). The PASI scoring was used to 4 
rank erythema (iv) and desquamation (v). Representative images display the lesions on the skin of 5 
IMQ-treated mice compared to the controls (vi). Data represent mean ± SEM (n=12 per group). P 6 
values shown are calculated by one-way ANOVA followed by Bonferroni’s correction (*p<0.05, 7 
**p<0.001 and ***p<0.0001).  8 
 9 
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  3.3.13.2 The effect of haemostasis in IMQ-treated mice 1 
 In order to determine whether the IMQ-treated mice exhibit a direct impact on haemostasis, a tail 2 
bleeding assay was performed. Notably, IMQ-treated mice did not exhibit significant difference in the 3 
bleeding time compared to the control group (Figure 3-21). These data demonstrate that despite the 4 
alteration of platelet function during psoriasis, the elevation of LL37 was not sufficient to impact 5 
haemostasis in these mice. Moreover, there may be a range of modulatory factors at play influencing 6 
haemostasis in these psoriatic mice.  7 
8 
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 1 
Figure 3-21: The impact of psoriasis in the modulation of haemostasis. The impact of psoriasis in 2 
the modulation of haemostasis was analysed in the control or IMQ-treated mice using tail bleeding 3 
assay. Data represent mean ± SEM (n=6 for IMQ-treated, and n=5 for Vaseline-treated mice). P 4 
values shown are calculated by non-parametric Mann-Whitney test. 5 
 6 
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  3.3.13.3 mCRAMP is elevated in the skin and plasma of IMQ-treated 1 
mice 2 
 Recent studies have reported the overexpression of LL37 during psoriasis in humans mainly 3 
at local sites of inflammation and lesions29, 51, and in the circulation52. In order to determine whether 4 
the LL37 murine orthologue, mCRAMP, is overexpressed both locally in the skin and plasma of 5 
IMQ-treated mice, the level of mCRAMP was measured in skin homogenates and plasma using an 6 
ELISA. The level of mCRAMP was markedly increased in the skin samples (150±2.4 pg/mL) 7 
obtained from IMQ-treated mice compared to the controls (23.1±2.7 pg/mL) (Figure 3-22i). 8 
Moreover, the level of mCRAMP was markedly increased in plasma samples (139.5±7 pg/mL) 9 
obtained from IMQ-treated mice compared to the control (35.4±1.5 pg/mL) (Figure 3-22ii). These 10 
data demonstrate the elevation of mCRAMP levels during the progression of psoriasis both locally 11 
in lesional skin and systemically in plasma.  12 
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 1 
Figure 3-22: The expression of mCRAMP in psoriatic lesions and plasma. The level of mCRAMP 2 
in skin homogenates (i) or plasma (ii) samples obtained from IMQ-treated and control mice was 3 
analysed using mCRAMP antibodies by an ELISA. Data represent mean ± SEM (n=6 for skin; n=19 4 
for plasma). P values shown are calculated by a two-tailed unpaired Student’s t test (***p<0.0001).  5 
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  3.3.13.4 Platelet activation is augmented during psoriasis  1 
 In order to determine whether the pathogenesis of psoriasis affects the regulation of platelet 2 
function, whole blood obtained from IMQ-treated mice was used to study platelet activation by flow 3 
cytometry. The effects of various concentrations of different platelet agonists such as, CRP-XL, ADP 4 
and U46619 were analysed in whole blood obtained from IMQ-treated and control mice. The level 5 
of fibrinogen binding and P-selectin exposure upon treatment with CRP-XL (Figure 3-23Ai and 3- 6 
23ii), ADP (Figure 3-23Bi and 3-23Bii) and U46619 (Figure 3-23Ci and 3-23Cii) was significantly 7 
increased in IMQ-treated mice compared to the controls. These data validate the impact of psoriasis 8 
pathogenesis in the modulation of platelet-mediated responses during the progression of this disease.   9 
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 1 
Figure 3-23: The activation of platelets in psoriatic mice. The activation of platelets upon 2 
stimulation with CRP-XL (n=3) (A), ADP (n=4) (B), or U46619 (n=3) (C) in whole blood obtained 3 
from IMQ-treated and control mice was analysed by measuring the level of fibrinogen binding (i) 4 
and P-selectin exposure (ii) by flow cytometry. P values shown are calculated by two-way ANOVA 5 
followed by Bonferroni’s correction (*p<0.05, **p<0.001 and ***p<0.0001).  6 
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  3.3.13.5 Effect of psoriatic plasma on healthy platelets  1 
 In order to determine the direct impact of psoriatic plasma samples on healthy platelets, the 2 
levels of fibrinogen binding and P-selectin exposure were measured using healthy mouse and human 3 
platelets in the presence and absence of IMQ-treated mouse plasma. The treatment of healthy human 4 
platelets (PRP) with psoriatic plasma markedly increased the levels of fibrinogen binding and P- 5 
selectin exposure in the absence (Figure 3-24i and 2-24ii) or presence (Figure 3-24iii and 3-24iv) of 6 
CRP-XL compared to the controls. Similar results were obtained upon the treatment of normal mouse 7 
isolated platelets, wherein psoriatic plasma markedly increased platelet activation in the absence 8 
(Figure 3-25Ai and 3-25Aii) or presence (Figure 3-25Aiii and 3-25Aiv) of a CRP-XL compared to 9 
the controls. Furthermore, psoriatic plasma also increased platelet activation in mouse PRP in the 10 
absence (Figure 3-25Bi and 3-25Bii) or presence (Figure 3-25Biii and 3-25Biv) of CRP-XL 11 
compared to the controls.  12 
 In order to investigate whether the augmentation of platelet function in IMQ-treated mice are 13 
mediated through FPR2/ALX, the effect of psoriatic plasma was investigated in the presence of 14 
WRW4 or in Fpr2/3-/- mouse platelets. The treatment of control mouse platelets (PRP) with psoriatic 15 
plasma significantly reduced platelet activation in the presence of WRW4 (Figure 3-26Ai and 3- 16 
26Aii). Similarly, the treatment of Fpr2/3-/- mouse platelets displayed significantly reduced platelet 17 
activation compared to the controls (Figure 3-26Bi and Figure 3-26Bii). Together, these data 18 
demonstrate the direct impact of psoriasis on platelet function and its involvement in the modulation 19 
of platelet reactivity (mainly through FPR2/ALX), which could exacerbate the pathogenesis and 20 
thrombotic complications during psoriasis at local inflammatory sites and in circulation. 21 
 22 
  23 
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 1 
 2 
Figure 3-24: The impact of psoriatic plasma on human platelets. The impact of IMQ-treated 3 
mouse plasma on healthy human platelets (PRP) was analysed by measuring the level of fibrinogen 4 
binding in the absence (i) or presence (iii) of CRP-XL (0.25µg/mL) (n=18). Similarly, the level of P- 5 
selectin exposure was measured in the absence (ii) or presence (iv) of CRP-XL (0.25µg/mL) (n=18). 6 
P values shown are calculated by a two-tailed unpaired Student’s t test (*p<0.05).  7 
  8 
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 2 
Figure 3-25: The impact of psoriatic plasma on mouse platelets. A, the impact of IMQ-treated 3 
mouse plasma on control mouse isolated platelets was analysed by measuring the levels of fibrinogen 4 
binding in the absence (Ai) or presence (Aiii) of CRP-XL (0.25µg/mL) (n=7). Similarly, P-selectin 5 
exposure was measured in the absence (Aii) or presence (Aiv) of CRP-XL (0.25µg/mL) (n=7). B, the 6 
impact of IMQ-treated plasma on control mouse PRP was analysed by measuring the levels of 7 
fibrinogen binding in the absence (Bi) or presence (Biii) of CRP-XL (0.25µg/mL) (n=6). P-selectin 8 
exposure was also measured in the absence (Bii) or presence (Biv) of CRP-XL (0.25µg/mL) (n=4). 9 
Data represent mean ± SEM. P values shown are calculated by a two-tailed unpaired Student’s t test 10 
(*p<0.05, **p<0.001 and ***p<0.0001).  11 
  12 
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Figure 3-26: FPR2/ALX-mediated effects of psoriatic plasma. A, the impact of IMQ-treated 3 
plasma on healthy mouse PRP in the presence of WRW4 was analysed by measuring the levels of 4 
fibrinogen binding (Ai) or P-selectin exposure (Aii) (n=5). B, the impact of IMQ-treated plasma on 5 
control and Fpr2/3-/- mouse PRP was analysed by measuring the levels of fibrinogen binding (Bi) or 6 
P-selectin exposure (Bii) (n=6). P values shown are calculated by a two-tailed unpaired Student’s t 7 
test (*p<0.05, **p<0.001 and ***p<0.0001).   8 
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3.4 Discussion 1 
LL37 is a powerful antimicrobial peptide that plays substantial roles in the initiation of 2 
chemotaxis and subsequent inflammatory responses in immune cells including monocytes22, mast 3 
cells53, eosinophils and neutrophils54. Moreover, the involvement of LL37 in the development of 4 
pathological conditions such as psoriasis, sepsis, inflammatory bowel disease and cystic fibrosis has 5 
been previously reported, and hence, its therapeutic potential has been analysed in detail38. LL37 has 6 
also been found to play a role in the pathogenesis of atherosclerosis55, 56, wherein it leads to the 7 
development of lesions and recruitment of inflammatory cells at the site of injury27. In addition, LL37 8 
has been found to play a role in wound healing57, where the LL37 analogue, Cys-LC-LL37, has been 9 
incorporated in cotton gauzes to produce antimicrobial wound dressings58. However, the role of LL37 10 
in the modulation of platelet reactivity, thrombosis and haemostasis has not been investigated 11 
previously in detail. Platelets play pivotal roles during inflammatory diseases, specifically in psoriasis 12 
where the modulation of platelet function leads to disseminated intravascular coagulation, thrombus 13 
formation in the microvasculature that culminates in thrombocytopenia. Henceforth, the impact of 14 
LL37 in the modulation of platelet reactivity, thrombosis and haemostasis under physiological and 15 
pathological conditions, such as psoriasis, was investigated in this study.  16 
The expression of LL37 has been reported in numerous cell types including epithelial cells 17 
and immune cells such as neutrophils and monocytes13. Since platelets are also derived from the 18 
myeloid lineage59, we hypothesised that platelets may possess LL37, and indeed the presence of LL37 19 
in platelets and its release to the external milieu upon activation was confirmed. Similar to 20 
neutrophils, platelets may also contain LL37 in their granules and release it upon stimulation to 21 
enhance the secondary platelet activation. Platelets are also known to contain several other 22 
antimicrobial peptides including platelet factor 4 (PF4), platelet basic protein (PBP) and its 23 
derivatives, connective tissue activating peptide 3 (CTAP-3), thymosin B-4 (TB-4), CAMP and 24 
fibrinopeptides A and B (FPA and FPB), and release them upon activation in order to control 25 
microbial infection60. Similarly, they may also contribute to the elevation of LL37, the only 26 
cathelicidin in humans, upon activation to support the microbial clearance, activation of inflammatory 27 
137  
 
responses, and modulation of thrombosis and haemostasis during pathological settings. The activation 1 
of platelets during inflammatory diseases is inevitable due to the presence of several molecules that 2 
activate platelets61. However, here we demonstrate LL37 as a major contributor to thrombosis and 3 
other platelet-related complications during inflammatory diseases.  4 
Thrombosis and subsequent bleeding are associated with psoriasis62. Similarly, disseminated 5 
intravascular coagulation, thrombosis in the microvasculature and sequestration of platelets are some 6 
of the common clinical manifestations in sepsis63. The level of LL37 is significantly higher in 7 
psoriasis39 and sepsis64 patients compared to healthy individuals. In line with thrombosis in 8 
vasculature, LL37 augmented in vitro thrombus formation under arterial flow conditions and 9 
shortened the bleeding time in mice. These data demonstrate a fundamental function for LL37 in the 10 
modulation of thrombosis and haemostasis under pathological settings. Similarly, LL37 induced 11 
platelet aggregation, fibrinogen binding, granule secretion, adhesion, spreading and intracellular 12 
calcium mobilisation in platelets.  13 
The concentrations used in the present study (up to 50 µM) revealed activatory roles of LL37 14 
in platelets. A recent study reported the inhibitory effects of LL37 in platelets at concentrations 15 
between 0.1 and 1.2 mM37. These concentrations are not only substantially greater than the achievable 16 
levels under a range of pathological conditions, but also exert toxic effects in several cell types40 17 
including platelets  at 100 µM. However, in pathological conditions such as severe psoriasis, a median 18 
concentration of 304 µM LL37 in psoriatic lesions has been reported39, which can exert cytotoxicity 19 
towards platelets at the local sites and reduce the number of functional platelets in the circulation. In 20 
other conditions such as pulmonary infections, a concentration of 5 µM LL37 has been detected65. 21 
Notably, the normal plasma concentration of LL37 in healthy individuals is suggested to be 22 
approximately 1.2 µM66, which did not exert any effects on platelets. The concentrations of LL37 23 
used in the present study are similar to those achievable during pathological conditions, such as 24 
sepsis64, and early stages of other inflammatory diseases including psoriasis. Hence, the inhibitory 25 
effects of LL37 that were previously reported in platelets may be due to the cytotoxic effects of LL37, 26 
although additional causes cannot be excluded. Together with the previous report, our data 27 
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demonstrate that LL37 induces platelet activation at the early stages of inflammatory diseases 1 
resulting in the initiation of thrombosis and modulation of haemostasis. However, at concentrations 2 
of 100 µM and above (such as in local psoriatic lesions), LL37 may exert cytotoxic effects that can 3 
result in the reduction of platelet function and decrease the circulating platelet number, which 4 
subsequently leads to bleeding complications. We were able to demonstrate the involvement of LL37 5 
in platelet-related complications in inflammatory diseases, psoriasis is the case in point. Furthermore, 6 
we displayed the direct impact of disease (psoriasis) pathogenesis in the dysregulation of platelet 7 
function. Together with the modulation of thrombosis and haemostasis, LL37 may also induce other 8 
platelet-related complications (e.g. thrombocytopenia and inflammation) during various 9 
inflammatory diseases where its level is elevated. 10 
LL37 has been reported to act mainly through FPR2/ALX in other cell types22, 30, although 11 
additional receptors such as toll-like receptors (TLRs), receptor tyrosine kinases (RTKs), ligand- 12 
gated ion channel (LGIC), CCR3, P2Y11 and P2X7 have shown to bind this peptide67. To investigate 13 
the underlying molecular mechanisms through which LL37 modulates platelet function, the effects 14 
of LL37 in human platelets treated with WRW4 and platelets obtained from Fpr2/3−/− mice were 15 
analysed. LL37-mediated activation was largely reduced by WRW4 and in platelets obtained from 16 
Fpr2/3−/− mice compared to the controls, verifying the functional dependence of LL37 primarily on 17 
FPR2/ALX. LL37 binding assays that were performed using platelets obtained from Fpr2/3−/− mice 18 
confirmed the substantial reduction in the binding of LL37 to Fpr2/3−/− platelet surface compared to 19 
Fpr1−/− and control mouse platelets. Additionally, we were able to demonstrate that FPR2/ALX 20 
inhibition in human platelets or deletion of Fpr2/3 gene in mice lead to the elevation of cAMP levels, 21 
which is a major inhibitory molecule for platelet activation. This indicates the involvement of cAMP- 22 
dependent signalling pathways in the regulation of FPR2/ALX in platelets. Nevertheless, the 23 
activation of platelets by LL37 through receptors other than FPRs cannot be excluded and further 24 
investigations will be needed to explore the contributions of such receptors in the modulation of 25 
platelet function upon ligation with LL37. 26 
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In conclusion, this study demonstrates that LL37 is stored in platelets and secreted upon 1 
platelet activation. Moreover, LL37 promotes thrombus formation and altered haemostasis in mice. 2 
In line with these results, LL37 induced platelet activation in a range of platelet functional assays 3 
such as platelet aggregation, inside-out signalling to integrin ɑIIbβ3 and outside-in signalling by the 4 
same integrin, granule secretion and intracellular calcium mobilisation. These activatory roles of 5 
LL37 were diminished in the presence of a FPR2/ALX pharmacological inhibitor, and in platelets 6 
obtained from Fpr2/3−/− mice confirming the functional dependence of LL37 primarily via this 7 
receptor in platelets. Additionally, we demonstrate an instrumental role for FPR2/ALX in the positive 8 
feedback regulation of platelet function, in which the deficiency or blockade of this receptor impaired 9 
haemostasis and the activation of platelets in general. The significant roles of LL37 and FPR2/ALX 10 
in the modulation of thrombosis and haemostasis renders them as potential candidates for the 11 
exacerbation of platelet-related complications and immune responses in numerous inflammatory 12 
diseases where platelets play essential roles. Notably, the presence of FPRs in platelets opens up new 13 
avenues to investigate the involvement of a multiplicity of FPR ligands in the modulation of 14 
thrombosis, haemostasis, and other platelet-related complications during inflammatory responses. 15 
Based on the data presented in this study, both LL37 and FPRs can act as potential therapeutic targets 16 
for cardiovascular and a range of inflammatory diseases.  17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
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3.5 Methods 1 
Preparation of human platelet-rich plasma and isolated platelets 2 
The University of Reading Research Ethics Committee approved all the experimental 3 
procedures using human blood from healthy volunteers. The blood samples were collected from 4 
healthy, aspirin-free volunteers after obtaining written informed consent. The blood was collected 5 
into VACUETTE® blood collection tubes containing 3.2% (w/v) sodium citrate. The blood samples 6 
were then centrifuged at 102g for 20 minutes at room temperature to obtain platelet-rich plasma 7 
(PRP). The PRP was rested at 30°C for 30 minutes prior to use. For the preparation of isolated 8 
platelets, the blood was mixed with ACD (2.5% sodium citrate, 2% D-glucose and 1.5% citric acid) 9 
at 1 (ACD): 9 (blood) ratio and centrifuged at 102g for 20 minutes. The PRP was collected, mixed 10 
with appropriate volume of ACD, and centrifuged at 1413g for 10 minutes at room temperature. The 11 
resultant platelet pellet was resuspended in modified Tyrodes-HEPES buffer (134mM NaCl, 2.9mM 12 
KCl, 0.34mM Na2HPO4.12H2O, 12mM NaHCO3, 20mM HEPES and 1mM MgCl2, pH 7.3) with 13 
appropriate volume of ACD, and centrifuged once again at 1413g for 10 minutes at room temperature. 14 
The resultant platelet pellet was resuspended to a final density of 4×108 cells/mL in modified 15 
Tyrode’s-HEPES buffer and allowed to rest for 30 minutes at 30ºC prior to use. 16 
Mouse blood collection and platelet preparation 17 
The mouse strains of Fpr1−/−1 and Fpr2/3−/−2 on a C57BL/6 background obtained from 18 
William Harvey Research Institute, London, UK and wild type C57BL/6 mice from Envigo, UK were 19 
used in this study. The mice were sacrificed with CO2 and the blood was directly collected by cardiac 20 
puncture into a syringe containing 3.2% (w/v) sodium citrate at 1 (citrate):9 (blood) ratio. The blood 21 
was then centrifuged at 203g for 8 minutes at room temperature and the PRP was collected. The 22 
remaining blood was resuspended in 500 µL of modified Tyrode’s-HEPES buffer and centrifuged 23 
once again at 203g for 5 minutes. The resultant PRP then centrifuged at 1028g for 5 minutes. The 24 
resultant platelet pellet was resuspended in modified Tyrode’s-HEPES buffer at a density of 2x108 25 
cells/mL. 26 
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Enzyme-linked immunosorbent assay (ELISA) for the detection of LL37 1 
 To investigate the presence of LL37 in platelets, a direct ELISA was performed using LL37- 2 
selective antibody (sc-166770, Santa Cruz Biotechnology, USA). Human isolated platelets were 3 
treated with a vehicle (modified Tyrode’s-HEPES buffer) or CRP-XL (1 μg/mL) for five minutes 4 
under stirring conditions to obtain resting or activated platelets, respectively. The platelets were 5 
centrifuged at 1413g for 10 minutes at room temperature. The supernatant was collected, stored at - 6 
80°C, lyophilised, and resuspended in Nonidet P40 (NP40) buffer. The resultant pellet was also 7 
resuspended in NP40 buffer. Briefly, a 96 well plate was coated with 50 µL of various concentrations 8 
of LL37 (for the standard curve), or the resting or activated platelet samples (pellets or supernatants), 9 
and incubated at 4ºC overnight. The plate was blocked with 150 µL of assay buffer (0.5% BSA in 10 
PBS) for one hour at room temperate. Following washing three times with a wash buffer (0.1% Triton 11 
X-100 in PBS), 50 µL of anti-LL37 antibody was added and the plate was then incubated for 4 hours 12 
at room temperature. Following incubation, the plates were washed with the wash buffer before the 13 
addition of goat anti-mouse horseradish peroxidase-conjugated IgG (Life Technologies, UK) and 14 
incubation for one hour at room temperate. The plates were then washed three times, and 100 µl 15 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate was added and allowed to incubate at room 16 
temperature until the development of a colour. The reaction was stopped by the addition of 100 µL 17 
stop solution (0.5M HCl). The level of absorbance was measured at 450nm using an ELISA 18 
microplate reader (EMax precision plate reader, Molecular Devices, UK). 19 
Immunofluorescence microscopy 20 
 Human platelets were stimulated with modified Tyrode’s-HEPES buffer (resting platelets) or 21 
3 µM U46619 (activated platelets) and were left to settle on poly-L-lysine coverslips for 1 hour at 22 
37ºC. The platelets were then fixed with 0.2% formyl saline and then permeablised with 0.2% Triton 23 
in PBS. Following washing with PBS, the coverslips were incubated with primary antibodies for 24 
LL37 (Novus Biological, UK) and phalloidin (Invitrogen, UK) overnight at 4ºC and washed with 25 
PBS prior to staining with Alexa 488 and Alexa 647-conjugated secondary antibodies for phalloidin 26 
and LL37, respectively, and incubated for one hour at room temperature in the dark. Coverslips were 27 
148 
 
extensively washed and mounted onto slides. Platelets were imaged with a magnification of 100x 1 
using a Nikon A1-R confocal microscope (Nikon Instruments, UK). 2 
In vitro thrombus formation assay 3 
In vitro thrombus formation was performed as described previously3, 4. In brief, human 4 
DiOC6-labelled (Sigma Aldrich, UK) human whole blood was pre-incubated with a vehicle or 5 
different concentrations of LL37 (10, 20 and 50 µM) for 10 minutes before perfusion over collagen 6 
(400µg/mL)-coated Vena8™ Biochips (Cellix Ltd, Ireland) at a shear rate of 20 dynes/cm2. Z-stack 7 
fluorescence images of thrombi were obtained every 30 seconds for up to 10 minutes using a Nikon 8 
eclipse (TE2000-U) microscope (Nikon Instruments, UK). The fluorescence intensity was calculated 9 
by analysing the data using ImageJ software (National Institutes of Health, USA). 10 
Tail bleeding assay 11 
Tail bleeding assay was performed as described previously5. The British Home Office 12 
approved the experimental procedures. In brief, C57BL/6 mice (10-12 weeks old; Envigo, UK) were 13 
anaesthetised using ketamine (80 mg/kg) and xylazine (5 mg/kg) administered via the intraperitoneal 14 
route for 20 minutes before the experiment and were then placed on a heated mat (37°C). Vehicle or 15 
LL37 (20 µM) was infused via femoral artery 5 minutes before the dissection of 1mm of tail tip, and 16 
the tail was immersed in sterile saline. The time to cessation of bleeding was measured and the assay 17 
was terminated at 20 minutes. 18 
Platelet aggregation assay 19 
In vitro platelet aggregation assays were performed by optical aggregometry using a two- 20 
channel platelet aggregometer (Chrono-Log Corporation, USA). Isolated platelets (270 µL) were 21 
added into a siliconised cuvette and pre-warmed at 37°C for 90 seconds. Upon the addition of an 22 
agonist, the platelets were allowed to aggregate under continuous stirring at 1200rpm for 5 minutes 23 
at 37ºC and the level of aggregation was monitored. To analyse the effects of FPR2/ALX on LL37- 24 
induced platelet aggregation, FPR2/ALX-selective inhibitor, WRW4, used. The platelets were pre- 25 
treated with WRW4 (5 µM) for 5 minutes before the addition of LL37 (20 µM) and the level of 26 
149 
 
aggregation was monitored. Data were analysed by calculating the percentage of maximum platelet 1 
aggregation obtained at 5 minutes. 2 
ATP secretion assay   3 
To assess the level of dense granule secretion in platelets, ATP secretion assays were 4 
performed using a luciferin–luciferase luminescence substrate by lumi-aggregometry (Chrono-log, 5 
USA). The level of ATP released from platelets upon stimulation with a platelet agonist, CRP-XL 6 
(0.25 µg/mL), in the presence and absence of different concentrations of WRW4 was measured by 7 
observing the level of luminescence released. 8 
Flow cytometry based assays 9 
 In order to measure the level of fibrinogen binding and P-selectin exposure on the platelet 10 
surface, flow cytometry based assays were performed. Five microliters of PRP or isolated platelets 11 
were incubated with 1 μl of FITC-conjugated fibrinogen antibody (1:50) and 1 μl of PECy5- 12 
conjugated anti-CD62P (P-selectin) (1:50) antibody in the presence and absence of various 13 
concentrations of LL37 or platelet agonists. The final volume was made up to 50 μl using HEPES- 14 
buffered saline (HBS) (150mM NaCl, 5mM KCl, 1mM MgSO4.7H2O and 10mM HEPES, pH 7.4) 15 
and the samples were incubated for 20 minutes at room temperature. Following fixation in 0.2% 16 
formyl saline, the samples were analysed using an Accuri C6 flow cytometer (BD Biosciences, UK) 17 
by counting 5000 events within the gated population for platelets. The median fluorescence intensity 18 
was calculated using Accuri C6 software to quantify the levels of fibrinogen binding and P-selectin 19 
exposure on the surface of platelets. Similarly, for the analysis of FPR2/ALX expression on platelets, 20 
five microliters of PRP were incubated with 1 μl of anti-FPR2/ALX (5μg/mL) and 2 μl of Cy5- 21 
conjugated anti-mouse IgG (80 μg/mL) with or without 1 μg/mL CRP-XL. Following 20 minutes 22 
incubation at room temperature, the platelets were fixed in 0.2% formyl saline and analysed by flow 23 
cytometry. For the LL37 binding assay, following the incubation of isolated platelets with 5-FAM- 24 
LC-conjugated LL37 or 5-FAM-conjugated scrambled LL37 (20 μM) for 20 minutes, the platelets 25 
were fixed in 0.2% formyl saline and analysed by flow cytometry.  26 
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Intracellular calcium mobilisation assay 1 
PRP (2mL) was mixed with 2 µL of Fluo-4 AM dye (1 µM) (Life technologies, UK) and 2 
incubated for 20 minutes at 30ºC in dark. The PRP was then centrifuged at 1413g for 10 minutes at 3 
20ºC. The resultant platelet pellet was suspended in 500 µL modified Tyrode’s-HEPES buffer and 4 
maintained at 30ºC in dark. The platelets were stimulated with different concentrations of LL37 or 5 
platelet agonists and the level of fluorescence intensity was measured by FluoStar Optima 6 
Spectrofluorimeter (BMG Labtech, Germany) at 37ºC for 180 seconds using an excitation 7 
wavelength of 485nm and emission at 510nm. Data were analysed by calculating the percentage of 8 
calcium released at 90 seconds. 9 
SDS-PAGE and immunoblotting analysis 10 
Immunoblot analysis was performed using platelet lysates prepared under reducing 11 
conditions. The samples were heated to 90°C for 10 minutes and subjected to SDS-PAGE using 10% 12 
resolving gels. The gels were then transferred to polyvinylidene difluoride (PVDF) membranes and 13 
blocked by incubation in 5% milk in TBS-T (20mM Tris, 140mM NaCl and Tween-20, pH 7.6). 14 
Following an overnight incubation with primary anti-FPR2/ALX antibody (1:500) (Abcam, UK), the 15 
blots were washed with TBS-T and incubated with secondary Cy5-conjugated goat anti-rabbit IgG 16 
antibodies (1:1000) (Invitrogen, UK) in TBS-T containing 5% milk for one hour at room temperature. 17 
Following washing in TBS-T for one hour at room temperature, the blots were analysed using a 18 
Typhoon 9400 Variable Mode Imager system (GE Healthcare, UK). Equal loading of proteins in each 19 
lane was determined using anti-human 14-3-3# antibodies (1:1000) (Santa Cruz Biotechnology, 20 
USA). 21 
Lactate dehydrogenase (LDH) Cytotoxicity assay 22 
To test whether LL37 has cytotoxic effects on platelets, the level of LDH released from LL37- 23 
treated human isolated platelets was determined using LDH Cytotoxicity Assay Kit (Pierce, UK) 24 
according to the manufacturer's instructions. In brief, the platelets were incubated at 37°C under 5% 25 
CO2 for 30 minutes. The vehicle or a range of concentrations of LL37 (1 to 100 µM) was added in 26 
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duplicates to different wells of a 96 well plate and incubated for 10 minutes. One set of wells were 1 
treated with the lysis buffer provided from the kit as a positive control for maximum LDH release, 2 
and another set was treated with modified Tyrode’s-HEPES buffer for the detection of spontaneous 3 
LDH release. Results provided represent mean values from duplicate absorbance measurements, and 4 
are given as fractional LDH release compared to the positive control, which yields maximum LDH 5 
release (i.e. 100% cytotoxicity). 6 
Cyclic nucleotide assay  7 
A cAMP ELISA kit (Cambridge Bioscience, UK) was used for the detection of the total 8 
cellular levels of cAMP in human and mouse platelets. Human isolated platelets were pre-incubated 9 
for 10 minutes with a selective inhibitor for FPR2/ALX, WRW4. Similarly, platelets obtained from 10 
control or Fpr2/3−/− mice were also used. The platelets were lysed with 0.1M HCl and the levels of 11 
cAMP were calculated according to the manufacturer’s protocol. 12 
Mass spectrometry analysis for LL37 stability in plasma 13 
 Plasma stability of LL37 was determined using human plasma from three individual donors. 14 
LL37 was spiked into plasma at a final concentration of 100μg/mL and the solution was subsequently 15 
incubated at 37°C for up to 2 hours. Aliquots were removed at 0, 30, 60 and 120 minutes and diluted 16 
1:4 in ice cold methanol. Samples were centrifuged at 2500rpm for 45 min at 4ºC. The supernatant 17 
was collected and analysed by mass spectrometry (LC-MS) (Orbitrap, C8 column, Solvent system: 18 
0.1% formic acid in water and 0.1% formic acid in acetonitrile). Stability in plasma was calculated 19 
by integrating m/z peak areas of samples using Analyst software (XCalibur, Thermofisher, UK). 20 
Similar experiments were also performed in PRP obtained from three separate donors.  21 
Platelet adhesion and spreading on fibrinogen  22 
 Isolated human platelets were treated with different concentrations of LL37 or an FPR2/ALX- 23 
selective inhibitor, WRW4, prior to loading onto fibrinogen (100 µg/mL)-coated coverslips and 24 
incubation for 30 minutes. The coverslips were then washed with PBS to remove non-adhered 25 
platelets. Adhered platelets were fixed with 0.2% formyl saline for 10 minutes prior to 26 
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permeabilisation with 0.2% Triton X-100 for five minutes at room temperature. Adhered platelets 1 
were stained with Alexa 488-conjugated phalloidin for 30 minutes at room temperature. The 2 
coverslips were then mounted onto slides and scanned using a Nikon A1-R confocal microscope (60x 3 
objective).  Ten random fields of view were recorded for each sample. The data were analysed to 4 
quantify the number of adhered and spread platelets, and the relative area of spread platelets using 5 
ImageJ. The relative surface area of spread platelets was obtained by subtracting the surface area of 6 
resting platelets.  7 
Structural modelling and molecular docking analysis 8 
 The X-ray crystal structures of FPR2/ALX are not available; hence, homology models of this 9 
receptor were developed to determine the plausible interactions between LL37 and this receptor. The 10 
amino acid sequence of FPR2/ALX (accession code: P25090) was retrieved from UniProt6 and 11 
submitted to MODELLER-ModWeb server7 for protein structural modelling. The top three structural 12 
models generated were analysed for the sequence similarity, identity and orientation of amino acids. 13 
Homology models built on the structural template of human delta opioid 7 transmembrane receptor 14 
(PDB code - 4N6H; 1.8 Å) with which FPR2/ALX was found to share 29% identity and was identified 15 
as the most appropriate model for FPR2/ALX. This homology model was validated by docking with 16 
LL37 using Sybyl-X8. The interactions of LL37 with this receptor was identified using PatchDock9. 17 
The docking results were visualised using the program, PyMOL10 and the molecular interactions of 18 
the docked ligands were analysed by the programme, CONTACTS, as provided in the CCP4 suite of 19 
programs11, 12. Potential hydrogen bonds were assigned if the distance between two electronegative 20 
atoms was less than 3.3Å. 21 
Imiquimod-induced “psoriasis-like” skin inflammation  22 
 A 4cm2 mouse dorsal skin area was shaved and depilated (Veet, France) prior to daily topical 23 
treatment of 75mg of Aldara™ (Imiquimod, IMQ) cream (Meda Pharma, UK) or Vaseline for 4 24 
consecutive days following a previously published protocol13. Sample collection and further assays 25 
were performed on day 5. Daily double fold skin thickness was measured using a micrometer (Farnell, 26 
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UK) with 0.1mm accuracy and the change in thickness was calculated against day 0 skin thickness. 1 
PASI scoring for skin scaling (desquamations) and redness (erythema) was performed by assessors 2 
blinded to the treatments. Spleen weights were normalised to body weights.  3 
Statistical analysis 4 
Data presented in this study are represented as mean ± SEM. The statistical significance was 5 
analysed using two-tailed unpaired Student’s t test for two-sample comparisons for the data obtained 6 
from ELISA for LL37 and mCRAMP quantification, flow cytometric assay for FPR2/ALX 7 
expression and platelet receptor characterisation, cAMP assay, LL37 binding assay and platelet 8 
aggregometry in the presence of a FPR2/ALX-selective inhibitor. For multiple comparisons, 9 
statistical significance was established using one-way or two-way ANOVA followed by Bonferroni's 10 
correction for data obtained from in vitro thrombus formation, LL37 plasma stability, LL37 binding 11 
in mice, ATP release, platelet aggregation and activation, calcium mobilisation, and LDH 12 
cytotoxicity assays. Data obtained from the tail bleeding assay were analysed using a non-parametric 13 
Mann-Whitney test. All statistical analyses were performed using GraphPad Prism 7 software 14 
(GraphPad Software Inc., USA). 15 
 16 
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 24 
 25 
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4.1 Abstract 9 
 Annexin A1 (AnxA1) is an endogenous protein that is known to play a role in the resolution 10 
of inflammation. It plays a pivotal role in the modulation of inflammatory responses in order to reach 11 
homeostasis. Annexin A1 is known to bind formyl peptide receptor 2 (FPR2/ALX), which are a group 12 
of G-protein coupled receptors that play a role in host defense and inflammation. Despite the detailed 13 
research in the role of Annexin A1 in the modulation of immunological response in various immune 14 
cells, including neutrophils and monocytes, its effects on the regulation of haemostasis, thrombosis 15 
and platelet-mediated inflammatory responses remain unexplored. Additionally, there is a paucity of 16 
studies to the role of platelets in the regulation of resolution of inflammation. Here, we demonstrate 17 
the role of the AnxA1 N-terminal peptide, Ac2-26, in the regulation of platelet haemostatic function, 18 
where we were able to confirm its activatory role. Ac2-26 activated platelets, evident in its ability to 19 
induce fibrinogen binding and P-selectin exposure. Moreover, it induced calcium mobilisation in a 20 
concentration-dependent manner. All of which were abrogated in the absence of Fpr2/3. Conversely, 21 
the activatory effects of Ac2-26 were exaggerated in AnxA1-deficient mice. This might be attributed 22 
to our findings of the overexpression of FPR2/ALX receptor in these mice. Moreover, these mice 23 
exhibited dysfunctional platelet receptor levels (GPIb), but normal haemostasis (tail bleeding assay). 24 
Understanding the function of AnxA1 and FPR2/ALX in the modulation of platelet function and 25 
platelet-associated inflammation can lead to the development of improved therapeutics that can target 26 
the resolution of inflammation without compromising the immune state of the host. 27 
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 1 
4.2 Introduction 2 
 3 
Platelets are non-nucleated blood cells that play a primary role in haemostasis by arresting 4 
bleeding upon vascular injury. Under pathophysiological conditions, the inappropriate activation of 5 
platelets leads to the formation of blood clots (thrombus) within the circulation1. This can reduce or 6 
retard the blood flow to vital organs including the heart and brain, ultimately causing heart attacks 7 
and strokes, respectively2. Cancer, type II diabetes, and cardiovascular diseases including coronary 8 
artery disease and atherosclerosis are among diseases associated with platelet reactivity. Conversely, 9 
failure of platelets to become activated leads to excessive bleeding and coagulopathies3. Apart from 10 
their haemostatic function, platelets are recognised as immune cells, mediating inflammation and 11 
innate immune responses4. This notion was supported by the presence of known immunologic 12 
receptors on platelets, including Toll-like receptors (TLRs)5, chemokine receptors6 and formyl 13 
peptide receptors (FPRs)7. 14 
 15 
Inflammation is a protective, physiological event induced by the body to remove stimulus and 16 
facilitate tissue repair in cases of injury8. Under physiological conditions, inflammation is followed 17 
by a process known as ‘resolution’, which limits the inflammatory cell migration, induces apoptosis 18 
and clearance of activated inflammatory cells9, regaining/restoring homeostasis. However, failure to 19 
contain such processes contributes to the chronicity of inflammatory diseases10, 11. A crucial step in 20 
the resolution is the production of specialized pro-resolving mediators (SPMs), including lipids 21 
(resolvins, protectins, maresins and lipoxins), and proteins such as annexin A1 (AnxA1)12. In 22 
particular, AnxA1 (a glucocorticoid-regulated protein) is known to play a role in the regulation of 23 
inflammation, and cell proliferation, differentiation and apoptosis13.  It is expressed in the cytosol of 24 
various resting cells, including neutrophils, monocytes, macrophages and epithelial cells13. 25 
Furthermore, a limited number of studies have reported its expression in platelets14, 15. The activation 26 
of such immune cells leads to the externalization of AnxA1 on the cell membrane surface and/or its 27 
secretion16. The extracellular AnxA1 then undergoes conformational changes, exposing its active 28 
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form, the N-terminal region that mediates the binding to its N-formyl peptide receptor, FPR2/ALX17. 1 
The externalization and secretion of Anxa1 is typically accompanied by a proteolytic cleavage of its 2 
N-terminal region, such cleavage is implicated with the down-regulation of Anxa1, rather than the 3 
release of bioactive peptides18-20. This was validated in a study whereby a cleavage-resistant Anxa1, 4 
termed Super Annexin A1 (SAnxA1), retained a prolonged function in the microvasculature21. While 5 
the full-length N-terminus has been shown to be inactive, a synthetic peptide containing the first 26 6 
amino acids of its sequence displayed functionality22. The N-Acetyl 2–26 (Ac2-26) is a peptide 7 
sequence derived from this N-terminus form and has been shown to act as a pharmacophore 23 and 8 
plausibly maintain the properties of the full-length protein21, 24-27. Nonetheless, a limited/small 9 
number of studies reported an opposing effect28-30. Both full-length and cleaved forms of the protein 10 
have been found in inflammatory exudates and other extracellular biological fluids31-34. 11 
 12 
AnxA1 has been shown to play a role in the regulation of inflammation, albeit an opposing 13 
one, in various cell types13. However, its role in the regulation of platelet function; haemostasis and 14 
thrombosis remains unexplored. AnxA1 has been linked to inflammatory diseases associated with 15 
platelet reactivity35, including atherosclerosis36, myocardial infarctions37 and strokes38. Furthermore, 16 
the dysregulation of AnxA1 expression has been implicated in various diseases/pathologies; its up- 17 
regulation has been reported in cancer39, melanoma40, breast cancer41, 42, periods of remission in 18 
ulcerative colitis11, and its downregulation in Crohn’s disease43, thyroid cancer44, 19 
signifying/postulating its prognostic significance and therapeutic efficacy. While numerous studies 20 
demonstrated its role in the regulation of inflammation, there is a paucity of studies on its role in the 21 
regulation of platelet function. Hence, in this study, we aimed to demonstrate the direct role of 22 
endogenous AnxA1 and its exogenous, peptidomimetic Ac2-26 in the regulation of the haemostatic 23 
function of platelets via FPR2/ALX-mediated signalling pathways using a range of platelet functional 24 
assays. We were able to confirm the activatory/haemostatic role of Ac2-26 in the regulation of platelet 25 
function. Ac2-26 activated platelets, evident in its ability to induce fibrinogen binding and P-selectin 26 
exposure. Moreover, it induced calcium mobilisation in a concentration-dependent manner. These 27 
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results were abrogated in Fpr2/3-deficient mice. Conversely, the activatory effects of Ac2-26 were 1 
exaggerated in AnxA1-deficient mice, which might be attributed to our findings of the overexpression 2 
of FPR2/ALX receptor in these mice. Moreover, these mice exhibited dysfunctional platelet receptor 3 
levels (GPIb), but normal haemostasis (tail bleeding assay). Together, these findings demonstrate a 4 
central role of FPR2/ALX in the regulation of platelet function out of the scope of haemostasis. 5 
Understanding the function of AnxA1 and FPR2/ALX in the modulation of platelet function and 6 
platelet-associated inflammation might lead to the development of improved treatment modalities. 7 
 8 
4.3 Results 9 
 10 
 4.3.1. Characterization of platelets obtained from Anxa1−/− mice 11 
 In order to assess the effect of Annexin A1 in the regulation of platelet function in this study, 12 
we have utilized Anxa1−/− mice. The AnxA1 protein is encoded by the Anxa1 gene in mice 45. Many 13 
studies have reported biological defects associated with such deficiency, including exaggerated 14 
inflammatory responses during myocardial ischaemia and cardiovascular dysfunction (in diabetes)46- 15 
49. Thus, to determine whether these mice exhibit any functional defects that might influence platelets 16 
and their haemostatic function, we have investigated the levels of major adhesion platelet receptors, 17 
including GPVI, GPIbα, αIIbβ3 and ɑ2β1, and their expression levels on the surface of platelets by 18 
using flow cytometry. Notably, the characterisation of platelets obtained from Anxa1−/− mice failed 19 
to display any difference in GPVI, αIIbβ3 and ɑ2β1 surface expression, However, a significant 20 
reduction in the levels of GPIbα were observed on the surface of platelets obtained from Anxa1−/− 21 
mice in comparison to the control mouse platelets (Figure 4-1A). This data indicates down-regulation 22 
of GPIbα receptors on the surface of platelets obtained from Anxa1−/− mice.  23 
 24 
 25 
 26 
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 1 
 4.3.2 Systemic haemostasis is intact in Anxa1−/− mice  2 
 3 
 Since one of the major platelet adhesion receptors was down-regulated in Anxa1−/− mice, we 4 
sought to investigate whether the haemostasis is compromised in these mice using a tail bleeding 5 
model. No significant difference was observed in the mean bleeding time Anxa1−/− mice (225.2±3.6 6 
seconds) compared to the control group (217.5±20.4 seconds)  (Figure 4-1B). These data indicate that 7 
the loss of the ANXA1 gene does not interfere with systemic haemostasis, rendering it intact. 8 
 4.3.3 Role of Annexin A1 in platelet activation  9 
 Many studies have reported an “anti-inflammatory” role of Annexin A1 in many cell types 16, 10 
22, 23, 26, 50, 51. However, other studies have reported “pro-inflammatory” properties of such protein. 11 
Presumably, anti-inflammatory molecules lead to an inhibition in platelet function52-54, whereas the 12 
activation of platelets mediates pro-inflammatory responses4. The activation of platelets results in 13 
inside-out signaling to the integrin aIIbb3 on the surface of platelet, converting it to a high affinity 14 
state that allows fibrinogen binding and subsequent platelet aggregation55. Moreover, upon activation, 15 
platelets secrete granules that mediate in the secondary platelet activation, namely, P-selectin is 16 
released from a-granules and then exposed to the surface of platelets56. In order to determine the 17 
effect of the “anti-inflammatory” Annexin A1 in the regulation of platelet function, platelet activation 18 
(evident by the levels of fibrinogen binding and P-selectin exposure) induced by CRP-XL (via GPVI 19 
receptor) and ADP (acts via P2Y receptors) was measured by flow cytometry. Upon the activation of 20 
platelets by CRP-XL, the level of both fibrinogen binding (Figure 4-1Ci) and P-selectin exposure 21 
(Figure 4-1Cii) were reduced in platelets obtained from Anxa1−/− compared to the control platelets. 22 
Similarly, these levels were reduced upon activation of platelets by ADP (Figure 4-1Di and 4-1Dii). 23 
Together, these data indicate an activatory/protective role for the endogenous, full-length Annexin 24 
A1 in the regulation of platelet function. 25 
  26 
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 1 
Figure 4-1: Deletion of Anxa1 in mice affects platelet function. The characterisation of platelets 2 
obtained from AnxA1-/- mice (A). The expression levels of major platelet receptors such as αIIbβ3, 3 
ɑ2β1, GPVI and GPIbα in platelets obtained from control and AnxA1-/- mice were analysed by flow 4 
cytometry using selective fluorescent-labelled antibodies.  Data represent mean ± SEM (n=8). B, the 5 
impact of AnxA1 deletion on the modulation of haemostasis was analysed by tail bleeding assay in 6 
control or AnxA1-/- mice. Data represent mean ± SEM (n=7). C, the levels of fibrinogen binding (i) 7 
and P-selectin exposure (ii) were analysed in whole blood obtained from control or AnxA1-/- mice 8 
upon stimulation with various concentrations of CRP-XL by flow cytometry. Data represent mean ± 9 
SEM (n=4). D, the levels of fibrinogen binding (i) and P-selectin exposure (ii) were analysed in whole 10 
blood obtained from control or AnxA1-/- mice upon stimulation with various concentrations of ADP 11 
by flow cytometry. Data represent mean ± SEM (n=4). The statistical significance was calculated by 12 
two-way ANOVA followed by Bonferroni’s correction in most of the experiments except for the data 13 
shown in panel A and B, which were calculated by two-tailed unpaired Student’s t test, and non- 14 
parametric Mann-Whitney test, respectively (*p<0.01. **p<0.001 and ***p<0.0001).  15 
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 4.3.4 Role of Annexin A1 N-terminal cleavage peptide, Ac2-26, in platelet 1 
function  2 
Many studies have reported “anti-inflammatory” properties of Annexin A1 in various cell 3 
types by utilization of AnxA1 recombinant proteins while others utilized its pharmacophore, the Ac2- 4 
26 N-terminal peptide cleavage molecule, to demonstrate such properties24, 29, 57-59. Conversely, a 5 
limited number of studies have reported opposing “pro-inflammatory” properties29. Hence, to 6 
investigate the role of this cleavage peptide in the regulation of platelet function, its effect on platelet 7 
activation was measured using flow cytometry. ANXA1Ac2-26 induced platelet activation as evidenced 8 
in its ability to trigger fibrinogen binding (Figure 4-2Ai) and P-selectin exposure (Figure 4-2Aii) in 9 
a concentration-dependent manner. Moreover, these results were exaggerated/pronounced in platelets 10 
obtained from Anxa1−/− mice compared to control mouse platelets. Together, these data indicate an 11 
activatory role of the ANXA1Ac2-26. 12 
 4.3.5 Ac2-26 and acts through FPR2/ALX to induce platelet activation and 13 
platelet-leukocyte aggregation 14 
The Annexin A1 peptide is known to act through FPR2/ALX in various cell types25, 60, 61. 15 
Thus, following our findings on the activatory roles of ANXAc2-26 on platelet function, we sought to 16 
investigate whether these effects were mediated through FPR2/ALX in platelets as well. The 17 
activatory effects of ANXAc2-26 were abrogated in the presence of an FPR2/ALX-selective inhibitor, 18 
WRW4, as evidenced in its ability to reduce the level of fibrinogen binding compared to the control 19 
(Figure 4-2Ci). Furthermore, the level of P-selectin exposure was reduced in platelets obtained from 20 
Fpr2/3−/− mice compared to control mouse platelets (Figure 4-2Cii). Notably, the characterization 21 
of platelets obtained from Fpr2/3−/− mice failed to display any defects in the size and number of 22 
platelets or the levels of major platelet receptors including GPVI, GPIbα, αIIbβ3 and ɑ2β1 (Figure 4- 23 
2Ciii) in comparison to the control mouse platelets. 24 
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To corroborate the activatory effects of ANXAc2-26 on platelet function through FPR2/ALX, 1 
its ability to induce calcium mobilization in Fpr2/3−/− mice was investigated. Upon the activation 2 
of platelets, mobilization of Ca2+ stored in the dense tubular system in platelets and influx of 3 
extracellular Ca2+ across the plasma membrane occurs, ultimately leading to thrombus formation62. 4 
To assess the ability of ANXAc2-26 to induce calcium mobilization in platelets, intracellular calcium 5 
levels were measured in Fluo-4 AM dye-loaded mouse platelets using flow cytometry. Indeed, 6 
ANXAc2-26 induced calcium mobilization in mouse platelets in a concentration-dependent manner. 7 
Furthermore, these effects were abrogated in platelets obtained from Fpr2/3−/− mice compared to 8 
the control platelets (Figure 4-2D). Together, these data confirm the role of FPR2/ALX in mediation 9 
of ANXAc2-26 activatory roles in platelet function.  10 
 11 
 12 
  13 
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 1 
 2 
 3 
Figure 4-2: Ac2-26 effects are mediated through FPR2/ALX in platelets. The activation of platelets (A). The levels of fibrinogen binding (Ai) and 4 
P-selectin exposure (Aii) were analysed in whole blood obtained from control or AnxA1-/- mice upon stimulation with various concentrations of Ac2-26 5 
by flow cytometry. Data represent mean ± SEM (n=4). B, the level of P-selectin exposure upon stimulation with Ac2-26 was measured by flow cytometry 6 
in control or Fpr2/3-/- mice. Data represent mean ± SEM (n=4). C, the level fibrinogen binding was analysed in whole blood obtained from control or 7 
AnxA1-/- mice upon stimulation with Ac2-26 in the presence or absence of WRW4 by flow cytometry (i), and the level of P-selectin exposure (ii) was 8 
analysed in whole blood obtained from control or Fpr2/3-/- mice upon stimulation with Ac2-26 by flow cytometry. Data represent mean ± SEM (n=4). 9 
Ciii, the characterisation of platelets obtained from Fpr2/3-/- mice; expression levels of major platelet receptors such as αIIbβ3, ɑ2β1, GPVI and GPIbα 10 
in platelets obtained from control and AnxA1-/- mice were analysed by flow cytometry using selective fluorescent-labelled antibodies.  Data represent 11 
mean ± SEM (n=8). D, Ca2+ mobilisation was measured using Fluo-4 AM dye-loaded human isolated platelets upon stimulation with Ac2-29 in platelets 12 
obtained from control or Fpr2/3-/- mice by flow cytometry. Data represent mean ± SEM (n=4). The statistical significance was calculated by two-way 13 
ANOVA followed by Bonferroni’s correction in most of the experiments except for the data shown in panel Ciii, which were calculated by two-tailed 14 
unpaired Student’s t test (*p<0.01. **p<0.001 and ***p<0.0001).   15 
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 4.3.6 Fpr2/3 is overexpressed in Anxa1−/− mice 1 
 Following confirmation on the role of FPR2/ALX in mediating the functions of ANXAc2-26 on 2 
platelets, and its exaggerated role in Anxa1−/− mice, we sought to investigate whether the levels of 3 
this receptor were altered in Anxa1−/− mice. Interestingly, the levels of Fpr2/3 were significantly 4 
increased in Anxa1−/− mice compared to controls as evidenced in electron microscopy (Figure 4- 5 
3A) and flow cytometry (Figure 4-3B). These data indicate the upregulation/overexpression of Fpr2/3 6 
in Anxa1−/− mice. 7 
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 1 
Figure 4-3: FPR2/ALX is overexpressed in AnxA1-/-. The presence of FPR2/ALX in overexpressed 2 
in AnxA1-/- mice as analysed by microscopy (A) and by flow cytometry (B). Data represent mean ± 3 
SEM (n=4). The statistical significance was calculated by two-tailed unpaired Student’s t test 4 
(*p<0.01 and ***p<0.0001). 5 
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4.4 Discussion 1 
 2 
AnxA1 has been shown to induce opposing physiological roles. Albeit a plethora of studies 3 
have reported its ‘anti-inflammatory and pro-resolving’ role in various immune cells47, some have 4 
demonstrated its ‘pro-inflammatory’ capabilities29, 30, 63, 64. Moreover, the dysregulation of AnxA1 5 
has been implicated in various pathological conditions, including cancer61, infections65, inflammatory 6 
bowel disease43. Furthermore, a pathogenic role of Ac2-26 has been previously described in cancer, 7 
wherein it facilitated metastasis/pro-invasiveness66, and in rheumatoid arthritis, where it facilitated 8 
the secretion of matrix metalloproteinases (MMPs)29.  Here, we demonstrate for the first time the role 9 
of AnxA1 and its N-terminal peptide sequence, Ac2-26, in the activation of the haemostatic platelet 10 
function through Fpr2/3 in mice. 11 
The Anxa1−/− mice utilized in this study demonstrated decreased activation of platelets 12 
compared to mice expressing the Anxa1 gene, signifying the positive role of the full-length protein 13 
in the activation of platelet function that is induced by conventional platelet agonists such as CRP- 14 
XL (via GPIV) and ADP (via P2Y1 and P2Y12).  Conversely, the activation of platelets with the N- 15 
terminal AnxA1 peptide sequence, Ac2-26, was exaggerated in Anxa1−/− mice compared to the 16 
control mice, this could be ascribed to a compensatory mechanism implicated with the deficiency of 17 
Anxa1 gene in these mice, buffering its deletion. Notably, the systemic haemostasis was intact and 18 
not impacted by/in the absence of AnxA1, plausibly indicating that AnxA1 may act on the site of 19 
injury, while leaving the physiological haemostasis intact. Furthermore, we observed a significant 20 
reduction in the expression of one of the major adhesion receptors on the platelets of these mice, 21 
GPIbα. Additionally, these mice displayed a marked expression/up-regulation in Fpr2/3, a receptor 22 
that mediates the signaling of both AnxA1 and its N-terminal peptide Ac2-26. This may explain the 23 
exaggerated Ac2-26 response that was observed in Anxa1−/− mice. The altered factors in these mice 24 
may be so in order to maintain a new physiological balance, allowing overall haemostasis. To further 25 
add to this, the dysregulation of other members of the Annexin superfamily has been previously 26 
reported in these mice47. 27 
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Contrasting roles/mechanisms of action between ANXA1 and its N-terminal peptide Ac2-26 1 
were previously reported29, 59. Here, we demonstrate that Ac2-26 evoked both an activatory platelet 2 
haemostatic function and a pro-inflammatory response, while the endogenous full-length Anxa1 3 
limited/controlled such responses, demonstrating possible protective roles. Ac2-26 activated platelets 4 
as evident by its ability to induce calcium mobilization, integrin aIIbb3 conformation and P-selectin 5 
exposure. All of these responses were mediated through Fpr2/3 in platelets. A protective role of 6 
ANXA1 in many pathological conditions implicated with platelet pathogenesis has been reported 7 
previously, including atherosclerosis36, 67-69, myocardial infarctions37, 70 and strokes27, 38, 71, 72.  The 8 
contrasting effects we have observed in this study could be attributed to the ability of Ac2-26 to 9 
heterodimerize FPR2/ALX with FPR1, which can result in the activation of pro-apoptotic signaling 10 
pathways and can elicit distinctive pathways73. Nonetheless, there is a paucity of studies addressing 11 
this phenomenon. Furthermore, Ac2-26 can active all FPRs family members26, 28, whereas Anxa1 12 
binds FPR2/ALX only74. There is a multiplicity of ligands that bind FPRs with diverse functions75. 13 
Notably, pro-inflammatory responses of such ligands are elicited via FPR1, while the majority of the 14 
anti-inflammatory/pro-resolving functions are mediated through FPR2/ALX76. Nonetheless, there are 15 
various ligands that can activate pro-inflammatory signaling mechanisms through FPR2/ALX, such 16 
as the endogenous antimicrobial peptide, LL37, that has been shown to exacerbate inflammatory 17 
responses, promoting atherosclerosis77. 18 
 Deciphering the role of the ANXA1-FPR2/ALX axis in the regulation of platelet function 19 
could open up new avenues toward improved therapeutic strategies for the management of 20 
inflammatory responses, and particularly with those associated with bleeding or thrombotic events. 21 
Furthermore, it could provide insight into the mechanisms underlying platelet-associated 22 
complications in inflammatory diseases. Targeting ANXA1 contributes to immune dysfunction 23 
resolution in infections65. Since many of the pro-resolving mechanisms are mediated through 24 
FPR2/ALX, it could be utilized to suppress exacerbated inflammation without targeting the host 25 
defense78, in contrast to anti-inflammatory mechanisms, minimizing unwarranted side effects and 26 
yielding more effective therapeutic strategies and effectual management of inflammation. 27 
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Additionally, many individuals suffering from autoimmune and inflammatory diseases are prescribed 1 
supraphysiological doses of glucocorticoids (GCs) to ameliorate signs of inflammation/inflammatory 2 
responses79. Nonetheless, GCs are associated with several unwarranted risks, including 3 
immunosuppression, cardiovascular disease79, 80, Cushing’s syndrome and psychiatric disorders81. 4 
Notably, GCs can induce the activation of platelets82, and have been associated with 5 
hypercoagulability of blood83. Moreover, the positive regulation of the secretion, and the expression 6 
of AnxA113, 84-86 and its receptor, FPR2/ALX in monocytes87, 88 and neutrophils89 are implicated in 7 
response to GCs. Thus, targeting this pathway could complement current therapeutic strategies.   8 
In conclusion, this study demonstrates a prominent role of AnxA1 and its N-terminal peptide 9 
(Ac2-26) in the regulation of platelet function, evident in the ability of Ac2-26 to induce inside-out 10 
signalling to integrin ɑIIbβ3 and granule secretion. The activatory roles of Ac2-26 in platelets were 11 
diminished in the presence of FPR2/ALX pharmacological inhibitors or in Fpr2/3-deficient mice, 12 
corroborating the functional dependence of Ac2-26 on this receptor. Moreover, we demonstrate a key 13 
role of AnxA1 in the positive regulation of platelet function.  Together, the significant roles of AnxA1 14 
and Fpr2/3 in the modulation of thrombosis and haemostasis renders them potential attributes for the 15 
exacerbation of thrombotic complications and inflammatory responses in numerous diseases where 16 
platelet function plays essential roles. Notably, the presence of FPRs in platelets opens up new 17 
avenues to investigate the involvement of a multiplicity of FPR ligands in the modulation of 18 
thrombosis, haemostasis, and platelet-mediated inflammatory responses. 19 
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4.5 Methods 
 
Animals 
Animal experiments complied with the University of Reading Research guidelines 
approved by the British Home Office or Federal University of Sao Paulo Animal Care and Use 
Committee. Eight to ten-week-old male or female mice, wild-type (WT) C57BL/6, ANXA1-/- 
and FPR2/3-/- mice were used.  
 
Mouse blood collection and platelet preparation  
The mice were sacrificed with CO2 and the blood was directly collected by cardiac 
puncture into a syringe containing 3.2% (w/v) sodium citrate at 1:9 ratio. The blood was then 
centrifuged at 203g for 8 minutes at room temperature and the PRP was collected. The 
remaining blood was resuspended in 500 µL of modified Tyrode’s-HEPES buffer and 
centrifuged once again at 203g for 5 minutes. The PRP was then mixed and centrifuged at 
1028g for 5 minutes. The resultant platelet pellet was then resuspended in modified Tyrode’s 
buffer at a density of 2x108 cell/mL. 
 
Flow cytometric analysis 
Five microliters of whole blood were incubated with 1 µL of FITC-conjugated 
fibrinogen antibody (1:50) and 1 µL of PECy5-conjugated anti-CD62P (P-selectin) (1:50) 
antibody in the presence and absence of increasing concentrations of ANXA1 mimetic peptide 
Ac2-26 (ANXA1ac2-26: Ac-AMVSEFLKQAWFIENEEQEYVQTVK, Tocris, UK). 
Multiparameter acquisition was performed using a Fortessa analyser device (BD Biosciences), 
and the median fluorescence intensity was calculated using FlowJo software (Tree Star, 
Ashland, USA) to quantify the levels of fibrinogen binding and P-selectin exposure on the 
surface of platelets. Negative controls were set using an appropriate immunoglobulin G1 
(IgG1) k-isotype–matched control for the anti-CD62P antibody, and inclusion of EGTA 
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(10mM) to prevent ﬁbrinogen binding. Similarly, for the analysis of ANXA1 and FPR2/ALX 
expression on platelets, samples were incubated with 1 µL of anti-ANXA1 or anti-FPR2/ALX 
(5 µg mL-1) and 2 µL of Cy5-conjugated anti-mouse IgG (80 µg mL-1). Following 20 minutes 
of incubation at room temperature, samples were fixed in 0.2% formyl saline and analysed by 
flow cytometry. 
 
Intracellular calcium mobilization assay 
PRP (2 mL) derived from WT and FPR2/3-/- mice was mixed with 2 µL of Fluo-4 AM 
dye (1 µM) (Life technologies, UK) and incubated for 20 minutes at 30ºC in the dark. The PRP 
was then centrifuged at 1413g for 10 min at 20ºC. The resultant platelet pellet was suspended 
in 500 µL Tyrode’s-HEPES buffer and maintained at 30ºC in the dark. The platelets were 
stimulated with different concentration of ANXA1 mimetic peptide Ac2-26 and the level of 
fluorescence intensity was measured by FluoStar Optima spectrofluorimeter (BMG Labtech, 
Germany) at 37ºC for 180 seconds using an excitation wavelength of 485nm and emission at 
510nm. Data were analysed by calculating the percentage of calcium released at 90 seconds. 
 
Tail bleeding assay 
The experimental procedures were approved by the British Home Office. In brief, wild-
type (WT) C57BL/6 and ANXA1-/- (8-10 weeks old male or female mice) were anaesthetised 
using ketamine (80 mg Kg-1) and xylazine (5 mg Kg-1) administered via the intraperitoneal 
route for 20 minutes before the experiment and were then placed on a heated mat (37ºC). 1mm 
of tail tip was removed using a scalpel blade and the tail tip was placed in sterile saline at 37ºC. 
The time to cessation of bleeding into warmed saline was measured up to 20 minutes. 
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SDS-PAGE and immunoblotting analysis 
Immunoblot analysis was performed using platelets lysates prepared under reducing 
conditions. The samples were heated to 90ºC for 10 minutes and subjected to SDS-PAGE using 
10% resolving gels. Equal loading of proteins in each lane was determined using anti-human 
14-3-3ζ antibodies (1:1000) (Santa Cruz Biotechnology, USA). The gels were then transferred 
to polyvinylidene difluoride membranes and blocked by incubation in 5% milk in TBS-T 
(20mM Tris, 140mM NaCl, Tween-20, pH 7.6). Following overnight incubation with primary 
anti-FPR2/ALX antibody (1:500) (Abcam, UK), the blots were washed with TBS-T and 
incubated with secondary Cy5 goat anti-rabbit IgG antibody (1:1000) (Invitrogen, UK) in TBS-
T containing 5% milk for 1 hour at room temperature. Following washing in TBS-T for 1 hour 
at room temperature, the blots were analysed using the Typhoon 9400 variable mode imager 
system (GE Healthcare, UK). 
 
Electron microscopy analysis 
Platelets were fixed in a 4% paraformaldehyde, 0.5% glutaraldehyde solution (1:1) in 
sodium cacodylate buffer 0.1 M (pH 7.4) for 24 hours at 4 ° C. The cells were subsequently 
dehydrated through a methanol series and embedded in LRGold (London Resin; Reading, 
Berkshire, UK). To detect the localization of the FPR2, ultrathin sections (70 nm) of cells were 
incubated with the rabbit polyclonal anti-FPR2 (1:100; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) and goat anti-rabbit IgG antibody (1:50 in PBS containing 1% egg albumin) 
conjugated with 15 nm colloidal gold (British Biocell, Cardiff, UK). These sections were 
stained with uranyl acetate and lead citrate and then examined using a ZEISS EM900 electron 
microscope (Carl Zeiss, Jena, Germany) as described. Randomly photographed sections of 
cells were used for immunocytochemical analysis. The area of the cell compartment was 
determined with AxioVision software. The density of immunogold particles (number of gold 
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particles per μm2) was calculated and expressed for each cell compartment. Values are reported 
as the mean ± SEM of 25-30 electron micrographs analysed per group. 
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5 – General discussion
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Main findings of this study: 
 
• fMLF primes platelets and induces thrombus formation through FPR1 signalling 
 
• LL37 triggers platelet activation through FPR2/ALX signalling  
 
• mCRAMP implicated in pathological conditions such as psoriasis can affect platelet 
function via FPR2/ALX 
 
• AnxA1 N-terminal peptide, Ac2-26, activates the platelet function through FPR2/ALX  
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Formyl peptide receptors are known to play a crucial role in the regulation of innate 
immune responses and host defence. They bind a wide variety of ligands that exhibit 
various functions, thus they mediate numerous biological responses through the modulation 
of inflammatory cells355. Hence, FPRs and their ligands have been implicated in the 
pathogenesis of various diseases, and it has been also shown that the blockade of these 
receptors attenuated pathophysiological responses, especially those associated with 
dysregulated inflammatory responses244, 492. Because of these observations, explorations of 
FPR signalling mechanisms presents an attractive approach for the development of novel 
therapeutic strategies as an adjunct to the treatments of inflammatory and infectious 
diseases, especially those associated with thromboinflammatory responses.  
 
The hypothesis of this study was as follows; formyl peptide receptors regulate the 
haemostatic function of platelets through the modulation of thrombus formation and 
haemostasis. The chemotactic bacterial peptide fMLF primes platelet activation and 
modulates thrombus formation through FPR1. The antimicrobial peptide LL37 exhibits 
prothrombotic effects and thus may implicate the pathogenesis of cutaneous inflammatory 
diseases such as psoriasis through interaction with platelets via FPR2/ALX. The Annexin 
A1 N-terminal peptide, Ac2-26, affects platelet haemostasis through FPR2/ALX.  
 
In order to investigate this hypothesis, the activatory roles of FPR1 and FPR2/ALX 
ligands, such as fMLF, LL37 and AnxA1Ac2-26 were investigated in isolated platelets, 
platelet-rich plasma (PRP) and in whole blood (WB) using several platelet functional 
assays, as well as the mechanisms through which these FPR ligands regulate the function 
of platelets. 
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5.1 fMLF modulates platelet function through FPRl 
 
In this study, we demonstrate the activatory role of the chemotactic bacterial 
peptide, fMLF, in the modulation of platelet function through FPR1. fMLF has been 
previously shown to induce the aggregation of platelets indirectly through neutrophils. In 
this study we sought to demonstrate the direct role of fMLF in the activation of platelets. 
Thus, the direct binding of fMLF to FPR1 in platelets was first confirmed. The ability of 
fMLF to induce the activation of platelets in distinct platelet functions including fibrinogen 
binding to integrin αIIbβ3 and Data α-granule secretion was also confirmed. These effects 
were abrogated in the presence of an FPR1-selective inhibitor, Boc-MLF, and in platelets 
obtained from Fpr1-deficient mice. fMLF also augmented thrombus formation under 
arterial flow conditions. Although this may be due in part to the effects of other mediators 
in whole blood. fMLF failed to aggregate platelets on its own, however, it significantly 
augmented CRP-XL-, collagen- and thrombin-induced aggregation in a concentration-
dependent manner. These findings demonstrate the priming role of fMLF on platelets 
through FPR1. 
 
5.2 LL37 induces platelet activation through FRP2/ALX 
and modulates disease 
 
Following this, we were also able to demonstrate the activatory role of the 
endogenous antimicrobial peptide, LL37, in the modulation of platelet function through 
FPR2/ALX. We first sought to confirm the presence of this peptide in platelets. We 
demonstrate here that LL37 is present in activated platelets using confocal microscopy. 
Using an ELISA assay, we show that it is released from platelets (at nM concentrations) 
upon their activation; it release was significantly increased in activated platelets as opposed 
to resting platelets. In addition, we confirm the stability of LL37 in platelet-rich as opposed 
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to platelet-poor plasma using LC-MS. Collectively, these data demonstrate that LL37 is 
present in platelets and is released upon their activation.  
In order to explore the role of LL37 in the regulation of platelet function, we first 
sought to investigate its broad role in haemostasis and thrombus formation. LL37 (20 µM) 
significantly shortened the bleeding time in mice using the tail bleeding assay in vivo. 
Additionally, the incubation of whole blood with LL37 significantly augmented thrombus 
formation under arterial flow conditions in a concentration-dependent manner (10, 20 and 
50 µM). These two findings rendered LL37 an impactful modulator of platelet function. 
Consequently, we sought to investigate the direct role of LL37 on distinct platelet 
functions. Hence, using isolated platelets, we demonstrate here that LL37 (10 and 20 µM) 
induced immediate aggregation of platelets using light transmission aggregometry. 
Conversely, LL37 failed to aggregate platelets in PRP. This could be attributable to the 
presence of plasma protein that could bind to LL37, reducing its effect on platelet 
aggregation401, 493, 494. Nonetheless, in further distinct platelet functional assays including 
the binding of fibrinogen to integrin aIIbb3 (inside-out signalling) and a-granule secretion, 
we demonstrate that LL37 was able to significantly increase these responses equally in 
platelets both in isolation and in plasma. Following to this, were also able to demonstrate 
that LL37 affects outside-in signalling using the platelet spreading assay, and the calcium 
mobilisation in platelets. These findings clearly demonstrate the ability of LL37 to directly 
modulate an activatory role in platelets. In contrast, a previous study on the role of LL37 
concluded its negative effects on platelets402. The previous study revealed that 5 µM LL37 
failed to aggregate gel-filtered platelets, induce calcium mobilisation and exert any 
cytotoxicity towards platelets. Our study also concludes that 5 µM LL37 failed to exert any 
of these effects although at this concentration LL37 displayed minimal and negligible 
effects in platelet aggregation and calcium mobilisation, and thus were interpreted as 
nonsignificant. Another study reported a contrasting role of LL37 in platelets; suggesting 
 182 
an inhibitory role449. This is highly unlikely since LL37 was used at extremely high 
concentrations (0.3, 0.6 and 1.2 mM) that were previously reported to exert cytotoxicity 
towards eukaryotic cells. Indeed, we were able to confirm here that LL37 was cytotoxic 
towards isolated platelets at a concentration of 100 µM. Additionally, at the lower 
concentration (ranging from 1 to 50 µM), which were utilised in this study, LL37 failed to 
exert any cytotoxicity towards platelets.  A recently published study confirmed some of the 
findings presented here, where they demonstrated that LL37 primes platelets and induces 
prothrombotic properties. In contrast to our findings, they report that LL37 did not induce 
fibrinogen binding or platelet spreading on immobilized fibrinogen, however, LL37 
induced P-selectin expression, similar to our findings. This may be reflective of different 
experimental methods used between the two studies. They report that LL37 failed to exert 
aggregation in PRP, which we also reported and attributed to the presence of plasma 
proteins.  
 
Following the different activatory roles of LL37, the underlying mechanisms 
driving these effects in platelets were investigated. Since LL37 is known to display 
proinflammatory effects through FPR2/ALX, we were able to confirm the dependency of 
this receptor on exerting the effects demonstrated here. Using a pharmacological inhibitor 
for FPR2/ALX, WRW4, and platelets obtained from Fpr2/3-deficient mice, we 
demonstrated that LL37 binds to this receptor and acts through it to modulate platelet 
function. We were the first to demonstrate this, as the recently published study reported 
that WRW4 (1 µM) did not affect LL37 properties in platelets; probably due to the use of 
a lower concentration of WRW4.  
Subsequent to establishing a role of LL37 in platelets through FPR2/ALX, we 
sought to explore its effect in an inflammatory disease that is highly associated with LL37 
and platelet-related complications using an animal model of psoriasis. The haemostasis was 
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not affected in mice of the psoriatic animal model used in this study. However, the level of 
mCRAMP in the psoriatic lesions and plasma obtained from these mice were markedly 
increased compared to normal controls. In addition, psoriatic platelets demonstrated 
prothrombotic properties as the fibrinogen binding to integrin and granule secretion upon 
the stimulation of platelets with CRP-XL, ADP and U46619 were increased compared to 
the controls. Moreover, upon the treatment of control platelets with psoriatic lesions and 
plasma, the fibrinogen binding and granule secretion were significantly increased in the 
presence or absence of CRP-XL. Upon blockade of FPR2/ALX or use of platelets obtained 
from Fpr2/3-deficient mice, the effect of psoriatic plasma on platelet activation was 
significantly reduced. These confirm the association of LL37 and platelet dysregulation, 
and the involvement of FPR2/ALX-mediated signalling in psoriasis. In this work, we 
demonstrate the role of psoriatic plasma obtained from mice on human blood. While the 
mCRAMP peptide sequence differs from that of human LL37, it was shown to be an 
effective model for the investigation of human cathelicidins495. In addition, several studies 
demonstrate the administration of LL37 in mice to exert its function496-498. 
 
5.3 AnxA1 modulates platelet activatory responses through 
FPR2/ALX 
 
Succeeding the pro-thrombotic role of FPR2/ALX via ligation with LL37 in the 
platelets, we sought to investigate the role of AnxA1 (a pro-resolving molecule) in the 
regulation of platelet function. The endogenous AnxA1 is known to exert anti-
inflammatory and cardioprotective properties, and thus its therapeutic potential has been 
previously proposed474. Surprisingly, we demonstrate here that the N-terminal peptide Ac2-
26 exerts prothrombotic and proinflammatory properties in platelets through FPR2/ALX. 
In order to explore the role of AnxA1 in the regulation of platelet function, Anxa1-deficient 
mice were used in this study. Platelets obtained from Anxa1-deficient mice demonstrate a 
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normal expression of major platelet receptors including GPVI, a2 and aIIb, but a marked 
reduction in the expression of the GPIba receptor. Nonetheless, this finding did not impair 
the haemostasis as it was not affected in these mice compared to control mice. Anxa1-
deficient mice demonstrated reduced platelet activatory properties upon stimulation with 
subthreshold concentrations of CRP-XL and ADP as evidenced by fibrinogen binding to 
αIIbβ3 and alpha-granule secretion. This affect however was overcome when higher 
concentrations of these two agonists were used. The exogenous AnxA1 N-terminal peptide, 
Ac2-26, demonstrated increased platelet activation in Anxa1-deficient mice, possibly due 
to compensatory effects. Nonetheless, we later confirmed the overexpression of 
FPR2/ALX in these mice, another plausible explanation for the increased platelet activation 
by Ac2-26 in Anxa1-deficient mice. Ac2-26 displayed increased fibrinogen binding to 
αIIbβ3, which was reversed by an FPR2/ALX-selective inhibitor, WRW4. Ac2-26 also 
induced increased expression of P-selectin on the surface of platelets, which was reduced 
in Fpr2/3-deficient mice. In addition, Ac2-26 induced calcium mobilisation in platelets, 
which was also reduced in Fpr2/3-deficient mice. This indicates that the effects of Ac2-26 
are mediated through FPR2/ALX in platelets. Together, these findings demonstrate a role 
for AnxA1 in the modulation of platelet function.  
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5.4 FPRs regulate platelet function 
 
In this study, we provide evidence that FPRs regulate the haemostatic platelet 
function by the utilisation of FPR pharmacological inhibitors and Fpr-deficient mice. These 
mice display severe inflammation in both sterile and infections inflammation in addition to 
increased susceptibility to infections256, 257, 499, 500. This supported their role in the regulation 
of the innate immune response and host defence. In this study, we demonstrate the 
consequential effect of Fpr-deficiency in the regulation of the platelet function. We 
demonstrate that mouse platelets obtained from Fpr1- or Fpr2/3-deficient mice displayed 
a reduced activation induced by various conventional platelet agonists, including CRP-XL, 
ADP, AY-NH2, and U46619. In addition, the haemostatic function in these mice was 
compromised, indicated by a significantly prolonged tail bleeding time compared to control 
mice. The underlying mechanisms accompanying the genetic deletion of Fpr1 or Fpr2/3 
that might contribute to platelet dysfunction in these mice are beyond the scope of this 
study, and future studies focusing on these underlying mechanisms will provide great 
insight. Nonetheless, it demonstrates a crucial interplay between inflammation and 
thrombosis. Despite the functional abnormalities in these mice, these effects were 
recapitulated in human platelets by utilising FPR1 or FPR2/ALX-selective 
pharmacological inhibitors in several functional assays. These include reduced platelet 
activation (evident by fibrinogen binding and P-selectin exposure), platelet aggregation, 
ATP release, platelet spreading and thrombus formation. All of which were reduced in the 
presence of selective inhibitors for FPR1 or FPR2/ALX. FPRs belong to the family of Gi 
protein-coupled receptors and trigger downstream signalling pathways in neutrophils 
including phospholipase C (PLC), PI3K/AKT and MAPK, and can stimulate rapid calcium 
flux242. We sought to explore additional downstream signalling involved in FPR1- and 
FPR2/ALX-induced platelet responses. We were able to demonstrate here that the 
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inhibition FPR1 or FPR2/ALX, or the deletion of their respective genes in mice leads to 
the elevation of cAMP, which is a major inhibitor for platelet activation. This suggests the 
involvement of cAMP-dependent signalling pathways in the regulation of FPR-mediated 
effects in platelets. 
 
In conclusion, the data presented here demonstrate the role of endogenous peptides, 
such as the bacterial chemotactic peptide fMLF, the antimicrobial peptide LL37 and the 
pro-resolving protein AnxA1 in the regulation of platelet function. These peptides are 
involved in the pathogenesis of various infectious and sterile inflammatory diseases. Thus, 
these peptides can contribute to the amplification of such diseases by the dysregulation of 
platelet function. Understanding the molecular mechanisms involved in such dysregulation 
will provide insight into the development of enhanced therapeutic strategies for various 
inflammatory diseases.  
 
We provide novel findings here that demonstrate the expression of LL37 in platelets 
and its secretion upon their activation. Additionally, we demonstrate that the effects of 
LL37 in platelets are mediated through FPR2/ALX signalling pathways, which previous 
studies have failed to demonstrate402, 449, 450. Using a murine model for psoriasis, we reveal 
the effect of cathelicidins in platelet function through FPR2/ALX signalling during 
pathological conditions. In addition to LL37, we demonstrate a direct role for fMLF in 
distinct platelet functions, such as fibrinogen binding and P-selectin expression. Although 
fMLF failed to aggregate platelets on its own, it induced in vitro thrombus formation in 
whole blood, where the effect of other stimuli can contribute to the such effect. AnxA1 N-
terminal peptide also exerted activatory effects towards platelet functions.  
 
The findings of this study provide strong evidence on the role of FPRs in the 
regulation of the platelet haemostatic function. Moreover, it corroborates the pro-
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thrombotic role of LL37, and confirms the role of FPR2/ALX signalling in mediating such 
responses. A priming role for fMLF and Ac2-2-6 was also demonstrated here. This supports 
the involvement of these peptides in mechanisms that may augment or perpetuate platelet-
related complications in disease, and highlights FPRs and their ligands as potential 
therapeutic agents as an adjunct to the current treatments of infectious and inflammatory 
diseases, especially those associated with thrombo-inflammatory responses. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 – Future direction
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 FPRs are traditionally known to play a role in the regulation of innate immune response 
and host defence. Here, we were able to demonstrate a role for these receptors and some of 
their ligands in the regulation of the platelet function. However, there are several questions 
remaining regarding their role in thrombosis and their implication in pathological conditions 
that are associated with platelet function. Further in vivo work focusing on the role of these 
receptors and their ligands in thrombosis will provide stronger conclusions regarding their role 
in thrombosis. 
 
6.1 Role of fMLF in thromboinflammation 
 The role of fMLF in multiple disorders renders it an attractive target for clinical 
investigations. Examining the level of circulating fMLF in the plasma of patients suffering 
from sepsis and chronic inflammatory conditions such as inflammatory bowel disease, and its 
role in regulating the platelet function through FPR1 would provide insight into whether this 
peptide can exacerbate these inflammatory conditions. 
 
6.2 Role of mCRAMP/ LL37 in thromboinflammation and in the 
pathogenesis of psoriasis 
 Work on human samples obtained from patients suffering from psoriasis would 
complement the work demonstrated here on the psoriatic mouse model. Additionally, by 
depleting the mCRAMP from psoriatic samples, the effect of other stimuli that can affect 
FPR2/ALX signalling can be excluded, and thus corroborating the involvement of this 
pathway. The detection of platelet markers, such as PF4, in these samples would also provide 
more evidence and confirm the involvement of platelets during disease progression.  
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6.3 Role of AnxA1 in the regulation of haemostasis and thrombosis 
 Additional research needs to be conducted to confirm the role of the full-length 
Annexin A1 protein as opposed to its N-terminal peptides, which are not found in the human 
body as is but are rather sequences of larger peptides. Moreover, additional experiments 
utilising Fpr1-deficient mice and FPR1-selective pharmacological inhibitors can be performed 
to confirm whether any of the responses observed in platelets are mediated through FPR1 
signalling in platelets. Since it has been shown that Ac2-26 can elicit pro-inflammatory 
properties upon the heterodimerisation of FPR2/ALX with FPR1501. Moreover, the 
investigation of the heterodimerisation of FPR1 and FPR2/ALX in platelets would further 
provide insight into the underlying mechanisms that could contribute to the elicitation of 
prothrombotic effects of this peptide, since FPR2/ALX can elicit both pro-inflammatory (upon 
the ligation with SAA or LL37) and pro-resolving (upon ligation with AnxA1 or LXA4) 
properties, while FPR1 mainly triggers proinflammatory signalling461. 
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